4-Fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and analogues as CYP46A1 inhibitors for the treatment of neurodegenerative disorders
Patent Information
- Application Number
- JP2023531565
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-25
- Filing Date
- 2021-11-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-11-24
AI Technical Summary
Current treatments for neurological diseases associated with NMDA hyperactivity and neurodegenerative disorders, such as epilepsy, autism spectrum disorder, Alzheimer's disease, and Parkinson's disease, lack effective inhibitors for CYP46A1, which regulates 24S-hydroxycholesterol production, a key factor in these conditions.
Development of CYP46A1 inhibitor compounds, including 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives, to modulate CYP46A1 activity and reduce 24S-hydroxycholesterol levels, thereby addressing the underlying causes of these diseases.
The CYP46A1 inhibitors effectively target and reduce 24S-hydroxycholesterol production, providing therapeutic benefits for neurodegenerative diseases and neurological disorders by modulating NMDA receptor activity and glutamatergic hyperactivation.
Smart Images

Figure 2022115620000001 
Figure 2022115620000002 
Figure 2022115620000003
Abstract
Description
Technical field
[0001] Related applications This application claims the benefit and priority of U.S. Provisional Application No. 63 / 118,291, filed November 25, 2020, the entire contents of which are incorporated herein by reference. [Background technology]
[0002] CYP46A1 is also known as cholesterol 24-hydroxylase (CYP46A1 and CH24H), an enzyme that converts cholesterol to 24S-hydroxycholesterol (24-HC), which is a positive allosteric regulator of N-methyl-D-aspartate (NMDA) receptors. This is a gene expressed in the brain that encodes a known protein. Inhibition of 24-HC production in the brain by CYP46A1 inhibitors may be useful in neurological diseases associated with NMDA hyperactivity, such as epilepsy and autism spectrum disorder (ASD), or in 24-HC production, such as multiple sclerosis (MS). Glutamatergic hyperactivation can be negatively regulated in diseases associated with elevated HC levels. Findings suggest that CYP46A1 inhibitors may also be promising treatments for neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's disease, stroke, traumatic brain injury, glaucoma, and amyotrophic lateral sclerosis. has been done. The present disclosure provides compounds that can modulate (eg, inhibit) CYP46A1. [Summary of the invention] [Means to solve the problem]
[0003] Provided herein are compounds that act as CYP46A1 inhibitors and methods for their use. Compounds disclosed herein are useful for diseases associated with inhibition of CYP46A1, such as neurodegenerative diseases (e.g., Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain disease, etc.). therapies to treat epilepsy, developmental and epileptic encephalopathies (e.g., schizophrenia and autism spectrum disorder (ASD)), and convulsions (e.g., schizophrenia and autism spectrum disorders (ASD)); Useful as a medicine.
[0004] In a first aspect, the disclosure provides CYP46A1 inhibitors. In some embodiments, the present disclosure provides compounds of formula I, [ka] or a pharmaceutically acceptable salt thereof, in which: R 1 However, C 6 -C 10 Aryl, C 3 -C 7 selected from the group consisting of cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 10-membered heteroaryl, R 1 But if necessary, 1 to 4 R 4 replaced with R a and R b each independently H, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy, or R a and R b But along with the carbons to which they bond, C 3 -C 7 may form cycloalkyl or R a and R b but together they are oxo, R c ,R d ,R e , and R f Each of them is independently H, C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy, or R c and R e But along with the carbons to which they bond, C 1 -C 3 may form an alkylene bridge or R d and R f But along with the carbons to which they bond, C 1 -C 3 can form alkylene bridges, Each R 4 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , -S(O) 2 R 5 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 6 -C 10 Aryl, C 3 -C 7 selected from the group consisting of cycloalkyl, and 3- to 7-membered heterocyclyl, Each R 5 but independently, H and C 1 -C 6 selected from alkyl, Each R 2 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy; Each R 3 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 3 -C 7 cycloalkyl, and C 1 -C 6 selected from the group consisting of haloalkoxy; A is a 5- to 6-membered nitrogen-containing heteroaryl, B is C 6 -C 10 selected from aryls and 5-6 membered heteroaryls, m is 0, 1, 2, or 3; n is 0, 1, 2, 3, or 4; o is 0, 1, 2, or 3; p is 0, 1, or 2; However, if n is 0, R 1 is not 4-cyanophenyl or 4-trifluoromethylphenyl, or a pharmaceutically acceptable salt thereof.
[0005] In some embodiments, the compound of Formula I is [ka] or a pharmaceutically acceptable salt thereof.
[0006] In some embodiments, the compound of Formula I is [ka] or a pharmaceutically acceptable salt thereof.
[0007] In some embodiments, the compound of formula I is a compound of formula I-a-1, [ka] or a pharmaceutically acceptable salt thereof.
[0008] In some embodiments, R 1 is the replacement C 6 -C 10 It is an aryl. In some embodiments, R 1 is an unsubstituted C 6 -C 10 It is an aryl. In some embodiments, R 1 teeth, [ka] , where each R 4 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , -S(O) 2 R 5 ,C1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 6 -C 10 Aryl, C 3 -C 7 cycloalkyl, or 3- to 7-membered heterocyclyl, each R 5 is independently H or C 1 -C 6 is alkyl and q is 0, 1, 2, or 3.
[0009] In some embodiments, R 1 teeth, [ka] It is.
[0010] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0011] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0012] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0013] In some embodiments, R 1 is a substituted 5- to 10-membered heteroaryl. In some embodiments, R 1 is an unsubstituted 5- to 10-membered heteroaryl. In some embodiments, R 1 is pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, tetrazolyl, azosinyl, dithiazinyl, or oxazinyl. In some embodiments, R 1 is pyridyl, pyridinyl, pyridazinyl, pyrimidinyl, or pyrazinyl. In some embodiments, R 1 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, or 4-pyrimidinyl.
[0014] In some embodiments, R 1 teeth, [ka] and in the formula, each X is independently CH or N, and H of CH is 1 to 4 R 4 and each R 4 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 6 -C 10 Aryl, C 3 -C 7 cycloalkyl, or 3- to 7-membered heterocyclyl, each R 5 but independently, H or C 1 -C 6 It is an alkyl. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0015] In some embodiments, R 1 is a substituted 3- to 7-membered heterocyclyl. In some embodiments, R 1 is an unsubstituted 3- to 7-membered heterocyclyl. In some embodiments, R 1 is tetrahydrofuran, tetrahydropyran, pyrrolidine, piperidine, piperazine, dioxolane, dioxane, thiomorpholine, or dithiane. In some embodiments, R 1 is tetrahydrofuran or tetrahydropyran. In some embodiments, R 1 teeth, [ka] It is.
[0016] In some embodiments, each R 4 are, independently, halo, -CN, C 1 -C 6 haloalkyl, and q is 0, 1, 2, or 3.
[0017] In some embodiments, each R 4 are, independently, halo, -CN, substituted C 1 -C6 Alkyl, substituted C 1 -C 6 alkoxy, or substituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are, independently, halo, -CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, or unsubstituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are, independently, halo, -CN, C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 haloalkoxy, or C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are independently halo, -CN, -CH 3 ,-CF 3 ,-CH 2 F, -CHF 2 ,-OCH 3 ,-OCF 3 , or cyclopropyl. In some embodiments, each R 4 are, independently, halo, -CN, -CF 3 ,-OCF 3 , or cyclopropyl. In some embodiments, each R 4 are independently halo, -CN, -CH 3 ,-CF 3 ,-CH 2 F, or -CHF 2 It is. In some embodiments, each R 4 are independently Cl, F, Br, or I. In some embodiments, each R 4 are independently Cl or F.
[0018] In some embodiments, n is 4. In some embodiments, n is 3. In some embodiments, n is 2. In some embodiments, n is 1. In some embodiments, n is 0.
[0019] In some embodiments, n is 1 and R a is C 1 -C 6 is alkyl and R b is H. In some embodiments, n is 1 and R a is methyl and R b is H. In some embodiments, n is 1 and R a is -OH and R b is H. In some embodiments, n is 1 and R a and R b together form oxo. In some embodiments, n is 1 and R a and R b are both H.
[0020] In some embodiments, p is 2. In some embodiments, p is 1.
[0021] In some embodiments, p is 1 and R c ,R d ,R e and R f is H. In some embodiments, p is 1 and R c is methyl and R d ,R e , and R f is H. In some embodiments, p is 1 and R c and R e is H and R d and R f are, along with the carbons to which they bond, C 1 -C 3 Forms an alkylene bridge. In some embodiments, p is 1 and R d and R f is H and R c and R e are, along with the carbons to which they bond, C 1 -C 3 Forms an alkylene bridge.
[0022] In some embodiments, p is 0. In some embodiments, p is 0 and R c ,R d , and R f is H.
[0023] In some embodiments, B is [ka] , where each R 6 is independently N or CR 6a and R 6a is H or R 2 and ** is the bonding point with carbonyl, * is the connection point with A.
[0024] In some embodiments, up to 2 R 6 can be N and R 6 Another occurrence of is CH.
[0025] In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A. In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A. In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A. In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A. In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A. In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A. In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A. In some embodiments, B is [ka] In the formula, ** is the point of attachment to carbonyl, and * is the point of attachment to A.
[0026] In some embodiments, m is 3. In some embodiments, m is 2. In some embodiments, m is 1. In some embodiments, m is 0.
[0027] In some embodiments, A is pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazinyl, tetrazolyl, oxazolyl, isoxazolyl, or thiozolyl. In some embodiments, A is pyridinyloxazolyl, imidazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, or triazinyl.
[0028] In some embodiments, A is [ka] , where each R 7 are independently N or CH, up to two R 7 can be N and R 7 Other occurrences of are CH and the hydrogen of CH is R 3 can be replaced with In some embodiments, A is [ka] It is. In some embodiments, A is [ka] It is.
[0029] In some embodiments, the compound is selected from the group consisting of Compounds 1-98, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Compound 1, 4-7, 9, 11, 13-15, 18-20, 22-24, 26, 28-29, 31-35, 38-39, 43, 46 ~47, 51~52, 54~55, and 57. In some embodiments, the compound is selected from the group consisting of compounds 10, 12, 16-17, 21, 25, 27, 30, 36-37, 40-42, 44, 48-50, and 53. .
[0030] In a second aspect, the disclosure provides a pharmaceutical composition comprising a compound of the disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
[0031] In a third aspect, the disclosure provides a method for treating or preventing a disease or disorder involving inhibition of CYP46A1 in a subject in need thereof, comprising: a therapeutically effective amount of a compound of the disclosure; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure, to a subject, wherein the disease or disorder associated with inhibition of CYP46A1 is a neurodegenerative disorder, epilepsy, developmental and epileptic encephalopathy. , mental disorders, and convulsions.
[0032] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is a neurodegenerative disorder. In some embodiments, the neurodegenerative disease consists of Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, stroke, glaucoma, and multiple sclerosis selected from the group.
[0033] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is epilepsy.
[0034] In some embodiments, diseases or disorders involving inhibition of CYP46A1 are developmental and epileptic encephalopathies.
[0035] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is a psychiatric disorder. In some embodiments, the mental disorder is selected from the group consisting of schizophrenia, autism spectrum disorder, delusional disorder, schizoaffective disorder, and depression.
[0036] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is convulsions.
[0037] In a fourth aspect, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease or disorder involving inhibition of CYP46A1 in a subject. Acceptable salts or pharmaceutical compositions of the present disclosure are provided. In some embodiments, the disease or disorder involving inhibition of CYP46A1 is selected from the group consisting of neurodegenerative disorders, epilepsy, developmental and epileptic encephalopathies, psychiatric disorders, and convulsions.
[0038] In some embodiments, the compound or pharmaceutically acceptable salt thereof, or pharmaceutical composition is for use in treating or preventing a neurodegenerative disorder. In some embodiments, the neurodegenerative disease consists of Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, stroke, glaucoma, and multiple sclerosis selected from the group.
[0039] In some embodiments, the compound or pharmaceutically acceptable salt thereof, or pharmaceutical composition is for use in treating or preventing epilepsy.
[0040] In some embodiments, the compound or pharmaceutically acceptable salt thereof, or pharmaceutical composition is for use in treating or preventing developmental and epileptic encephalopathies.
[0041] In some embodiments, the compound or pharmaceutically acceptable salt thereof, or pharmaceutical composition is for use in treating or preventing a mental disorder. In some embodiments, the mental disorder is selected from the group consisting of schizophrenia, autism spectrum disorder, delusional disorder, schizoaffective disorder, and depression.
[0042] In some embodiments, the compound or pharmaceutically acceptable salt thereof, or pharmaceutical composition is for use in treating or preventing convulsions.
[0043] In a fifth aspect, the disclosure provides the use of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease or disorder involving inhibition of CYP46A1 in a subject. . In some embodiments, the disease or disorder involving inhibition of CYP46A1 is selected from the group consisting of neurodegenerative disorders, epilepsy, developmental and epileptic encephalopathies, psychiatric disorders, and convulsions.
[0044] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is a neurodegenerative disorder. In some embodiments, the neurodegenerative disease consists of Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, stroke, glaucoma, and multiple sclerosis selected from the group.
[0045] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is epilepsy.
[0046] In some embodiments, diseases or disorders involving inhibition of CYP46A1 are developmental and epileptic encephalopathies.
[0047] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is a psychiatric disorder. In some embodiments, the mental disorder is selected from the group consisting of schizophrenia, autism spectrum disorder, delusional disorder, schizoaffective disorder, and depression.
[0048] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is convulsions. [Form for carrying out the invention]
[0049] The present disclosure provides compounds that are CYP46A1 inhibitors. Compounds of the present disclosure are useful for neurodegenerative diseases (e.g., Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, stroke, glaucoma, and multiple sclerosis), It is useful as a therapeutic agent for treating epilepsy, developmental and epileptic encephalopathies, psychiatric disorders (eg, schizophrenia and autism spectrum disorders), and convulsions.
[0050] general definition The term "this specification" refers to the entire application.
[0051] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the terminology used in connection with the compounds, compositions and methods described herein is that which is well known and commonly used in the art.
[0052] None of the embodiments described herein, including those described under different aspects of the disclosure and different parts of the specification (including embodiments described only in the Examples), are expressly It is to be understood that the disclosure may be combined with one or more other embodiments of the present disclosure unless otherwise disclaimed or inappropriate. Combinations of embodiments are not limited to those specific combinations claimed via the scope of the multiple dependent claims. For example, any claim that is dependent on another claim includes one or more limitations found in any other claim that is dependent on the same base claim. It can be modified as follows. When the elements are presented as a list, for example in Markush group format, each subgroup of elements is also disclosed and any element can be removed from the group.
[0053] Throughout this specification, the word "comprise" or variations such as "comprises" or "comprising" refer to the stated integer (or component) or group of integers. It will be understood that the inclusion of (or a component) is not meant to exclude any other integer (or component) or group of integers (or component).
[0054] Throughout this specification, when a composition is described as having, including, or comprising (or variations thereof) certain ingredients, the composition also means that the composition consists essentially of the listed ingredients. It is contemplated that it can become or consist of. Similarly, when a method or process is described as having, including, or comprising particular process steps, the process also consists essentially of or consists of the recited process steps. or can consist of it. Furthermore, it is to be understood that the order of steps or order of performing particular operations is not important so long as the compositions and methods described herein remain operable. Additionally, two or more steps or actions can be performed simultaneously.
[0055] As used herein, the term "including" means "including, but not limited to." "Including" and "including, but not limited to" are used interchangeably. These terms are therefore meant to encompass the integer (or member) or group of integers (or member) mentioned, but not any other integer (or member) or group of integers ( It will be understood that this does not imply the exclusion of (or components).
[0056] As used herein, the term "about" or "approximately" means within a tolerance range for a particular value as determined by one of ordinary skill in the art; How is measured or determined, i.e. depends on the limitations of the measurement system.
[0057] The use of the terms "a," "an," and "the" and similar referents in the context of describing elements (particularly in the context of the following claims) does not refer to any other use herein. It should be construed to include both the singular and the plural unless otherwise clearly contradicted by the context.
[0058] The term "or" as used herein is to be understood to mean "and / or" unless the context clearly dictates otherwise.
[0059] References to ranges of values herein are intended solely to serve as a shorthand way of individually referring to each separate value included in the range, including the endpoints, unless otherwise indicated herein. and each separate value is incorporated herein as if individually mentioned herein. All methods described herein may be performed in any suitable order, unless indicated otherwise herein or clearly contradicted by context. Any and all examples provided herein or the use of exemplary terminology (e.g., "such as") are merely intended to better illustrate embodiments, and not otherwise stated. Insofar, no limitations on the scope of the claims are intended. No language in the specification should be construed as essential or indicating any non-claimed element.
[0060] All publications, patents and published patent applications mentioned in this application are specifically incorporated herein by reference. In case of conflict, the present specification, including specific definitions, will control. Furthermore, any particular embodiment of this disclosure that falls under prior art may be expressly excluded from any one or more of the claims. Such embodiments are considered known to those skilled in the art and may therefore be excluded even if the exclusion is not expressly stated herein. Any particular embodiment of this disclosure may be excluded from any claim for any reason, whether or not related to the existence of prior art.
[0061] Chemical substance definition Definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th Ed., and the specific functional groups are generally defined as described therein. In addition, general principles of organic chemistry, as well as specific functional moieties and reactivities, can be found in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999, Smith and March, March’s Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001, Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989, and Carruthers, Some Modern Methods of Organic Synthesis, 3. rd Edition, Cambridge University Press, Cambridge, 1987.
[0062] The compounds described herein may contain one or more than one asymmetric center and therefore exist in various isomeric forms, e.g. enantiomers and / or diastereomers. be able to. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, or as racemic mixtures and one or more stereoisomers. It may also be in the form of a mixture of stereoisomers, including enriched mixtures. Isomers, e.g. stereoisomers, may be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and chiral salt formation and crystallization, or preferred isomers are Can be prepared by asymmetric synthesis. For example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981), Wilen et al., Tetrahedron 33:2725 (1977), Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962). , and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). This disclosure further encompasses the compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.
[0063] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms, or in the arrangement of their atoms in space, are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers." Stereoisomers that are not mirror images of each other are termed "diastereoisomers," and stereoisomers that are non-superimposable mirror images of each other are termed "enantiomers." If a compound has an asymmetric center, for example attached to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric centers, using the R- and S-sequencing rules of Cahn and Prelog, or when the molecule rotates the plane of polarization and is designated as dextrorotatory or levorotatory. (ie, as the (+)- or (-)-isomer, respectively). Chiral compounds can exist as either individual enantiomers or mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."
[0064] As used herein, an enantiomerically pure compound is substantially free of other enantiomers or stereoisomers of the compound (ie, in enantiomeric excess). In other words, the "S" form of a compound is substantially free of the "R" form of the compound and is therefore in enantiomeric excess of the "R" form. The term "enantiomerically pure" or "pure enantiomer" means that a compound is greater than 75%, greater than 80%, greater than 85%, greater than 90%, 91% by weight of its enantiomer. Super, over 92 wt%, over 93 wt%, over 94 wt%, over 95 wt%, over 96 wt%, over 97 wt%, over 98 wt%, over 98.5 wt%, over 99 wt%, 99.2 wt% More than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight, or more than 99.9% by weight. In certain embodiments, weights are based on the total weight of all enantiomers or stereoisomers of the compound. As used herein, the term "diastereomeric purity" refers to the amount of a compound having the indicated absolute stereochemistry, expressed as a percentage of the total amount of the indicated compound and its diastereoisomers. The term "diastereomerically pure" means that a compound is greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 91%, greater than 92% by weight of diastereoisomers. , more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight , more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight, or more than 99.9% by weight. Methods for determining diastereoisomerism and enantiomeric purity are well known in the art. Diastereomeric purity can be determined by any analytical method that can quantitatively distinguish between a compound and its diastereoisomers, such as high performance liquid chromatography (HPLC).
[0065] In the compositions provided herein, enantiomerically pure compounds can be present with other active or inactive ingredients. For example, a pharmaceutical composition containing an enantiomerically pure R-position / center / carbon compound may contain, for example, about 90% excipient and about 10% enantiomerically pure R-compound. can be included. In embodiments, the enantiomerically pure R-compound in such compositions includes, for example, at least about 95% by weight R-compound and up to about 5% by weight S -Can contain compounds. For example, a pharmaceutical composition comprising an enantiomerically pure S-Compound can contain, for example, about 90% excipient and about 10% enantiomerically pure S-Compound. In embodiments, the enantiomerically pure S-compound in such compositions includes, for example, at least about 95% by weight S-compound and up to about 5% by weight R-compound, by total weight of the compound. -Can contain compounds. In certain embodiments, the active ingredients can be formulated with little or no excipients or carriers.
[0066] As used herein, the term "diastereomeric purity" refers to the amount of a compound having the indicated absolute stereochemistry, expressed as a percentage of the total amount of the indicated compound and its diastereoisomers. The term "diastereomerically pure" means that a compound is greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 91%, greater than 92% by weight of diastereoisomers. , more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight , more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight, or more than 99.9% by weight. Methods for determining diastereoisomerism and enantiomeric purity are well known in the art. Diastereoisomeric purity can be determined by any analytical method that can quantitatively distinguish between a compound and its diastereoisomers, such as high performance liquid chromatography (HPLC).
[0067] When a range of values is recited, it is intended to include each value and subrange within the range. For example, “C 1-6 "Alkyl" is C 1 ,C 2 ,C 3 ,C 4 ,C 5 ,C 6 ,C 1-6 ,C 1-5 ,C 1-4 ,C 1-3 ,C 1-2 ,C 2-6 ,C 2-5 ,C 2-4 ,C 2-3 ,C 3-6 ,C 3-5 ,C 3-4 ,C 4-6 ,C 4-5 , and C 5-6 It is intended to include alkyl.
[0068] The following terms are intended to have the meanings set forth below and are useful in understanding the specification and intended scope of this disclosure. Also, as described herein, any of the moieties defined herein may be substituted with a variety of substituents, each definition of which includes such substitutions as described below. It is also to be understood that the portions referred to herein are intended to be included within their scope. Unless otherwise specified, the term "substitution" shall be defined as set forth below. It is further to be understood that the terms "group" and "radical" as used herein can be considered interchangeable.
[0069] "Alkyl" means a straight or branched chain saturated hydrocarbon group having 1 to 20 carbon atoms ("C 1-20 Refers to the radical of "alkyl"). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1-6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1-5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C 1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1-3 alkyl”). In some embodiments, an alkyl group has 1-2 carbon atoms (“C 1-2 alkyl”). In some embodiments, an alkyl group has one carbon atom (“C 1 alkyl”). C 1-6 Examples of alkyl groups include methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), iso-butyl (C 4 ), n-pentyl (C 5 ), 3-pentanyl (C 5 ), Amil (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), and n-hexyl (C 6 ) can be mentioned. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, i.e., unsubstituted (“unsubstituted alkyl”), or one or more substituents, for example, 1 to 4 substituents, 1 to 3 substituents, or 1 substituent (“substituted alkyl”). The common abbreviation for alkyl is Me(-CH 3 ), Et(-CH 2 CH 3 ), iPr(-CH(CH 3 ) 2 ), nPr(-CH 2 CH 2 CH 3 ), n-Bu(-CH 2 CH 2 CH 2 CH 3 ), or i-Bu(-CH 2 CH(CH 3 ) 2 ) can be mentioned.
[0070] "Alkylene" refers to a divalent saturated hydrocarbon. Alkylene is -(CH 2 ) n -,-(CH 2 )-,-(CH 2 ) 2 -,-(CH 2 ) 3 -,-(CH 2 ) 4 -,-(CH 2 ) 5 -,-(CH 2 ) 6 -,-(CH 2 ) 7 -,-(CH 2 ) 8 -,-(CH 2 ) 9 -, or-(CH 2 ) 10 - can be represented by In some embodiments, alkylene has the indicated number of carbon atoms, e.g., C 1 -C 4 alkylene, C 1 -C 3 alkylene, or C 1 -C 2 Can be alkylene. Unless otherwise specified, each instance of an alkylene group is independently optionally substituted, i.e., unsubstituted (“unsubstituted alkylene”) or halo, -NO 2 ,-OH,C 1 -C 6 Alkoxy, C 1 -C6 alkyl or C 1 -C 6 Substituted (“substituted alkylene”) with one or more substituents (e.g., 1 to 4 substituents, 1 to 3 substituents, or 1 substituent), which can be a cycloalkyl Ru. The abbreviation for alkylene is -(CH(CH 3 ))-,-(CH(CH 2 CH 3 ))-,-(CH(CH 2 CH 2 CH 3 ))-,-(CH(CH 2 CH 2 CH 2 CH 3 ))-,-(CH 2 CH(CH 2 CH 2 CH 2 CH 3 ))-,-(CH 2 CH 2 CH(CH 2 CH 2 CH 2 CH 3 ))-,-(CH(CH 3 )CH 2 )-,-(CH(CH 3 )CH 2 CH 2 )-,-(CH(CH 3 )CH 2 CH 2 CH 2 )-,-(CH 2 CH(CH 3 )CH 2 )-,-(CH 2 CH(CH 3 )CH 2 CH 2 )-, and-(CH 2 CH 2 CH(CH 3 )CH 2 CH 2 )- can be mentioned.
[0071] "Aryl" has 6 to 14 ring carbon atoms and 0 heteroatoms provided in the aromatic ring system ("C 6ー14 aryl) monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., with 6, 10, or 14 pi electrons shared within the cyclic array) ) refers to the radical. In some embodiments, an aryl group has 6 ring carbon atoms (“C 6 "aryl", e.g. phenyl). "Aryl" also includes ring systems in which an aryl ring, as defined herein, is fused with one or more carbocyclyl or heterocyclyl groups in which the radical or point of attachment is on the aryl ring. However, in such cases, the number of carbon atoms continues to specify the number of carbon atoms in the aryl ring system. Typical aryl groups include, but are not limited to, groups derived from benzene. Particular aryl groups include phenyl and indenyl. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (“unsubstituted aryl”), or one or more Substituted with a substituent (“substituted aryl”).
[0072] "Heteroaryl" means a 5- to 10-membered monocyclic or bicyclic 4n+2 aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms provided in the aromatic ring system (e.g. , with 6 or 10 π electrons shared in a cyclic array), where each heteroatom is independently selected from nitrogen, oxygen, and sulfur (a 5- to 10-membered heteroaryl). In heteroaryl groups containing one or more than one nitrogen atom, the point of attachment can be a carbon atom or a nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can contain one or more than one heteroatom in one or both rings. "Heteroaryl" includes a ring system, and a heteroaryl ring, as defined herein, is fused to one or more carbocyclyl or heterocyclyl groups, the point of attachment being on the heteroaryl ring, and that In such cases, the number of ring members continues to specify the number of ring members in the heteroaryl ring system.
[0073] In some embodiments, a heteroaryl group has 1 to 4 ring heteroatoms provided in an aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. . In some embodiments, a heteroaryl group is a 5- to 6-membered aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is , independently selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has one ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted heteroaryl") or one or more Substituted (“substituted heteroaryl”) with a number of substituents.
[0074] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively.
[0075] Examples of typical heteroaryls are: [ka] In the formula, each Z is carbonyl, N, NR 65 , O, and S, R 65 are independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 10 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl.
[0076] "Alkylene bridge" refers to a straight or branched chain divalent hydrocarbon bridge that connects two different carbons of the same cyclic structure. An alkylene bridge can connect any two carbons within a cyclic structure. In some embodiments, the alkylene bridge comprises the indicated number of carbon atoms, e.g., C 1 -C 6 Alkylene bridge, C 1 -C 5 Alkylene bridge, C 1 -C 4 Alkylene bridge, C 1 -C 3 alkylene bridge, or C 1 -C 2 It can be an alkylene bridge. Unless otherwise specified, each instance of an alkylene bridge is independently optionally substituted, i.e., unsubstituted (an "unsubstituted alkylene bridge") or halo, -NO 2 ,-OH,C 1 -C 6 Alkoxy, C 1 -C 6 alkyl or C 1 -C 6 Cycloalkyl can be substituted with one or more substituents (e.g., 1 to 4 substituents, 1 to 3 substituents, or 1 substituent (a "substituted alkylene bridge")) Examples of alkylene bridges include, but are not limited to, methylene, ethylene, propylene, tetramethylene, and n-butylene.
[0077] "Nitrogen-containing heteroaryl" refers to a monocyclic aromatic heterocyclic group containing at least one nitrogen atom. Exemplary nitrogen-containing heteroaryl groups include pyrrolyl, thiazolyl, isoxazolyl, pyrazinyl, imidazolyl, oxazolyl, pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyridyl), pyrimidinyl), pyridazinyl, triazolyl, triazinyl, tetrazolyl, azepinyl, azocynyl, dithiazinyl, and oxazinyl.
[0078] When used to describe a compound or a group present on a compound, "hetero" means that one or more carbon atoms in the compound or group are replaced by nitrogen, oxygen, or sulfur heteroatoms. means it has been replaced. Hetero is, for example, alkyl having 1 to 5, especially 1 to 3 heteroatoms, such as heteroalkyl, cycloalkyl, such as heterocyclyl, aryl, such as heteroaryl, cycloalkenyl, such as cycloheteroalkenyl. can be applied to any of the above-mentioned hydrocarbyl groups.
[0079] "Carbocyclyl" or "carbocyclic" means 3 to 10 ring carbon atoms ("C 3-10 "carbocyclyl") and non-aromatic cyclic hydrocarbon radicals having 0 heteroatoms. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3-8 carbocyclyl). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 carbocyclyl). Exemplary C 3-6 As a carbocyclyl group, cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), but are not limited to these. Exemplary C 3-8 As the carbocyclyl group, the above-mentioned C 3-6 Carbocyclyl group, as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ), but are not limited to these. Exemplary C 3-10 As the carbocyclyl group, the above-mentioned C 3-8 carbocyclyl group, as well as cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C 9 ), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ), but are not limited to these. As the foregoing examples illustrate, in certain embodiments, carbocyclyl groups are monocyclic ("monocyclic carbocyclyl") or fused, such as bicyclic systems ("bicyclic carbocyclyl"), It contains bridged or spiro ring systems and can be saturated or partially unsaturated. "Carbocyclyl" also includes a ring system, and a carbocyclyl ring, as defined herein, is fused to one or more aryl or heteroaryl groups, with the point of attachment on the carbocyclyl ring, and such , the number of carbons continues to specify the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently optionally substituted, i.e., unsubstituted (“unsubstituted carbocyclyl”) or with one or more Substituted with a substituent (“substituted carbocyclyl”). In certain embodiments, the carbocyclyl group is an unsubstituted C 3-10 It is carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C 3-10 It is carbocyclyl.
[0080] In some embodiments, “carbocyclyl” refers to a monocyclic saturated carbocyclyl group having 3 to 10 ring carbon atoms (“C 3-10 cycloalkyl). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3-8 cycloalkyl). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3-6 cycloalkyl). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5-6 cycloalkyl). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5-10 cycloalkyl). C 5-6 Examples of cycloalkyl groups include cyclopentyl (C 5 ) and cyclohexyl (C 5 ) can be mentioned. C 3-6 Examples of cycloalkyl groups include the aforementioned C 5-6 Cycloalkyl groups, as well as cyclopropyl (C 3 ) and cyclobutyl (C 4 ) can be mentioned. C 3-8 Examples of cycloalkyl groups include the aforementioned C 3-6 Cycloalkyl groups, as well as cycloheptyl (C 7 ), cyclooctyl (C 8 ) can be mentioned. Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (“unsubstituted cycloalkyl”) or substituted with one or more substituents (“substituted cycloalkyl”) or substituted with one or more substituents (“substituted cycloalkyl”). "alkyl"). In certain embodiments, the cycloalkyl group is an unsubstituted C 3-10 It is cycloalkyl. In certain embodiments, a cycloalkyl group is a substituted C 3-10 It is cycloalkyl.
[0081] "Heterocyclyl" or "heterocyclic" refers to a 3- to 10-membered non-aromatic ring system radical having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom independently represents selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("3-10 membered heterocyclyl"). In heterocyclyl groups containing one or more than one nitrogen atom, the point of attachment can be a carbon atom or a nitrogen atom, as valency permits. Heterocyclyl groups can be either fused, bridged or spiro ring systems, such as monocyclic ("monocyclic heterocyclyl") or bicyclic systems ("bicyclic heterocyclyl"), and can be saturated or or may be partially unsaturated. Heterocyclyl bicyclic ring systems can contain one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems, and a heterocyclyl ring, as defined herein, is fused to one or more carbocyclyl groups and the point of attachment is either the carbocyclyl ring or the heterocyclyl ring, or the ring A heterocyclyl ring on the system and as defined herein is fused with one or more aryl or heteroaryl groups and the point of attachment is on the heterocyclyl ring, in which case the ring members The number continues to specify the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (“unsubstituted heterocyclyl”) or with one or more substitutions. substituted with a group (“substituted heterocyclyl”). In certain embodiments, a heterocyclyl group is an unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3-10 membered heterocyclyl.
[0082] In some embodiments, a heterocyclyl group is a 5- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently nitrogen, oxygen, , sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5- to 8-membered non-aromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms, where each heteroatom is independently nitrogen, oxygen, , and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5- to 6-membered non-aromatic ring system having a ring carbon atom and 1 to 4 ring heteroatoms, where each heteroatom is independently nitrogen, oxygen, , and sulfur (“5-6 membered heterocyclyl”). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0083] Exemplary three-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azildinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. However, it is not limited to these. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. C 6 Exemplary 5-membered heterocyclyl groups fused to an aryl ring (also referred to herein as 5,6 bicyclic heterocycle) include indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl Examples include, but are not limited to, the following. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as 6,6 bicyclic heterocycle) include tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc. but not limited to.
[0084] A "nitrogen-containing heterocyclyl" group refers to a non-aromatic heterocyclic group containing at least one nitrogen atom. Exemplary nitrogen-containing heterocyclyl groups include morpholinyl, piperidinyl (e.g., 2-piperidinyl, 3-piperidinyl, and 4-piperidinyl), pyrrolidinyl (e.g., 2-pyrrolidinyl and 3-pyrrolidinyl), azetidinyl, pyrrolidonyl, imidazolinyl, imidazo Examples include, but are not limited to, lysinonyl, 2-pyrazolinyl, pyrazolidinyl, piperazinyl (eg, N-alkylpiperazine, eg, N-methylpiperazine).
[0085] "Alkoxy" is -OR 29 Refers to the group R 29 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. Particularly alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy groups, ie, alkoxy groups having 1 to 6 carbon atoms. Further particular alkoxy groups have 1 to 4 carbon atoms.
[0086] In certain embodiments, R 29 is amino, substituted amino, C 6 -C 10 Aryl, aryloxy, carboxyl, cyano, C 3 -C 10 Cycloalkyl, 4- to 10-membered heterocyclyl, halogen, 5- to 10-membered heteroaryl, hydroxyl, nitro, thioalkoxy, thioaryloxy, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S (O) 2 -, and aryl-S(O) 2 - groups having one or more substituents, such as 1 to 5 substituents, and especially 1 to 3 substituents, especially 1 substituent, selected from the group consisting of be. Exemplary "substituted alkoxy" groups include -O-(CH 2 ) t (C 6 -C 10 aryl), -O-(CH 2 ) t (5-10 membered heteroaryl), -O-(CH 2 ) t (C 3 -C 10 cycloalkyl), and -O-(CH 2 ) t (4-10 membered heterocyclyl), where t is an integer from 0 to 4, and any aryl, heteroaryl, cycloalkyl, or heterocyclyl group present is itself but unsubstituted C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 alkoxy, unsubstituted C 1 -C 4 haloalkyl, unsubstituted C 1 -C 4 hydroxyalkyl, or unsubstituted C 1 -C 4 Can be substituted with haloalkoxy or hydroxy. Certain exemplary "substituted alkoxy" groups are -OCF 3 ,-OCH 2 C.F. 3 ,-OCH 2 Ph, -OCH 2 -cyclopropyl, -OCH 2 CH 2 OH, and -OCH 2 CH 2 NMe 2 It is.
[0087] "Substituted amino" has the formula -N(R 38 ) 2 refers to the amino group of, in the formula, R 38 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or amino protected is a group and R 38 At least one of them is not hydrogen. In certain embodiments, each R 38 are independently hydrogen, C 1 -C 8 Alkyl, C 3 -C 8 alkenyl, C 3 -C 8 Alkynyl, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl, or C 3 -C 10 cycloalkyl; or C substituted with halo or hydroxy 1 -C 8 Alkyl; C substituted with halo or hydroxy 3 -C 8 C substituted with alkenyl, halo or hydroxy 3 -C 8 Alkynyl, or -(CH 2 ) t (C 6 -C 10 Aryl), -(CH 2 ) t (5-10 membered heteroaryl), -(CH 2 ) t (C 3 -C 10 cycloalkyl), or -(CH 2 ) t (4-10 membered heterocyclyl), t is an integer from 0 to 8, each of which is an unsubstituted C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 alkoxy, unsubstituted C 1 -C 4 haloalkyl, unsubstituted C 1 -C 4 hydroxyalkyl, or unsubstituted C 1 -C 4 R substituted by haloalkoxy or hydroxy, or both 38 are linked to form an alkylene group.
[0088] Exemplary "substituted amino" groups include -NR 39 -C 1 -C 8 Alkyl, -NR 39 -(CH 2 ) t (C 6 -C 10 aryl), -NR 39 -(CH 2 ) t (5-10 membered heteroaryl), -NR 39 -(CH 2 ) t (C 3 -C 10 cycloalkyl), and -NR 39 -(CH 2 ) t (4-10 membered heterocyclyl), t is an integer from 0 to 4, for example, 1 or 2, and each R 39 is independently H or C1 -C 8 Alkyl represents any alkyl group present which may itself be substituted by halo, substituted or unsubstituted amino, or hydroxy; any aryl, heteroaryl, cycloalkyl, or heterocyclyl group present is itself is unsubstituted C 1 -C 4 Alkyl, halo, unsubstituted C 1 -C 4 alkoxy, unsubstituted C 1 -C 4 haloalkyl, unsubstituted C 1 -C 4 hydroxyalkyl, or unsubstituted C 1 -C 4 May be substituted by haloalkyl or hydroxy. For the avoidance of doubt, the term "substituted amino" means an alkylamino group, a substituted alkylamino group, an alkylarylamino group, a substituted alkylarylamino group, an arylamino group, a substituted arylamino group, a dialkyl group, as defined below. Contains amino groups and substituted dialkylamino groups. Substituted amino includes both mono- and di-substituted amino groups.
[0089] "Haloalkoxy" refers to a haloalkyl group, as defined herein, attached through an oxygen bridge (oxygen of an alcohol radical).
[0090] "Halo" or "halogen" refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). In certain embodiments, a halo group is either fluoro or chloro.
[0091] "Haloalkyl" refers to an alkyl radical in which the alkyl group is substituted with one or more halogens. Typical haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, fluoromethyl, chloromethyl, dichloromethyl, dibromoethyl, tribromomethyl, tetrafluoroethyl, and the like.
[0092] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups as defined herein are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or " ``unsubstituted'' heterocyclyl, ``substituted'' or ``unsubstituted'' aryl, or ``substituted'' or ``unsubstituted'' heteroaryl group). Generally, the term "substituted," whether or not preceded by the term "optionally," means that at least one hydrogen (e.g., a carbon or nitrogen atom) present on a group is a permissible substitution. It is meant to be substituted with a group, eg, a substituent that, upon substitution, results in a stable compound, eg, a compound that does not spontaneously undergo transformation, such as by rearrangement, cyclization, removal, or other reactions. Unless otherwise indicated, a "substituted" group has substituents at one or more substitutable positions on the group and at two or more than two within any given structure. When positions are substituted, the substituents are either the same or different at each position. The term "substituted" is intended to include substitution of organic compounds with all permissible substituents, including any of the substituents described herein, that results in the formation of a stable compound. . This disclosure contemplates any and all such combinations to arrive at stable compounds. For purposes of this disclosure, a heteroatom such as nitrogen has a hydrogen substituent and / or any suitable substituent described herein that satisfies the valence of the heteroatom and results in the formation of a stable moiety. It is possible.
[0093] Exemplary carbon atom substituents include halogen, -CN, -NO 2 ,-N 3 ,-SO 2 H, -SO 3 H, -OH, -OR aa ,-ON(R bb ) 2 , -N(R bb ) 2 , -N(R bb ) 3 + X - , -N(OR cc )R bb , -SH, -SR aa ,-SSR cc , -C(=O)R aa ,-CO 2 H, -CHO, -C(OR cc ) 2 ,-CO 2 R aa , -OC(=O)R aa ,-OCO 2 R aa , -C(=O)N(R bb ) 2 , -OC(=O)N(R bb ) 2 ,-NR bb C(=O)R aa ,-NR bb C.O. 2 R aa ,-NR bb C(=O)N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb )OR aa , -OC(=NR bb )R aa , -OC(=NR bb )OR aa , -C(=NR bb )N(R bb ) 2 , -OC(=NR bb )N(R bb ) 2 ,-NR bb C(=NR bb )N(R bb ) 2 , -C(=O)NR bb S.O. 2 R aa ,-NR bb S.O. 2 R aa ,-SO 2 N(R bb ) 2 ,-SO 2 R aa ,-SO 2 OR aa ,-OSO 2 R aa , -S(=O)R aa , -OS(=O)R aa , -Si(R aa ) 3 ,-OSi(R aa ) 3 -C(=S)N(R bb ) 2 , -C(=O)SR aa , -C(=S)SR aa ,-SC(=S)SR aa ,-SC(=O)SR aa , -OC(=O)SR aa , -SC(=O)OR aa , -SC(=O)R aa , -P(=O) 2 R aa ,-OP(=O) 2 R aa , -P(=O)(R aa ) 2 , -OP(=O)(R aa ) 2 , -OP(=O)(OR cc ) 2 , -P(=O) 2 N(R bb ) 2 ,-OP(=O) 2 N(R bb ) 2 , -P(=O)(NR bb ) 2 , -OP(=O)(NR bb ) 2 ,-NR bb P(=O)(OR cc ) 2 ,-NR bb P(=O)(NR bb ) 2 , -P(R cc ) 2 , -P(R cc ) 3 ,-OP(R cc ) 2 ,-OP(R cc ) 3 , -B(R aa ) 2 , -B(OR cc ) 2 ,-BR aa (OR cc ), C 1-10 Alkyl, C 1-10 haloalkyl, C 2-10 alkenyl, C 2-10 Alkynyl, C 3-10 Carbocycloyl, 3-14 membered heterocyclyl, C 6-14 Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently 0, 1, 2, 3, 4 or 5 R dd or two geminal hydrogens on a carbon atom are substituted with a group =O, =S, =NN(R bb ) 2 ,=NNR bb C(=O)R aa ,=NNR bb C(=O)OR aa ,=NNR bb S(=O) 2 R aa ,=NR bb , or =NOR cc replaced with R aa Each example of C 1-10 Alkyl, C 1-10 haloalkyl, C 2-10 alkenyl, C 2-10Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5- to 14-membered heteroaryl, or 2 R aa The groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, and each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently 0, 1, 2 , 3, 4, or 5 R dd substituted with a group, R bb Each example is independently hydrogen, -OH, -OR aa , -N(R cc ) 2 , -CN, -C(=O)R aa , -C(=O)N(R cc ) 2 ,-CO 2 R aa ,-SO 2 R aa , -C(=NR cc )OR aa , -C(=NR cc )N(R cc ) 2 ,-SO 2 N(R cc ) 2 ,-SO 2 R cc ,-SO 2 OR cc ,-SOR aa , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S)SR cc , -P(=O) 2 R aa , -P(=O)(R aa ) 2 , -P(=O) 2 N(R cc ) 2 , -P(=O)(NR cc ) 2 ,C 1-10 Alkyl, C 1-10 haloalkyl, C 2-10 alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5- to 14-membered heteroaryl, or 2 R bb The groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, and each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently 0, 1, 2 , 3, 4, or 5 R dd substituted with a group, R cc Each example is independently hydrogen, C 1-10 Alkyl, C 1-10 haloalkyl, C 2-10 alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5- to 14-membered heteroaryl, or 2 R cc The groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, and each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently 0, 1, 2 , 3, 4, or 5 R dd substituted with a group, R dd Each example is independently a halogen, -CN, -NO 2 ,-N 3 ,-SO 2 H, -SO 3 H, -OH, -OR ee ,-ON(R ff ) 2 , -N(R ff ) 2 , -N(R ff ) 3 + X - ,-N(OR ee )R ff , -SH, -SR ee ,-SSR ee , -C(=O)R ee ,-CO 2 H, -CO 2 R ee , -OC(=O)R ee ,-OCO 2 R ee , -C(=O)N(R ff ) 2 , -OC(=O)N(R ff ) 2 ,-NR ff C(=O)R ee ,-NR ff C.O. 2 R ee ,-NR ff C(=O)N(R ff ) 2 , -C(=NR ff )OR ee , -OC(=NR ff )R ee , -OC(=NR ff )OR ee , -C(=NR ff )N(R ff ) 2 , -OC(=NR ff )N(R ff ) 2 ,-NR ff C(=NR ff )N(R ff ) 2 ,-NR ff S.O. 2 R ee ,-SO 2 N(R ff ) 2 ,-SO 2 R ee ,-SO 2 OR ee ,-OSO 2 R ee , -S(=O)R ee , -Si(R ee ) 3 ,-OSi(R ee ) 3 , -C(=S)N(R ff ) 2 , -C(=O)SR ee , -C(=S)SR ee ,-SC(=S)SR ee , -P(=O) 2 R ee , -P(=O)(R ee ) 2 , -OP(=O)(R ee ) 2 , -OP(=O)(OR ee ) 2 ,C 1-6 Alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently having 0, 1, 2, 3, 4, or 5 R gg substituted with a group or two geminal R dd The substituents can be combined to form =O or =S, R ee Each example of C 1-6 Alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 selected from aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, where each alkyl, alkenyl, alkynyl, carbocycloyl, heterocyclyl, aryl, and heteroaryl is independently 0, 1, 2, 3 , 4, or 5 R gg substituted with a group, R ff Each example is independently hydrogen, C 1-6 Alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl, and 5-10 membered heteroaryl, or 2 R ff The groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, and each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently 0, 1, 2 , 3, 4 or 5 R gg substituted with a group, R for each example gg are independently halogen, -CN, -NO 2 ,-N 3 ,-SO 2 H, -SO 3 H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 alkyl) 2 , -N(C 1-6 alkyl) 2 , -N(C 1-6 alkyl) 3 + X - , -NH(C 1-6 alkyl) 2 + X - ,-NH 2 (C 1-6 alkyl) + X - ,-NH 3 + X - , -N(OC 1-6 alkyl)(C 1-6 alkyl), -N(OH)(C 1-6alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO 2 H, -CO 2 (C 1-6 alkyl), -OC(=O)(C 1-6 alkyl), -OCO 2 (C 1-6 alkyl), -C(=O)NH 2 , -C(=O)N(C 1-6 alkyl) 2 , -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 alkyl), -NHCO 2 (C 1-6 alkyl), -NHC(=O)N(C 1-6 alkyl) 2 , -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH 2 , -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 alkyl) 2 , -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH 2 , -OC(=NH)N(C 1-6 alkyl) 2 , -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH 2 , -NHC(NH)N(C 1-6 alkyl) 2 , -NHC(=NH)NH 2 ,-NHSO 2 (C 1-6 alkyl), -SO 2 N(C 1-6 alkyl) 2 ,-SO 2 NH(C 1-6 alkyl), -SO 2 N.H. 2 ,-SO 2 C 1-6 Alkyl, -SO 2 O.C. 1-6 Alkyl, -OSO 2 C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl) 3 ,-OSi(C 1-6 alkyl) 3 -C(=S)N(C 1-6 alkyl) 2 , C(=S)NH(C 1-6 alkyl), C(=S)NH 2 , -C(=O)S(C 1-6 alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O) 2 (C 1-6 alkyl), -P(=O)(C 1-6 alkyl) 2 , -OP(=O)(C 1-6 alkyl) 2 , -OP(=O)(OC 1-6 alkyl) 2 ,C 1-6 Alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclyl, C 6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or two geminal R gg Substituents can be combined to form =O or =S, and X - is the counterion.
[0094] In certain embodiments, the substituents present on the oxygen atom are oxygen protecting groups (also referred to as hydroxyl protecting groups). As an oxygen protecting group, -R aa , -N(R bb ) 2 , -C(=O)SR aa , -C(=O)R aa ,-CO 2 R aa , -C(=O)N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb )OR aa , -C(=NR bb )N(R bb ) 2 , -S(=O)R aa ,-SO 2 R aa , -Si(R aa ) 3 , -P(R cc ) 2 , -P(R cc ) 3 , -P(=O) 2 R aa , -P(=O)(R aa ) 2 , -P(=O)(OR cc ) 2 , -P(=O) 2 N(R bb ) 2 , and -P(=O)(NR bb ) 2 Examples include, but are not limited to, R aa ,R bb , and R cc is as defined herein. Oxygen protecting groups are well known in the art and are described in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3, incorporated herein by reference. rd edition, John Wiley & Sons, 1999.
[0095] Exemplary oxygen protecting groups include methyl, methoxylmethyl (MOM), 2-methoxyethoxymethyl (MEM), benzyl (Bn), triisopropylsilyl (TIPS), t-butyldimethylsilyl (TBDMS), t-butyl These include, but are not limited to, methoxyphenylsilyl (TBMPS), methanesulfonate (mesylate), and tosylate (Ts).
[0096] In certain embodiments, the substituents present on the nitrogen atom are amino protecting groups (also referred to herein as nitrogen protecting groups). Amino protecting groups include -OH, -OR aa , -N(R cc ) 2 , -C(=O)R aa , -C(=O)OR aa , -C(=O)N(R cc ) 2 , -S(=O) 2 R aa , -C(=NR cc )R aa , -C(=NR cc )OR aa , -C(=NR cc )N(R cc ) 2 ,-SO 2 N(R cc ) 2 ,-SO 2 R cc ,-SO 2 OR cc ,-SOR aa , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S)SR cc ,C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkynyl, C 3-10 Carbocycloyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5- to 14-membered heteroaryl groups, each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently represents 0, 1, 2, 3 , 4, or 5 R dd substituted with a group, R aa ,R bb ,R cc , and R dd is as defined herein. Amino protecting groups are well known in the art and are described in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3, incorporated herein by reference. rd edition, John Wiley & Sons, 1999.
[0097] Exemplary amino protecting groups include, but are not limited to, amide groups (e.g., -C(=O)R aa ), 9-fluorenylmethyl carbamate (Fmoc), t-butyl carbamate (BOC), and benzyl carbamate (Cbz). aa ), p-toluenesulfonamide (Ts), methanesulfonamide (Ms), and N-[2-(trimethylsilyl)ethoxy]methylamine (SEM). S(=O) 2 R aa ), but are not limited to these.
[0098] other definitions "Pharmaceutically acceptable" means approved or capable of being approved by a federal regulatory agency, state government, or corresponding agency in a country other than the United States, or the United States for use in animals, more specifically humans. means listed in a pharmacopoeia or other recognized pharmacopoeia;
[0099] "Pharmaceutically acceptable salt" refers to a salt of a compound disclosed herein that is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and can be inorganic or organic acid and base addition salts. Specifically, such salts include (1) acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric; or acetic, propionic, hexanoic, cyclo Pentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoic acid)benzoic acid, cinnamic acid, Mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphor Sulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylbutyric acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxy Acid addition salts formed with organic acids such as naphthoic acid, salicylic acid, stearic acid, muconic acid; or (2) acidic protons present in the parent compound are linked to metal ions, e.g., alkali metal ions, alkaline earth ions, or Salts formed when replaced by aluminum ions or equivalent to organic bases such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc. are mentioned. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc., and when the compound contains basic functionality, hydrochloride, hydrobromide, tartrate, Included are salts of non-toxic organic or inorganic acids such as mesylate, acetate, maleate, oxalate, and the like. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counterion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like. See, eg, Berge, et al., J. Pharm. Sci. (1977) 66(1):1-79.
[0100] "Pharmaceutically acceptable carrier" refers to compositions, carriers, diluents, and reagents that are pharmaceutically acceptable materials that can be administered to or to a subject. A pharmaceutically acceptable carrier may be involved in carrying or transporting the subject agent from one organ or part of the body to another organ or part of the body. The carrier can be in the form of a solid, semisolid, or liquid diluent, cream, or capsule. The active ingredient can be mixed with excipients in amounts that are pharmaceutically acceptable and compatible with the active ingredient and suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, etc., and combinations thereof.
[0101] "Subjects" to which administration is contemplated include human subjects (i.e., male or female of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults). or older adults)), and / or non-human animals, e.g., mammals such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cows, pigs, horses, sheep, goats, rodents, cats, and / or dogs. These include, but are not limited to: In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal.
[0102] Disease, disorder, and condition are used interchangeably herein.
[0103] As used herein, the terms "treat," "treating," or "treatment" refer to the symptoms, clinical signs, and underlying symptoms of a condition in a manner that ameliorates or stabilizes the condition in question. Including reversing, alleviating, or stopping pathology. As used herein and as is well known in the art, "therapy" is an approach to obtaining beneficial or desired results, including clinical results. A beneficial or desired clinical outcome is the alleviation, amelioration, or reduction in the severity of one or more symptoms or conditions associated with a condition, whether detectable or undetectable. may include delaying progression, reducing the extent of the disease, stabilizing the disease state (i.e., not worsening), slowing or slowing the progression of the disease, improving or alleviating the disease state, and remission (partial or complete); Not limited to these. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Exemplary beneficial clinical results are described herein.
[0104] As used herein, unless otherwise specified, the term "prophylactic" contemplates an effect that occurs before the subject begins to suffer from the specified disease, disorder or condition.
[0105] Generally, an "effective amount" of a compound refers to an amount sufficient to elicit a desired biological response. As will be understood by those skilled in the art, an effective amount of a compound of the present disclosure will depend on the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject. may vary depending on factors. Effective amounts encompass therapeutic and prophylactic treatment.
[0106] The term "pharmaceutically effective amount," "therapeutically effective amount," or "therapeutically effective dose" refers to an amount that treats a disease in a patient, e.g., produces a beneficial and / or desirable change in the health of a patient suffering from a disease. Refers to an amount sufficient to treat, cure, inhibit or ameliorate a physiological response or condition, delay or minimize one or more symptoms associated with a disease, disorder, or condition. The full therapeutic effect does not necessarily occur with the administration of one dose, but may occur only after the administration of a series of doses. Accordingly, a therapeutically effective amount may be administered in one or more than one administration. The precise effective amount required by a subject will depend, for example, on the subject's size, health and age, the nature and extent of the disease, the therapeutic agent or combination of therapeutic agents selected for administration, and the mode of administration. . Those skilled in the art can readily determine the effective amount for a given situation by routine experimentation. The terms "pharmaceutically effective amount," "therapeutically effective amount," or "therapeutically effective dose" also refer to the amount necessary to ameliorate the clinical symptoms of a patient. A therapeutically effective amount of a compound also refers to an amount of a therapeutic agent that, alone or in combination with other therapies, provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" can include an amount that improves overall therapy, reduces or avoids a symptom or cause of a disease or condition, or enhances the therapeutic effectiveness of another therapeutic agent. can.
[0107] As used herein, and unless otherwise specified, a "prophylactically effective amount" of a compound refers to a "prophylactically effective amount" of a compound that prevents the disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition. or in an amount sufficient to prevent its recurrence. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other agents, that provides a prophylactic benefit in the prevention of a disease, disorder or condition. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or enhances the prophylactic effectiveness of another prophylactic agent.
[0108] As used herein, and unless otherwise specified, "pharmacokinetics" may be defined as the study of the absorption, distribution, metabolism, and excretion of a drug within the body. "Pharmacokinetics" also refers to the characteristic interactions of a drug with the body in terms of its absorption, distribution, metabolism, and excretion, or the way in which a drug is taken up, moved, and eliminated from the body. It can also be defined as a branch of pharmacology related to
[0109] “Administering” or “administering” a substance, compound or agent to a subject may be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or drug can be administered intravenously, intraarterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, intraocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and It may be administered transdermally (by absorption, eg, through skin ducts). The compound or drug may also be suitably introduced by rechargeable or biodegradable polymeric or other devices, such as patches and pumps, or formulations that provide extended, delayed or controlled release of the compound or drug. can be done. Administration can be carried out, for example, once, multiple times, and / or over one or more times over an extended period of time. In some embodiments, administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing the drug. For example, as used herein, a physician who instructs a patient to self-administer a drug, or has the drug administered by another, and / or provides a patient with a prescription for the drug, may administer. Where the method is part of a treatment regimen involving more than one agent or treatment modality, this disclosure contemplates that the agents may be administered at the same or different times and via the same or different routes of administration. Suitable methods of administering a substance, compound, or drug to a subject will depend on, for example, the age of the subject, whether the subject is active or inactive at the time of administration, whether the subject is cognitively impaired or functional at the time of administration. It will also depend on the extent of the disorder, the chemical and biological properties of the compound or drug (eg, solubility, digestibility, bioavailability, stability, and toxicity).
[0110] Compound In one aspect, the present disclosure provides compounds of Formula I. In some embodiments, the compounds inhibit CYP46A1 and can be used to treat neurodegenerative diseases, epilepsy, developmental and epileptic encephalopathies, psychiatric disorders, and convulsions. For example, in one aspect, described herein is a compound of formula I, [ka] or a pharmaceutically acceptable salt thereof, in which: R 1 However, C 6 -C 10 Aryl, C 3 -C 7 selected from the group consisting of cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 10-membered heteroaryl, R 1 But if necessary, 1 to 4 R 4 replaced with R a and R b each independently H, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy, or R a and R b But along with the carbons to which they bond, C 3 -C 7 may form cycloalkyl or R a and R b but together they are oxo, R c ,R d ,R e , and R f Each of them is independently H, C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy, or R c and R e But along with the carbons to which they bond, C 1 -C 3 may form an alkylene bridge or R d and R f But along with the carbons to which they bond, C 1 -C 3 can form alkylene bridges, Each R 4 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , -S(O) 2 R 5 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 6 -C 10 Aryl, C 3 -C 7 selected from the group consisting of cycloalkyl, and 3- to 7-membered heterocyclyl, Each R 5 but independently, H and C 1 -C 6 selected from alkyl, Each R 2 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy; Each R 3 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 3 -C 7 cycloalkyl, and C 1 -C 6 selected from the group consisting of haloalkoxy; A is a 5- to 6-membered nitrogen-containing heteroaryl, B is C 6 -C 10 selected from aryls and 5-6 membered heteroaryls, m is 0, 1, 2, or 3; n is 0, 1, 2, 3, or 4; o is 0, 1, 2, or 3; p is 0, 1, or 2; However, if n is 0, R 1 is not 4-cyanophenyl or 4-trifluoromethylphenyl, or a pharmaceutically acceptable salt thereof.
[0111] In some embodiments, the compound of Formula I is [ka] or a pharmaceutically acceptable salt thereof.
[0112] In some embodiments, the compound of Formula I is [ka] or a pharmaceutically acceptable salt thereof.
[0113] In some embodiments, the compound of formula I is a compound of formula I, [ka] or a pharmaceutically acceptable salt thereof, in which: R 1 However, C 6 -C 10 Aryl, C 3 -C 7 selected from the group consisting of cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 10-membered heteroaryl, R 1 But if necessary, 1 to 4 R 4 replaced with R a and R b each independently H, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy, or R a and R b But along with the carbons to which they bond, C 3 -C 7 may form cycloalkyl or R a and R b but together they are oxo, R c ,R d ,R e , and R f Each of them is independently H, C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy, or R c and R e But along with the carbons to which they bond, C 1 -C 3 may form an alkylene bridge or R d and R f But along with the carbons to which they bond, C 1 -C 3 can form alkylene bridges, Each R 4 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , -S(O) 2 R 5 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 6 -C 10 Aryl, C3 -C 7 selected from the group consisting of cycloalkyl, and 3- to 7-membered heterocyclyl, Each R 5 but independently, H and C 1 -C 6 selected from alkyl, Each R 2 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, and C 1 -C 6 selected from the group consisting of haloalkoxy; Each R 3 are, independently, halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 3 -C 7 cycloalkyl, and C 1 -C 6 selected from the group consisting of haloalkoxy; A is a 5- to 6-membered nitrogen-containing heteroaryl, B is C 6 -C 10 selected from aryls and 5-6 membered heteroaryls, m is 0, 1, 2, or 3; n is 0, 1, 2, 3, or 4; o is 0, 1, 2, or 3; p is 0, 1, or 2; However, if n is 0, R 1 is not 4-cyanophenyl or 4-trifluoromethylphenyl, and further the compound of formula I is [ka] or a pharmaceutically acceptable salt thereof.
[0114] In some embodiments, the compound of formula I is a compound of formula I-a, [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 ,R 2 ,R 3 , m, n, and o are as defined herein.
[0115] In some embodiments, the compound of formula I-a is a compound of formula I-a-1 [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 , and n are as defined herein.
[0116] In some embodiments, the compound of formula I-a is a compound of formula I-a-2 [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 ,R 2 , m, and n are as defined herein.
[0117] In some embodiments, the compound of formula I-a is a compound of formula I-a-3 [ka] or a pharmaceutically acceptable salt thereof, In the formula, A, B, R 1 ,R 3 , n, and o are as defined herein.
[0118] In some embodiments, the compound of formula I is a compound of formula I-b, [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 ,R 2 ,R 3 ,R a ,R b , m, and o are as defined herein.
[0119] In some embodiments, the compound of formula I-b is a compound of formula I-b-1, [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 ,R a , and R b is as defined herein.
[0120] In some embodiments, the compound of formula I-b is a compound of formula I-b-2, [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 ,R 2 ,R a ,R b , and m are as defined herein.
[0121] In some embodiments, the compound of formula I-b is a compound of formula I-b-3, [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 ,R 3 ,R a ,R b , and o are as defined herein.
[0122] In some embodiments, the compound of formula I is a compound of formula I-c, [ka] or a pharmaceutically acceptable salt thereof, In the formula, A, B, R 1 ,R 2 ,R 3 ,R c , m, and o are as defined herein.
[0123] In some embodiments, the compound of formula I-c is a compound of formula I-c-1, [ka] or a pharmaceutically acceptable salt thereof, In the formula, A, B, R 1 , and R C is as defined herein.
[0124] In some embodiments, the compound of formula I-c is a compound of formula I-c-2, [ka] or a pharmaceutically acceptable salt thereof, In the formula, A, B, R 1 ,R 2 ,R c , and m are as defined herein.
[0125] In some embodiments, the compound of formula I-c is a compound of formula I-c-3, [ka] or a pharmaceutically acceptable salt thereof, In the formula, A, B, R 1 ,R 3 ,R c , and o are as defined herein.
[0126] In some embodiments, the compound of formula I is a compound of formula I-d, [ka] or a pharmaceutically acceptable salt thereof, In the formula, A, B, R 1 ,R 2 ,R 3 , m, and o are as defined herein.
[0127] In some embodiments, the compound of formula I is a compound of formula I-e, [ka] or a pharmaceutically acceptable salt thereof, where A, B, R 1 ,R 2 ,R 3 , m, and o are as defined herein.
[0128] In some embodiments, the compound of formula I is a compound of formula I-f, [ka] or a pharmaceutically acceptable salt thereof, In the formula, A, B, R 1 ,R 2 ,R 3 , m, and o are as defined herein.
[0129] R1 unit In some embodiments, R 1 is the replacement C 6 -C 10 It is an aryl. In some embodiments, R 1 is an unsubstituted C 6 -C 10 It is an aryl. In some embodiments, R 1 is the replacement C 6 It is an aryl. In some embodiments, R 1 is an unsubstituted C 6 It is an aryl.
[0130] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0131] In some embodiments, R 1 teeth, [ka] , where each R 4 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , -S(O) 2 R 5 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 6 -C 10 Aryl, C 3 -C 7 cycloalkyl, or 3- to 7-membered heterocyclyl, each R 5 is independently H or C 1 -C 6 is alkyl and q is 0, 1, 2, or 3.
[0132] In some embodiments, R 1 teeth, [ka] It is.
[0133] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0134] In certain embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0135] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0136] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0137] In some embodiments, R 1 is a substituted 5- to 10-membered heteroaryl. In some embodiments, R 1 is an unsubstituted 5- to 10-membered heteroaryl. In some embodiments, R 1 is a substituted 5-membered heteroaryl. In some embodiments, R 1 is a substituted 6-membered heteroaryl. In some embodiments, R 1is an unsubstituted 5-membered heteroaryl. In some embodiments, R 1 is an unsubstituted 6-membered heteroaryl.
[0138] In some embodiments, R 1 is pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyridazinyl, pyrimidinyl, 2-pyrimidinyl, 4-pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, tetrazolyl, azocinyl, dithiazinyl, or oxazinyl. In some embodiments, R 1 is pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyridazinyl, pyrimidinyl, 2-pyrimidinyl, 4-pyrimidinyl, pyridazinyl, or pyrazinyl. In some embodiments, R 1 is pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, tetrazolyl, azosinyl, dithiazinyl, or oxazinyl. In some embodiments, R 1 is pyridyl, pyridinyl, pyridazinyl, pyrimidinyl, or pyrazinyl. In some embodiments, R 1 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, or 4-pyrimidinyl.
[0139] In some embodiments, R 1 teeth, [ka] , where each X is independently CH or N, and H of CH is R 4 may be substituted with one or more instances of each R 4 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, C 6 -C 10 Aryl, C 3 -C 7 cycloalkyl, or 3- to 7-membered heterocyclyl, each R 5 is independently H or C 1 -C 6 It is an alkyl.
[0140] In some embodiments, R 1 teeth, [ka] It is.
[0141] In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0142] In some embodiments, R 1 teeth, [ka] It is.
[0143] In some embodiments, R 1 teeth, [ka] It is.
[0144] In some embodiments, R 1 teeth, [ka] It is.
[0145] In some embodiments, R 1 teeth, [ka] It is.
[0146] In some embodiments, R 1 teeth, [ka] It is.
[0147] In some embodiments, R 1 teeth, [ka] It is.
[0148] In some embodiments, R 1 teeth, [ka] It is.
[0149] In some embodiments, R 1 teeth, [ka] It is.
[0150] In some embodiments, R 1 is the replacement C 3 -C 7 It is cycloalkyl. In some embodiments, R 1 is an unsubstituted C 3 -C 7 It is cycloalkyl. In some embodiments, R 1 is cyclopropyl or cyclobutyl. In some embodiments, R 1 teeth, [ka] It is. In some embodiments, R 1 teeth, [ka] It is.
[0151] In some embodiments, R 1 is a substituted 3- to 7-membered heterocyclyl. In some embodiments, R 1 is an unsubstituted 3- to 7-membered heterocyclyl. In some embodiments, R 1 is tetrahydrofuran, tetrahydropyran, pyrrolidine, piperidine, piperazine, dioxolane, dioxane, thiomorpholine, or dithiane. In some embodiments, R 1 is tetrahydrofuran or tetrahydropyran. In some embodiments, R 1 teeth, [ka] It is.
[0152] R 4 basis In some embodiments, each R 4 are, independently, halo, -CN, substituted C 1 -C 6 Alkyl, substituted C 1 -C 6 alkoxy, or substituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are, independently, halo, -CN, substituted C 1 -C 6 Alkyl, substituted C 1 -C 6 alkoxy, or substituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are, independently, halo, -CN, substituted C 1 -C 6 Alkyl, substituted C 1 -C 6 alkoxy, or substituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are, independently, halo, -CN, -CF 3 ,-OCF 3 , or cyclopropyl. In some embodiments, each R 4are independently Cl, F, Br, or I. In some embodiments, each R 4 are independently Cl or F.
[0153] In some embodiments, each R 4 is, independently, the permutation C 1 -C 6 Alkyl, substituted C 1 -C 6 alkoxy, or substituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 is independently, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, or unsubstituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 is, independently, halo, -NH 2 , -NH(C 1 -C 6 alkyl), -N(C 1 -C 6 alkyl) 2 ,C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 haloalkoxy, or C 6 -C 10 It is an aryl. In some embodiments, each R 4 is independently, halo, C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 haloalkoxy, or C 6 -C 10 It is an aryl. In some embodiments, each R 4 are independently halo, -CN, -CH 3 ,-CH 2 CH 3 ,-CF 3 ,-OCH 3 ,-OCF 3 , -C(CH 3 ) 2 OH, or -C 6 H 5 It is.
[0154] In some embodiments, each R 4 are independently halo, substituted or unsubstituted C 1 -C 6 Alkyl or -CN. In some embodiments, each R 4 are, independently, halo, -CN, unsubstituted C 1 -C 6 alkyl, or C 1 -C 6 It is ahaloalkyl. In some embodiments, each R 4 are independently halo, -CN, -CH 3 ,-CF 3 ,-CH 2 F, or -CHF 2 It is. In some embodiments, each R 4 are independently F, Cl, -CN, -CH 3 ,-CF 3 ,-CH 2 F, or -CHF 2 It is.
[0155] In some embodiments, each R 4 are independently halo, -CN, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, or substituted or unsubstituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are, independently, halo, -CN, unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, unsubstituted C 1 -C 6 Alkoxy, C 1 -C 6 haloalkoxy, or unsubstituted C 3 -C 7 It is cycloalkyl. In some embodiments, each R 4 are independently halo, -CN, -CH 3 ,-CF 3 ,-CH 2 F, -CHF 2 ,-OCH 3 ,-OCF 3 , or cyclopropyl. In some embodiments, each R 4 are independently -F, -Cl, -CN, -CH 3 ,-CF 3 ,-CH 2 F, -CHF 2 ,-OCF 3 , or cyclopropyl.
[0156] B group In some embodiments, B is [ka] , where each R 6 is independently N or CR 6a and R 6a is H or R 2 and ** is the bonding point with carbonyl, * is the connection point with A.
[0157] In some embodiments, R 2 is halo, -CN, -OH, -NO 2 ,-CH 3 ,-CH 2 CH 3 ,-CHF 2 ,-CF 3 ,-OCF 3 ,-OCH 3 ,-OCH 2 CH 3 , or -OCH 2 C.F. 3 It is. In some embodiments, up to 2 R 6 can be N and R 6 Another occurrence of is CH.
[0158] In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0159] In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0160] In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0161] In certain embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A. In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0162] In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0163] In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0164] In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0165] In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A. In some embodiments, B is [ka] and in the formula, ** is the bonding point with carbonyl, * is the connection point with A.
[0166] R 2 base In some embodiments, R 2 is halo, -CN, -OH, -NO 2 ,-CH 3 ,-CH 2 CH 3 , cyclopropyl, -CHF 2 ,-CF 3 ,-OCF 3 ,-OCH 3 ,-OCH 2 CH 3 , or -OCH 2 C.F. 3 It is. In some embodiments, R 2 is -CN.
[0167] A group In some embodiments, A is pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazinyl, tetrazolyl, oxazolyl, isoxazolyl, or thiozolyl. In embodiments, A is pyridinyloxazolyl, imidazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, or triazinyl. In some embodiments, A is [ka] , where each R 7 are independently N or CH, up to two R 7 can be N and R 7 Another occurrence of is CH. In some embodiments, the hydrogen of CH is R 3 can be replaced with
[0168] In some embodiments, A is [ka] It is. In some embodiments, A is [ka] It is. In some embodiments, A is [ka] It is.
[0169] n In some embodiments, n is 4. In some embodiments, n is 3. In some embodiments, n is 2. In some embodiments, n is 1. In some embodiments, n is 0.
[0170] In some embodiments, n is 1 and R a is C 1 -C 6 is alkyl and R b is H. In some embodiments, n is 1 and R a is ethyl and R b is H. In some embodiments, n is 1 and R a is methyl and R b is H. In some embodiments, n is 1 and R a is -OH and R b is H. In some embodiments, n is 1 and R a and R b together form oxo. In some embodiments, n is 1 and R a and R b are both H. In some embodiments, n is 1 and R a and R b together with the carbons to which they are attached form cyclopropyl.
[0171] m In some embodiments, m is 3. In some embodiments, m is 2. In some embodiments, m is 1. In some embodiments, m is 0.
[0172] o In some embodiments, o is 3. In some embodiments, o is 2. In some embodiments, o is 1. In some embodiments, o is 0.
[0173] p In some embodiments, p is 2. In some embodiments, p is 1. In some embodiments, p is 0.
[0174] In some embodiments, p is 1 and R c ,R d ,R e and R f is H. In some embodiments, p is 1 and R c is methyl and R d ,R e , and R f is H. In some embodiments, p is 1 and R c and R e is H and R d and R f are, along with the carbons to which they bond, C 1 -C 3 Forms an alkylene bridge. In some embodiments, p is 1 and R d and R f is H and R c and R e are, along with the carbons to which they bond, C 1 -C 3 Forms an alkylene bridge. In some embodiments, p is 0 and R c ,R d , and R f is H.
[0175] q In some embodiments, q is 3. In some embodiments, q is 2. In some embodiments, q is 1. In some embodiments, q is 0.
[0176] In some embodiments, the compound is any one of the compounds in Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13]
[0177] Alternative embodiment In alternative embodiments, compounds of Formula I may also contain one or more than one isotopic substitution. For example, hydrogen is 2 H (D or deuterium) or 3 Carbon may be substituted by H (T or tritium), e.g. 13 C or 14 C may be substituted, and oxygen may be substituted by, for example, 18 Nitrogen may be substituted by O, e.g. 15 Can be substituted with N, etc. In other embodiments, specific isotopes (e.g. 3 H, 13 C, 14 C, 18 O, or 15 N) is at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35% of the total isotopic abundance of the element occupying a particular site in the compound , at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or Can represent at least 99.9%.
[0178] pharmaceutical composition In another aspect, the disclosure provides a pharmaceutical composition comprising a compound of the disclosure (e.g., a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient) . Compounds of Formula I can be used to treat certain disorders described herein.
[0179] In certain embodiments, a compound of the present disclosure is provided in an effective amount in a pharmaceutical composition. In certain embodiments, compounds of the present disclosure are provided in a therapeutically effective amount. In certain embodiments, compounds of the present disclosure are provided in a prophylactically effective amount.
[0180] In certain embodiments, the pharmaceutical composition comprises an effective amount of the active ingredient. In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of an active ingredient. In certain embodiments, the pharmaceutical composition comprises a prophylactically effective amount of the active ingredient.
[0181] The pharmaceutical compositions provided herein can be administered orally (enterally), parenterally (by injection), rectally, transdermally, intradermally, intrathecally, subcutaneously (SC), Administration can be by a variety of routes including, but not limited to, intravenous (IV), intramuscular (IM), and intranasal administration.
[0182] Generally, the compounds provided herein are administered in an effective amount. The actual amount of compound administered will typically depend on the condition being treated, the route of administration chosen, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms. determined by the physician in the light of the relevant circumstances, including:
[0183] The pharmaceutical compositions provided herein can also be administered chronically ("chronic administration"). Chronic administration refers to administering a compound or its pharmaceutical composition over an extended period of time, such as for example, 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, or for example, for the lifetime of the subject. may continue indefinitely. In certain embodiments, chronic administration is intended to provide a constant level of the compound in the blood, eg, over an extended period of time and within a therapeutic window.
[0184] The pharmaceutical compositions of the present disclosure can further be delivered using a variety of methods of administration. For example, in certain embodiments, the pharmaceutical composition may be given as a bolus, eg, to increase the concentration of the compound in the blood to an effective level. The placement of the bolus dose depends on the desired systemic levels of the active ingredient throughout the body, for example, an intramuscular or subcutaneous bolus dose allows a slow release of the active ingredient, whereas a bolus dose delivered directly into the vein A bolus (e.g., via an IV infusion) allows for much faster delivery, rapidly raising the concentration of active ingredient in the blood to an effective level. In other embodiments, the pharmaceutical composition may be administered as a continuous infusion, such as by IV infusion, to provide maintenance of a steady state concentration of the active ingredient within the body of the subject. Furthermore, in yet still other embodiments, the pharmaceutical composition may be initially administered as a bolus dose followed by continuous infusion.
[0185] Compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage form to facilitate accurate dosing. The term "unit dosage form" refers to physically discrete units suitable as unit dosage forms for human subjects and other mammals, each unit comprising: Contains a predetermined amount of active substance calculated to produce the desired therapeutic effect. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. for solid compositions. In such compositions, the compound is usually a minor component (about 0.1% to about 50% by weight, preferably about 1% to about 40% by weight), with the remainder being sufficient to form the desired dosage form. Various vehicles or excipients and processing aids are useful.
[0186] For oral administration, a typical regimen is 1 to 5, especially 2 to 4, typically 3 oral administrations per day. Using these dosing patterns, each dose provides about 0.01 to about 20 mg / kg of a compound provided by the invention, with preferred doses each providing about 0.1 to about 10 mg / kg, particularly about 1 to about Provides 5mg / kg.
[0187] Transdermal doses are generally selected to provide similar or lower blood levels than those achieved using injectable doses, and generally range from about 0.01 to about 20% by weight, preferably from about 0.1 to about The amount ranges from 20% by weight, preferably from about 0.1 to about 10%, more preferably from about 0.5 to about 15%.
[0188] Injection dose levels range from about 0.1 mg / kg / hour to at least 20 mg / kg / hour, all for about 1 to about 120 hours, especially 24 to 96 hours. A preloading bolus of about 0.1 mg / kg to about 10 mg / kg or more may be administered to achieve appropriate steady state levels. The maximum total dose is not expected to exceed about 5 g / day for a 40-80 kg human patient.
[0189] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors, and the like. The solid form may, for example, contain any of the following ingredients or compounds of similar nature: a binder such as crystalline cellulose, gum tragatanth, or gelatin, an excipient such as starch or lactose, alginic acid, primogel, or corn starch. may include disintegrants such as magnesium stearate, lubricants such as colloidal silicon dioxide, sweetening agents such as sucrose or saccharin, or flavoring agents such as peppermint, methyl salicylate, or orange flavor.
[0190] Injectable compositions are typically based on sterile saline or phosphate buffered saline for injection or other injectable excipients known in the art. As mentioned above, the active compound in such compositions is typically a minor ingredient, often about 0.05-10% by weight, with the remainder being injectable excipients and the like.
[0191] Transdermal compositions are typically formulated as topical ointments or creams containing the active ingredient. When formulated as an ointment, the active ingredient is typically combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream, for example with an oil-in-water cream base. Such transdermal formulations are well known in the art and generally include additional ingredients to enhance skin penetration of the active ingredient or formulation stability. All such known transdermal formulations and ingredients are included within the scope provided herein.
[0192] Compounds provided herein can also be administered by transdermal devices. Thus, transdermal administration can be accomplished using patches of either the reservoir or porous membrane type, or of the solid matrix variety.
[0193] The above-described components of orally administrable, injectable, or topically administrable compositions are merely representative. Other materials, processing techniques, etc. are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.
[0194] Compounds of the present disclosure can also be administered in sustained release form or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.
[0195] The disclosure also relates to pharmaceutically acceptable acid addition salts of the compounds of the disclosure. Acids that can be used to prepare pharmaceutically acceptable salts include non-toxic acid addition salts, i.e. hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, Contains pharmacologically acceptable anions such as phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, paratoluenesulfonate It forms a salt that is
[0196] In another aspect, the disclosure provides pharmaceutical compositions comprising a compound of the disclosure and a pharmaceutically acceptable excipient, eg, a composition suitable for injection, such as intravenous (IV) administration.
[0197] Pharmaceutically acceptable excipients include any and all diluents or other liquid vehicles, dispersing or suspending aids, surface active agents, suitable for the particular dosage form desired, e.g. injectables. agent, isotonic agent, preservative, lubricant, etc. General considerations in the formulation and / or manufacture of pharmaceutical compositions are discussed, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E.W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy,21 st Edition (Lippincott Williams & Wilkins, 2005).
[0198] Injectable preparations, for example, sterile injectable aqueous suspensions, may be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Exemplary excipients that can be used include, but are not limited to, water, sterile or phosphate buffered saline, or Ringer's solution.
[0199] Injectable compositions contain a sterilizing agent in the form of a sterile solid composition which can be, for example, filtered through a bacteria-retaining filter or dissolved or dispersed in sterile water or other sterile injectable medium before use. Can be sterilized by incorporation.
[0200] Generally, the compounds provided herein are administered in an effective amount. The actual amount of compound administered will typically depend on the condition being treated, the route of administration chosen, the actual compound administered, the individual patient's age, weight, response, and the severity of the patient's symptoms. determined by the physician in the light of the relevant circumstances, including:
[0201] The compositions are presented in unit dosage form to facilitate accurate dosing. The term "unit dosage form" refers to physically discrete units suitable as unit dosage forms for human subjects and other mammals, each unit comprising: Contains a predetermined amount of active substance calculated to produce the desired therapeutic effect. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of liquid compositions. In such compositions, the compound is usually a minor component (about 0.1% to about 50% by weight, preferably about 1% to about 40% by weight), with the remainder providing the desired dosage form. Various vehicles or carriers and processing aids are useful in the formation.
[0202] The compounds provided herein can be administered as the sole active agent or in combination with other active agents. In one aspect, the disclosure provides a combination of a compound of the disclosure and another pharmaceutically active agent. Combined administration can proceed by any technique apparent to those skilled in the art, including, for example, separate, sequential, simultaneous, and alternating administration.
[0203] Although the description of pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions that are suitable for administration to humans, such compositions are generally suitable for administration to animals of any kind. It will be understood by those skilled in the art that this is suitable. The modification of pharmaceutical compositions suitable for human administration to make the compositions suitable for administration to a variety of animals is well understood and can be accomplished by those skilled in the art using routine experimentation. Such modifications can be designed and / or implemented. General considerations in the formulation and / or manufacture of pharmaceutical compositions are discussed, for example, in Remington: The Science and Practice of Pharmacy 21. st ed., Lippincott Williams & Wilkins, 2005.
[0204] In one aspect, a kit is provided that includes a composition (eg, a solid composition) that includes a compound of Formula I.
[0205] Usage and treatment One aspect of the present disclosure relates to compounds that may be useful as therapeutic agents for the treatment of diseases associated with inhibition of CYP46A1 (e.g., convulsions, neurodegenerative diseases, epilepsy, schizophrenia, and autism spectrum disorders). . For example, in aspects of the present disclosure, provided herein are methods of treating a disorder in a subject in need of treatment, the methods comprising administering to the subject a compound of Formula I as defined herein. comprising administering to the subject a therapeutically effective amount of a compound or composition described herein, including. Examples of disorders that can be treated by compounds include diseases associated with inhibition of CYP46A1 (e.g., convulsions, neurodegenerative diseases, epilepsy, and schizophrenia), neurodegenerative diseases, epilepsy, psychiatric disorders (e.g., schizophrenia, and autism spectrum disorders), convulsions, and developmental and epileptic encephalopathies.
[0206] In some embodiments, the disease or disorder involving inhibition of CYP46A1 is a neurodegenerative disorder. In some embodiments, the neurodegenerative disease consists of Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, stroke, glaucoma, and multiple sclerosis selected from the group. In certain embodiments, the disease or disorder involving inhibition of CYP46A1 is epilepsy. In certain embodiments, diseases or disorders involving inhibition of CYP46A1 are developmental and epileptic encephalopathies. In embodiments, the mental disorder is selected from the group consisting of schizophrenia, delusional disorder, schizoaffective disorder, depression, and autism spectrum disorder. In embodiments, the disease or disorder involving inhibition of CYP46A1 is convulsions.
[0207] In certain embodiments, the compound is administered chronically to a subject. In certain embodiments, the compound is administered to a subject orally, subcutaneously, intramuscularly, or intravenously. In some embodiments, the compound is administered by the oral route of administration.
[0208] In one aspect, the disclosure provides a compound of the disclosure, a compound of the disclosure or a pharmaceutically acceptable salt thereof, or a compound of the disclosure or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or disorder involving inhibition of CYP46A1. A pharmaceutically acceptable composition comprising a pharmaceutically acceptable salt is provided. Examples of disorders that can be treated by compounds include diseases associated with inhibition of CYP46A1 (e.g., convulsions, neurodegenerative diseases, epilepsy, and schizophrenia), neurodegenerative diseases, epilepsy, psychiatric disorders (e.g., schizophrenia, and autism spectrum disorders), convulsions, and developmental and epileptic encephalopathies.
[0209] In one aspect, the disclosure provides the use of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease or disorder associated with inhibition of CYP46A1. Examples of disorders that can be treated by compounds include diseases associated with inhibition of CYP46A1 (e.g., convulsions, neurodegenerative diseases, epilepsy, and schizophrenia), neurodegenerative diseases, epilepsy, psychiatric disorders (e.g., schizophrenia, and autism spectrum disorders), convulsions, and developmental and epileptic encephalopathies.
[0210] Neurodegenerative diseases and disorders A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition comprised of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, includes a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as described herein. Can be used in methods such as treating neurodegenerative diseases and disorders.
[0211] The term "neurodegenerative disease" includes diseases and disorders associated with progressive loss of neuronal structure or function, or death of neurons. Neurodegenerative diseases and disorders include Alzheimer's disease (including associated symptoms of mild, moderate, or severe cognitive impairment), amyotrophic lateral sclerosis (ALS), anoxic and ischemic insults, ataxia and convulsions. (convulsion) (including the treatment and prevention and prophylaxis of seizures caused by drugs used to treat schizoaffective disorder or schizophrenia), benign amnesia, cerebral edema, McLeod neuroacanthocytic syndrome (MLS) ), cerebellar ataxia, closed head injury, coma, contusion (e.g. spinal cord injury and head injury), dementia including multi-infarct dementia and senile dementia, impaired consciousness, Down syndrome, Drug-induced or drug-induced parkinsonism (neurally-induced acute akathisia, acute dystonia, parkinsonism, or tardive dyskinesia, neuroleptic malignant syndrome, or drug-induced postural tremor), epilepsy, fragile X syndrome , Gilles de la Tourette syndrome, head trauma, hearing impairment and loss, Huntington's disease, Lennox syndrome, levodopa-induced dyskinesia, mental retardation, akinesia and akinesia (rigidity) syndrome (basal ganglia calcification, corticobasal movement disorders including nuclear degeneration, multiple system atrophy, parkinsonism-ALS dementia complex, Parkinson's disease, postencephalitic parkinsonism, and progressive supranuclear palsy; chorea (benign hereditary chorea; drug-induced chorea, hemiballism, Huntington's disease, neuroacanthocytosis, Sydenham's chorea, and symptomatic chorea), dyskinesias (including tics such as complex tics, simple tics, and symptomatic tics), myoclonus (including generalized myoclonus, and focal cycloclonus), tremor (such as resting tremor, postural tremor, and intention tremor), and dystonia (axial dystonia, dystonic cramps, hemiplegic dystonia) muscle spasms and disorders associated with muscle spasm or muscle weakness, including paroxysmal dystonia, and focal dystonias such as blepharospasm, oromandibular dysphonia, spasmodic dysphonia, and torticollis; Ocular damage, neurological damage including retinopathy or macular degeneration, stroke, thrombotic stroke, hemorrhagic stroke, cerebral ischemia, cerebrovascular spasm, hypoglycemia, memory loss, hypoxia, anoxia, perinatal asphyxia and Neurotoxic damage following cardiac arrest, glaucoma (including associated symptoms of blindness, normal-tension visual field constriction), Parkinson's disease, epileptic seizures, status epilepticus, stroke, tinnitus, tubular sclerosis, and viral infection-induced neurodegeneration. (eg, caused by acquired immunodeficiency syndrome (AIDS) and encephalopathy). Neurodegenerative diseases include neurotoxicity following stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebrovascular spasm, hypoglycemia, memory loss, hypoxia, anoxia, perinatal asphyxia, and cardiac arrest. Also includes, but is not limited to, damage. Methods of treating or preventing neurodegenerative diseases also include treating or preventing the loss of neuronal function that is characteristic of neurodegenerative disorders.
[0212] mental disorder A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition comprised of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is described herein. For example, in the treatment of mental disorders.
[0213] The term "mental disorder" refers to a clinically significant impairment in an individual's cognition, emotional regulation, or behavior that reflects a dysfunction in the underlying psychological, biological, or developmental processes of mental functioning. including diseases and disorders that Mental disorders include schizophrenia (including associated symptoms of hallucinations, delusions, disorganized thinking, loss of motivation, and decreased emotional expression), delusional disorder, schizoaffective disorder, dissociative identity disorder, and depression. Depression, also known as a sexual disorder (persistent anxiety, feelings of helplessness, hopelessness, pessimism, worthlessness, low energy, restlessness, difficulty sleeping, insomnia, irritability, fatigue, motor tasks, pleasurable activities or hobbies) loss of interest in, loss of concentration, loss of energy, insufficient self-esteem, lack of positive thinking or planning, excessive sleeping, overeating, loss of appetite, insomnia, self-harm, suicidal thoughts, and suicide psychotic major depression (PMD), autism spectrum disorder, autism (including associated symptoms of impairments in social interaction, and disorders of verbal and nonverbal communication); These include, but are not limited to, bipolar disorder (including associated symptoms of anxiety and mood instability), and attention-deficit / hyperactivity disorder (including associated symptoms of attention-deficit, hyperactivity, and impulsivity).
[0214] epilepsy A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition comprised of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, includes a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as described herein. The methods can be used, for example, in the treatment of the disorders described herein, such as epilepsy, developmental and epileptic encephalopathies, status epilepticus, or seizures.
[0215] Epilepsy is a syndrome of paroxysmal brain dysfunction characterized by recurrent, unpredictable, spontaneous seizures. Cerebellar dysfunction is a recognized complication of temporal lobe epilepsy and is associated with seizure occurrence, movement disorders, and memory impairment. Types of epilepsy include generalized epilepsy, such as childhood absence epilepsy, juvenile myoclonic epilepsy, epilepsy with grand mal seizures upon awakening, West syndrome, Lennox-Gastaut syndrome, partial epilepsy, such as temporal lobe epilepsy, These include, but are not limited to, frontal lobe epilepsy and benign focal epilepsy of childhood.
[0216] epileptic encephalopathy A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition comprised of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, includes a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as described herein. Methods can be used, for example, in the treatment of developmental and epileptic encephalopathies.
[0217] Epileptic encephalopathy is a condition in which neurological deterioration is due wholly or partially to epileptic activity. This may be due to very frequent or severe seizures and / or semicontinuous paroxysmal interictal activity. Developmental and epileptic encephalopathies represent a group of epileptic disorders that appear early and are characterized by drug-resistant generalized or focal seizures, persistent severe electroencephalogram (EEG) abnormalities, and cognitive impairment or decline.
[0218] Epileptogenesis A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition comprised of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, includes a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as described herein. The method can be used, for example, in the treatment of epileptogenesis.
[0219] Epileptogenesis is a gradual process by which a normal brain develops epilepsy, a chronic condition in which seizures occur. Epileptogenesis results from neuronal damage precipitated by an earlier insult (eg, status epilepticus).
[0220] Status epilepticus (SE) A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition comprised of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, includes a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as described herein. Methods can be used, for example, in the treatment of status epilepticus (SE).
[0221] Status epilepticus (SE) includes, for example, convulsive status epilepticus, e.g. early status epilepticus, established status epilepticus, refractory status epilepticus, very refractory status epilepticus; Convulsive status epilepticus include generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharge; and periodic lateralized epileptiform discharge. Convulsive status epilepticus is characterized by the presence of a convulsive seizure state and includes early status epilepticus, established status epilepticus, refractory status epilepticus, and very refractory status epilepticus. Can be done. Early status epilepticus is treated with first-line therapy. Established status epilepticus is characterized by a persistent seizure state despite treatment with first-line therapy, and second-line therapy is administered. Refractory status epilepticus is characterized by a persistent epileptic seizure state despite first- and second-line therapy, and general anesthetics are commonly administered. Extremely refractory status epilepticus is characterized by a persistent epileptic seizure state despite treatment with first-line therapy, second-line therapy, and general anesthetics for 24 hours or more.
[0222] Non-convulsive status epilepticus includes, for example, focal non-convulsive status epilepticus, complex partial non-convulsive status epilepticus, simple partial non-convulsive status epilepticus, minimal non-convulsive status epilepticus conditions, generalized non-convulsive status epilepticus, such as late-onset absence non-convulsive status epilepticus, atypical absence non-convulsive status epilepticus, or typical absence non-convulsive status epilepticus Can contain state.
[0223] convulsions A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition comprised of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, includes a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as described herein. It can be used in methods such as the treatment of convulsions.
[0224] Spasm is a disease that occurs with abnormal electrical activation of nerve cells in the brain, including muscle cramps, altered level of consciousness or lethargy, nausea, severe headaches, sudden numbness, and Includes associated symptoms of vomiting. Convulsions are one of the characteristic clinical findings in Alzheimer's disease.
[0225] Combination therapy and treatment When the compounds of the present disclosure are applied to each of the above-mentioned diseases, they can be administered in combination with pharmaceuticals or treatment methods commonly used for the disease. Combined administration can proceed by any technique apparent to those skilled in the art, including, for example, separate, sequential, simultaneous, and alternating administration.
[0226] Examples of pharmaceuticals used in combination with the compounds of the present disclosure (hereinafter abbreviated as "concomitant drugs") include acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine, zanapezil, etc.), anti-dementia drugs ( memantine), inhibitors of the production, secretion, accumulation, coagulation and / or deposition of β-amyloid protein, β-secretase inhibitors (e.g. 6-(4-biphenylyl)methoxy-2-[2-(N,N- dimethylamino)ethyl]tetralin, 6-(4-biphenylyl)methoxy-2-(N,N-dimethylamino)methyltetralin, 6-(4-biphenylyl)methoxy-2-(N,N-dipropylamino)methyl Tetralin, 2-(N,N-dimethylamino)methyl-6-(4'-methoxybiphenyl-4-yl)methoxytetralin, and 6-(4-biphenylyl)methoxy-2-[2-(N,N- diethylamino)ethyl]tetralin), γ-secretase inhibitors, β-amyloid protein coagulation inhibitors (e.g., PTI-00703, ALZHEMED (NC-531), PPI-368 (JP-A-11-514333), and PPI-558 ( JP-A-2001-500852)), β-amyloid vaccines, β-amyloid-degrading enzymes, brain function active agents (e.g., aniracetam, nicergoline), other therapeutic agents for Parkinson's disease (e.g., dopamine receptor agonists), monoamine oxidases (MAO) inhibitors (e.g. deprenyl, sergiline (selegiline), remacemide, riluzole), anticholinergics (e.g. trihexyphenidyl, biperiden), COMT inhibitors (e.g. entacapone)], amyotrophic laterals Drugs to treat sclerosis (e.g., neurotrophic factors such as riluzole), drugs to treat abnormal behavior and wandering caused by the progression of dementia (e.g., sedatives, anxiolytics), and apoptosis inhibitors (e.g., CPI-1189, IDN-6556, CEP-1347), neuronal differentiation or regeneration promoters (e.g., leteprinim, xaliproden (SR-57746-A), SB-216763, Y-128, VX-853, prosaptide, 5,6-dimethoxy-2 -[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-b-benzofuran-5-yl]isoindoline, as well as optically active forms, salts, and hydrates), antidepressants (e.g., desipramine, amitriptyline, imipramine, tramadol), antiepileptics (e.g., lamotrigine), anxiolytics (e.g., benzodiazepines), nonsteroidal anti-inflammatory drugs (e.g., meloxicam, tenoxicam, indomethacin, ibuprofen, celecoxib, rofecoxib, aspirin, indomethacin), disease-modifying antirheumatic drugs (DMARDs), anticytokine drugs (e.g., TNF inhibitors, MAP kinase inhibitors), steroid drugs (e.g., dexamethasone, hexestrol, cortisone acetate), drugs to treat incontinence or frequent urination (e.g., flavoxate hydrochloride, oxybutynin hydrochloride, propiverine hydrochloride), phosphodiesterase inhibitors (e.g., sildenafil (citrate)), dopamine agonists (e.g., apomorphine, etc.) ), antiarrhythmic drugs (e.g., mexiletine), sex hormones or their derivatives (e.g., progesterone, estradiol, estradiol benzoate), drugs for the treatment of osteoporosis (e.g., alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol , ipriflavone, pamidronate disodium, alendronate sodium hydrate, incadronate disodium), parathyroid hormone (PTH), calcium receptor antagonists, insomnia treatments (e.g., benzodiazepines, non-benzodiazepines) , melatonin agonists), and drugs to treat schizophrenia (e.g., typical antipsychotics such as haloperidol, atypical antipsychotics such as clozapine, olanzapine, risperidone, aripiprazole, metabotropic glutamate receptors or ionotropic glutamate receptors) Examples include pharmaceuticals that act on the body (phosphodiesterase inhibitors).
[0227] Further, in combination with a method for transplanting neural stem cells or neural progenitor cells prepared from embryonic stem cells or neural tissue, or fetal neural tissue, and in combination with a pharmaceutical agent such as an immunosuppressant after transplantation.
[0228] Additionally, compounds of the present disclosure may be used in combination with the following concomitant drugs:
[0229] 1. Drugs for treating diabetic complications For example, aldose reductase inhibitors (e.g., tolrestat, epalrestat, zenarestat, zopolrestat, minalrestat, fidarestat, CT-112), neurotrophic factors and their enhancers (e.g., NGF, NT-3, BDNF, neurotrophic factors and enhancers described in WO01 / 14372 (e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl-[oxazole] )), nerve regeneration promoters (e.g. Y-128), PKC inhibitors (e.g. ruboxistaurin mesylate), AGE inhibitors (e.g. ALT946, pimagegin, pyratoxanthin, N-phenacylthiazolium bromide) (ALT766), ALT-711, EXO-226, pyridine, pyridoxamine), active oxygen scavengers (e.g., thioctic acid), cerebral vasodilators (e.g., tiapride, mexiletine), somatostatin receptor agonists (e.g., BIM23190), Mention may be made of the apoptosis signal regulator kinase-1 (ASK-1) and the like.
[0230] 2.Treatment drug for hyperlipidemia For example, statin compounds (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, pitavastatin, or salts thereof (e.g., sodium salt, calcium salt)), squalene synthase inhibitors (e.g., lapakistat acetate, or salts thereof), fibrate compounds (e.g. bezafibrate, clofibrate, sinfibrate, clinofibrate), ACAT inhibitors (e.g. avasimibe, eflucimib), anion exchange resins (e.g. cholestyramine), probucol, nicotinic acid drugs (e.g. nicomol, niceritrol), ethyl icosapentate, phytosterols (e.g. soysterol, gamma oryzanol), etc.
[0231] 3.Diuretics For example, xanthine derivatives (e.g., theobromine sodium salicylate, theobromine calcium salicylate), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide), Aldosterone preparations (e.g. spironolactone, triamterene), carbonic anhydrase inhibitors (e.g. acetazolamide), chlorobenzenesulfonamide agents (e.g. chlorthalidone, mefluside, indapamide), azosemide, isosorbide, ethacrylic acid, piretanide, bumetanide, furosemide, etc.
[0232] 4. Chemotherapy agents For example, alkylating agents (e.g., cyclophosphamide, ifosfamide), metabolic antagonists (e.g., methotrexate, 5-fluorouracil, or derivatives thereof), antitumor antibiotics (e.g., mitomycin, adriamycin), antitumor agents of plant origin. agents (eg, vincristine, vindesine, taxol), cisplatin, carboplatin, etoposide, etc. Among these, 5-fluorouracil derivatives such as fluturon and neofurturon are preferred.
[0233] 5.Immunotherapeutics For example, microorganisms or bacterial components (e.g. muramyl dipeptide derivatives, picibanil), polysaccharides with immunopotentiating activity (e.g. lentinan, schizophyllan, krestin), cytokines obtained by genetic engineering techniques (e.g. interferon, interleukin (IL) )), colony stimulating factors (eg, granulocyte colony stimulating factor, erythropoietin), etc., and interleukins such as IL-1, IL-2, IL-12 are preferred.
[0234] 6.Antithrombotic agents For example, heparin (e.g., heparin sodium, heparin calcium, dalteparin sodium), warfarin (e.g., warfarin potassium), antithrombin drugs (e.g., argatroban), thrombolytic agents (e.g., urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase), platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride), etc.
[0235] 7. Cachexia improving drugs For example, cyclooxygenase inhibitors (e.g., indomethacin) [Cancer Research, Vol. 49, pages 5935-5939, 1989], progesterone derivatives (e.g., megestrol acetate) [Journal of Clinical Oncology, Vol. 12, pages 213- 225, 1994], glucosteroids (e.g., dexamethasone, etc.), metoclopramide agents, tetrahydrocannabinol agents (all publications are listed above), fat metabolism improvers (e.g., eicosapentanoic acid, etc.) [British Journal of Cancer, Vol. 68, pages 314-318, 1993], growth hormone, IGF-1, or antibodies against cachexia-inducing factors such as TNF-α, LIF, IL-6, and oncostatin M.
[0236] Two or more combination drugs mentioned above may be used in combination in appropriate proportions.
[0237] It is also possible to apply the compounds of the present disclosure to each of the above-mentioned diseases as a combination therapy in combination with biological agents (eg antibodies, vaccine preparations, etc.) or in combination with gene therapy methods and the like.
[0238] Examples of antibody and vaccine preparations include vaccine preparations to angiotensin II, vaccine preparations to CETP, CETP antibodies, TNF alpha antibodies and antibodies to other cytokines, amyloid beta vaccine preparations, type 1 diabetes vaccines ( Antibodies or vaccine preparations to cytokines, such as Peptor DIAPEP-277), anti-HIV antibodies, HIV vaccine preparations, renin-angiotensin enzymes and their products, antibodies to enzymes or proteins involved in blood lipid metabolism. Alternatively, examples thereof include vaccine preparations, antibodies or vaccines against enzymes or proteins involved in blood coagulation or fibrinolytic system, antibodies or vaccine preparations against proteins involved in glucose metabolism or insulin resistance, and the like.
[0239] Furthermore, a combination with biological preparations involving growth factors such as GH, IGF, etc. is also possible.
[0240] Examples of gene therapy methods include methods using genes for cytokines, renin-angiotensin enzymes and their products, G proteins, G protein-coupled receptors and their phosphorylating enzymes, and DNA decoys such as NF.kappa.B decoys. treatment methods using antisense, therapeutic methods using antisense, genes related to enzymes or proteins involved in blood lipid metabolism (e.g., genes involved in the metabolism, excretion, or absorption of cholesterol or triglycerides or HDL-cholesterol or blood phospholipids) therapeutic methods using enzymes or proteins (e.g., growth factors such as HGF, VEGF) involved in angiogenesis therapy targeting peripheral vascular occlusion, glucose metabolism or insulin resistance, TNF Examples include therapeutic methods using genes related to proteins involved in antisense to cytokines such as .
[0241] Furthermore, various organ regeneration methods such as heart regeneration, kidney regeneration, pancreas regeneration, and vascular regeneration, cell transplantation therapy using bone marrow cells (bone marrow monocytic cells, bone marrow stem cells), and artificial organs using tissue engineering (e.g. , artificial blood vessels and cardiomyocyte sheets).
[0242] The time of administration of the compounds of the present disclosure and concomitant drugs is not limited, and they may be administered to the subject simultaneously or in a staggered manner. Additionally, the compounds and drug combinations of the present disclosure can be administered as two preparations containing each active ingredient, or as a single preparation containing both active ingredients.
[0243] Doses of concomitant drugs can be appropriately determined based on the doses used in the clinical situation. The mixing ratio of the compound of the present disclosure and the concomitant drug can be appropriately determined depending on the subject of administration, route of administration, target disease, symptoms, concomitant use, and the like. When the subject to be administered is a human, for example, the concomitant drug can be used in an amount of 0.01 to 100 parts by weight per 1 part by weight of the compound of the present invention.
Example
[0244] In order that the invention described herein may be more fully understood, the following examples are included. The synthetic and biological examples described in this application are provided to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are in no way intended to limit the scope thereof. It is not to be interpreted.
[0245] material and method The compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures. It will be understood that where typical or preferred process conditions (ie, reaction temperature, time, molar ratios of reactants, solvent, pressure, etc.) are given, other process conditions can also be used, unless otherwise specified. Optimal reaction conditions may vary depending on the particular reactants or solvents used, but such conditions can be determined through routine optimization by one skilled in the art.
[0246] In addition, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The selection of suitable protecting groups for particular functional groups and suitable conditions for protection and deprotection are well known in the art. For example, a number of protecting groups and their introduction and removal are described in T.W. Greene and P.G.M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and the references cited therein. It is literature.
[0247] The compounds provided herein can be isolated and purified by known standard procedures. Such procedures include, but are not limited to, recrystallization, column chromatography, HPLC, or supercritical fluid chromatography (SFC). The schemes below are presented with details regarding the preparation of representative piperidines listed herein. The compounds provided herein can be prepared from known or commercially available starting materials and reagents by those skilled in the art of organic synthesis. Exemplary chiral columns available for use in the separation / purification of enantiomers / diastereomers provided herein include CHIRALPAK® AD-10, CHIRALCEL® OB, CHIRALCEL (registered trademark) OB-H, CHIRALCEL (registered trademark) OD, CHIRALCEL (registered trademark) OD-H, CHIRALCEL (registered trademark) OF, CHIRALCEL (registered trademark) OG, CHIRALCEL (registered trademark) OJ and CHIRALCEL (registered trademark) Examples include, but are not limited to, OK.
[0248] reported herein 1 H-NMR (e.g., for the region between about 0.5 and about 10 ppm δ(ppm)) will be understood to be an exemplary interpretation of an NMR spectrum (e.g., exemplary peak integration) of a compound. .
[0249] Exemplary general method for LCMS / LC ELSD: 30-90AB_2 min Lcm. (Mobile phase: 1.5 mL / 4 L TFA in water (solvent A) and 0.75 mL / 4 L TFA in acetonitrile (solvent B), elution A gradient 30% to 90% (solvent B) was used over 0.9 min and held at 90% for 0.6 min at a flow rate of 1.2 mL / min; Column: Xtimate C18 2.1*30 mm, 3 μm; Wavelength: UV 220 nm, Column temperature :50℃, MS ionization: ESI; detector: PDA&ELSD).
[0250] Abbreviation ACN: acetonitrile; AcOK or KOAc: potassium acetate; AUC: area under the curve; sec-BuLi: sec-butyllithium; BSA: bis(trimethylsilyl)acetamide; BuOH: butanol; BPO: benzoyl peroxide; n-BuLi: n-butyl Lithium; CAN: Cerium ammonium nitrate; CYP46A1: Cholesterol 24-hydroxylase; DIPEA or DIEA: Diisopropylethylamine; DEA: Diethanolamine; DME: Dimethoxyethane; DMF: Dimethylformamide; DCM: Dichloromethane; DMA: Dimethylacetamide; DIPA: Diisopropylamine ;DMSO:dimethylsulfoxide;EDCI:1-ethyl-3-(3-dimethylaminopropyl)carbodiimide;EtOH:ethanol;EtOAc:ethyl acetate;HATU:1-[bis(dimethylamino)methylene]-1H-1,2 ,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; HBSS: Hank's balanced salt solution; HOBt: hydroxybenzotriazole; HSS: high strength silica; IPA: isopropyl alcohol; LC: liquid chromatography; LDA : lithium diisopropylamide; MeOD: deuterated methanol; MeCN: acetonitrile; MS: mass spectrometry; MDCK: Madin-Darby dog kidney cells; MDR1: multidrug resistance mutations; MeOH: methanol; NADPH: dihydronicotinamide adenine dinucleotide phosphorus. Fart; NBS: N-bromosuccinimide; NMR: Nuclear magnetic resonance; i-Pr 2 O: diisopropyl ether; Pd 2 (dba) 3 :Tris(dibenzylideneacetone)dipalladium(0);Pd(OAc) 2:Palladium(II) acetate;Pd(dppf)Cl 2 :(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; PE: petroleum ether; PET: polyethylene membrane; PK: pharmacokinetics; PO: oral; RFU: relative fluorescence units; TEA: triethylamine; TFA: trifluoroacetic acid; THF: tetrahydrofuran; TQ: triple quadrupole; UPLC: ultra performance liquid chromatography.
[0251] General synthetic scheme Compounds of the invention can be prepared according to the following methods outlined in Schemes 1-3. The synthesis of certain compounds may require modifications to the reaction conditions and / or operations shown in Schemes 1-3, which are intended to be illustrative.
[0252] As illustrated in Scheme 1, treatment of N-protected 4-piperidinone A with an organometallic nucleophile can provide protected 4-piperidinol B. Deprotection affords piperidine C, followed by amide coupling with acid D to yield 4-piperidinol E. Finally, E is fluorinated to obtain target compound F. Alternatively, the protected 4-piperidinol B can be fluorinated and then deprotected, followed by amide coupling with acid D to yield target compound F. Scheme 1 [ka]
[0253] As illustrated in Scheme 2, N-protected 4-piperidinone A can be epoxidized to generate protected piperidine I. Ring opening of the nucleophilic epoxide via attack by an organometallic nucleophile provides 4-piperidinol J. Deprotection followed by amide coupling with acid D followed by fluorination provides the target compound L. Alternatively, L can be prepared from 4-piperidinol J via a synthetic procedure involving initial fluorination, subsequent deprotection, and subsequent amide coupling with acid D. Scheme 2 [ka]
[0254] As illustrated in Scheme 3, N-protected piperido-4-carbonaldehyde A can undergo nucleophilic addition with an organometallic reagent to generate protected piperidine P. Oxidation of the pendant alcohol followed by fluorination generates the piperidine-derived ketone Q. Treatment with acid then results in net deprotection and salt formation, giving R. Amide coupling with acid D generates the piperidine-derived ketone of interest (not shown), which can then undergo mild reduction to generate target compound S. Alternatively, ketone Q can be treated with a reducing agent to produce piperidine-derived alcohol T. Deprotection followed by amide coupling with acid D generates target compound S. Scheme 3 [ka]
[0255] Example 1. Synthesis of 2-(pyrimidin-4-yl)nicotinic acid (INT1) [ka]
[0256] step 1 To a solution of ethyl 2-acetyl nicotinate (2.7 g, 13.9 mmol) in MeCN (27 mL) was added DMF-DMA (27 mL) in one portion at 25 °C. The mixture was stirred at 85°C for 2 hours. The reaction mixture was concentrated to give ethyl (E)-2-(3-(dimethylamino)acryloyl)nicotinate (3.3g), which was used directly in the next step.
[0257] Step 2 To a solution of ethyl (E)-2-(3-(dimethylamino)acryloyl)nicotinate (3.3 g, 13.3 mmol) and acetic acid (9.96 g, 166 mmol) in n-BuOH (30 mL) was added 25 g of DIPEA (30 mL). Added all at once at °C. The mixture was stirred at 120°C for 40 hours. The residue was dissolved in water (50 mL) and saturated NaHCO 3 (18 mL) of the mixture. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the combined organic extracts were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to give ethyl-2-(pyrimidin-4-yl)nicotinate (2.3 g). 1 H NMR(400 MHz, CDCl 3 )δ H 9.29-9.12(m,1H),9.01-8.86(m,1H),8.83-8.68(m,1H),8.17-7.94(m,2H),7.58-7.38(m,1H),4.34-4.20(m ,2H),1.64(s,3H).
[0258] Step 3 Ethyl 2-(pyrimidin-4-yl)nicotinate (2.3g 10.0mmol) and LiOH H in THF (10mL) and MeOH (10mL) 2 A suspension of O (629 mg, 15.0 mmol) was stirred at 25° C. for 2 hours. The mixture was concentrated and the residue was dried in a vacuum oven at 70°C for 2 hours and then at 100°C for 10 minutes to give 2-(pyrimidin-4-yl)nicotinic acid (2.48g). 1 H-NMR(400 MHz, CDCl 3 )δ H 9.16-9.03(m,1H),8.84-8.72(m,1H),8.55-8.41(m,1H),7.97-7.84(m,1H),7.76-7.67(m,1H),7.44-7.32(m ,1H).
[0259] Example 2. Synthesis of lithium [2,4’-bipyridine]-3-carboxylate (INT2) [ka]
[0260] step 1 Pyridin-4-ylboronic acid (5g, 0.0406mmol), ethyl 2-chloropyridine-3-carboxylate (15g, 81.2mmol) and Na 2 C.O. 3 (12.8g, 121mmol) was added to a mixture of Pd(PPh 3 ) 4 (21.4 mg, 0.0186 mmol) was added. The reaction mixture was stirred at 130° C. for 15 hours, cooled and acidified (pH=2) with aqueous HCl (100 mL, 2M). The mixture was washed with EtOAc (2 x 100 mL). The pH of the aqueous phase was adjusted to pH=7 and extracted with EtOAc (2 x 200 mL). The combined organic layers were diluted with anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate to give ethyl-[2,4'-bipyridine]-3-carboxylate (7g, 75.6%). 1 H NMR(400 MHz, CDCl 3 )δ H 8.85-8.79(m,1H),8.72-8.66(m,2H),8.21(d,1H),7.49-7.42(m,3H),4.25-4.15(m,2H),1.12-1.07(m,3H) ).
[0261] Step 2 A solution of ethyl-[2,4'-bipyridine]-3-carboxylate (1 g, 4.38 mmol) in THF (10 mL), MeOH (5 mL) and water (1 mL) was added with LiOH H at 25 °C. 2 O (275 mg, 8.57 mmol) was added. The reaction mixture was stirred at 50° C. for 3 hours and concentrated to give lithium [2,4'-bipyridine]-3-carboxylate (1.1 g). 1 H-NMR(400 MHz,DMSO-d 6 )δ H 8.57-8.51(m,2H),8.50-8.45(m,1H),7.82-7.76(m,2H),7.69-7.61(m,1H),7.32-7.22(m,1H).
[0262] Example 3. Synthesis of (4-fluoro-4-(4-fluorobenzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 1) [ka]
[0263] step 1 A suspension of magnesium (600 mg, 24.9 mmol) and iodine (63.2 mg, 0.249 mmol) in THF (20 mL) was added with 1-(bromomethyl)-4-fluorobenzene (4.7 g, 24.9 mmol) in THF (10 mL). ) was added at 25°C under nitrogen. The mixture was stirred at 25°C for 1 hour. The mixture was cooled to 0° C. and tert-butyl 4-oxopiperidine-1-carboxylate (1 g, 5.01 mmol) was added to the mixture. The mixture was warmed to 25° C. and stirring continued for 15 hours before additional tert-butyl 4-oxopiperidine-1-carboxylate (700 mg) was added. The mixture was treated with water (10 mL) at 0° C. and extracted with ethyl acetate (2×50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (PE / EtOAc=30 / 1~1 / 1) to give tert-butyl-4-(4-fluorobenzyl)-4-hydroxypiperidine-1-carboxylate (1.5 g, 15 %) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 7.29-7.12(m,2H),7.10-6.90(m,2H),4.00-3.75(m,2H),3.25-2.94(m,2H),2.80-2.65(m,2H),2.50-2.20(m ,2H),2.00-1.50(m,2H),1.45(s,9H).
[0264] Step 2 To tert-butyl-4-(4-fluorobenzyl)-4-hydroxypiperidine-1-carboxylate (1.5 g, 4.84 mmol) was added 4M HCl in MeOH (20 mL) at 25°C. The reaction mixture was stirred at 25° C. for 1 hour and the reaction mixture was concentrated to give 4-(4-fluorobenzyl)piperidin-4-ol hydrochloride (1.1 g, 93.2%). 1 H-NMR(400 MHz,MeOD)δ H 7.41-7.18(m,2H),7.15-6.90(m,2H),3.30-3.10(m,5H),2.90-2.65(m,2H),2.05-1.88(m,1H),1.86-1.72(m ,2H),1.71-1.60(m,2H).
[0265] Step 3 To a solution of 2-(pyrimidin-4-yl)nicotinic acid (200 mg, 0.994 mmol) in DMF (10 mL) was added HATU (566 mg, 1.49 mmol) at 0°C. DIPEA (385 mg, 2.98 mmol) was added dropwise to this mixture. After stirring at 0° C. for 20 minutes, 4-[(4-fluorophenyl)methyl]piperidin-4-ol hydrochloride (244 mg, 0.99 mmol) was added. The reaction was warmed to 25°C and stirred for 30 minutes. The reaction mixture was concentrated under vacuum. A second reaction was carried out in parallel and the crude reaction mixtures were combined for purification. The combined reaction products were purified by preparative HPLC (column: Xamide 150*30mm 5μm, gradient: 15~45%B (A=water, 10mM NH 4 HCO 3 , B=ACN), flow rate: 25 mL / min) to produce (4-(4-fluorobenzyl)-4-hydroxypiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl). ) Methanone (325 mg, 100%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.19(s,0.5H),8.94(s,0.5H),8.90-8.81(m,1H),8.76-8.72(m,1H),8.29-8.18(m,1H),7.75-7.60(m,1H) ),7.52-7.38(m,1H),7.18-7.12(m,2H),7.05-6.98(m,2H),4.70-4.46(m,1H),3.64-2.88(m,4H),2.77(s ,2H),1.95-1.61(m,2H),1.41-1.24(m,1H),1.21(s,1H).LC-ELSD / MS purity 100%, C 22 H 22 FN 4 O 2 [M+H] + ESI calculated value for 393, actual value 393.
[0266] Step 4 A solution of (4-(4-fluorobenzyl)-4-hydroxypiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (300 mg, 0.8 mmol) in DCM (5 mL) To this, DAST (307 mg, 1.9 mmol) was added at -78°C. The mixture was stirred at -78°C for 8 hours. The mixture was warmed to 10°C and stirred for 10 hours. Saturated sodium bicarbonate solution (10 mL) was added and the aqueous layer was extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine (10 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate under reduced pressure to give 300 mg of crude reaction mixture. The crude reaction product was purified by preparative HPLC (column: Waters Xbridge 150×25 5um; conditions: A=water (10mM NH 4 HCO 3 )-B=ACN; Start B: 33; End B: 53; Retention time: 2; Flow rate (mL / min): 25), followed by (Column: DAICEL CHIRALPAK AD-H (250mm*30mm, 5μm );Condition: 0.1%NH 3 H 2 SFC purification by (4-fluoro-4-(4-fluorobenzyl)piperidin-1-yl)(2-( Pyrimidin-4-yl)pyridin-3-yl)methanone (59.0 mg, 20%) was obtained. 1 H-NMR(400MHz,DMSO-d6,t=80℃)δ H 9.07-8.90(m,2H),8.76(d,J=1.6 Hz,1H),8.16(d,J=5.2 Hz,1H),7.80(d,J=1.6 Hz,1H),7.60(dd,J =4.8,8.0 Hz,1H),7.30-7.18(m,2H),7.10(t,J=8.8 Hz,2H),4.40-4.27(m,1H),3.35-2.96(m,5H),1.90- 1.50(m,4H).LC ELSD / MS purity ≧96%, C 22 H 21 F 2 N 4 O[M+H] + MS ESI calculated value for 395, measured value 395. 19 F-NMR (376.5MHz, CDCl 3 )δ F- 115.7, -161.1.
[0267] Example 4. (4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 2) Synthesis [ka]
[0268] step 1 A solution of tert-butyl 4-hydroxy-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidine-1-carboxylate (300 mg, 1.00 mmol) in DCM (4 mL) was added with DAST (322 mg, 2.00 mmol). mmol) was added at -70°C. After stirring for 1 h at -70 °C, the mixture was diluted with saturated NaHCO 3 (10 mL) and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine (10 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (PE:EtOAc 10%~15%~20%) to give tert-butyl 4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidine-1-carboxy rate (180 mg, 59.8%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 3.94-3.90(m,4H),3.42-3.36(m,2H),3.09-3.03(m,2H),1.67-1.64(m,3H),1.57-1.51(m,2H),1.50(s,2H) ),1.45-1.37(m,2H),1.36(s,9H),1.34-1.29(m,2H).
[0269] Step 2 A solution of tert-butyl 4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidine-1-carboxylate (230 mg, 0.76 mmol) in MeOH (3 mL) was added with 4 M HCl / dioxane ( 222 mg, 1.52 mL) was added at 25°C. The mixture was stirred at 25° C. under nitrogen for 2 hours and concentrated to give 4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidine hydrochloride (210 mg). 1 H NMR(400 MHz, CDCl 3 )δ H 3.92(br dd,J=3.8,10.8 Hz,2H),3.62(s,1H),3.51-3.40(m,2H),3.35(br s,2H),3.27-3.16(m,2H),2.18( br dd,J=7.8,13.3 Hz,2H),1.99-1.79(m,3H),1.77-1.69(m,3H),1.46-1.26(m,2H).
[0270] Step 3 A solution of 4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidine hydrochloride (95 mg, 0.40 mmol) in DMF (1 mL) was added with HATU (227 mg, 0.60 mmol) and DIPEA (0.206 mL, 1.19 mmol) was added at 25°C. After stirring at 25° C. for 30 minutes, 2-(pyrimidin-4-yl)nicotinic acid (80.3 mg, 0.40 mmol) was added. The mixture was stirred at 25°C for 10 hours, concentrated and preparative HPLC (column: Phenomenex Gemini-NX 150*30mm*5um; conditions: A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN; Start B: 22, End B: 52; Gradient time (min): 3; 100% B retention time (min): 2; Flow rate (ml / min): 30; Injection: 7) and the product (4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (26.4 mg, 17.2%). 1 H-NMR(400 MHz, CDCl 3 )δ H 9.25-9.06(m,1H),8.89(br d,J=4.5 Hz,1H),8.76(dd,J=1.6,4.6 Hz,1H),8.25(br d,J=4.8 Hz,1H),7.69 (br d,J=6.5 Hz,1H),7.47(dd,J=4.8,7.5 Hz,1H),4.78-4.46(m,1H),3.94(br d,J=11.3 Hz,2H),3.47- 3.35(m,3H),3.28-3.09(m,2H),2.18-1.99(m,1H),1.98-1.66(m,5H),1.55(br d,J=5.3 Hz,2H),1.45-1.33 (m,2H),1.29-0.94(m,1H).LC-MS purity 100%, C 21 H 25 FN 4 O 2[ M+H] + MS ESI calculated value for 385.3, measured value 385.3. 19 F-NMR (376.5MHz, CDCl 3 )δ F -162.
[0271] Example 5. Synthesis of [2,4'-bipyridin]-3-yl(4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-1-yl)methanone compound 3) [ka] A solution of 4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidine hydrochloride (95 mg, 0.40 mmol) in DMF (1 mL) was added with HATU (227 mg, 0.60 mmol) and DIPEA (0.206 mL, 1.19 mmol) was added at 25°C. After stirring at 25°C for 30 minutes, [2,4'-bipyridine]-3-carboxylic acid (79.9 mg, 0.4 mmol) was added to the solution. The mixture was stirred at 25°C for 10 hours, concentrated and preparative HPLC (column: Phenomenex Gemini-NX 150*30mm*5um; conditions: A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN; Start B: 22, End B: 52; Gradient time (min): 3; 100% B retention time (min): 2; Flow rate (ml / min): 30; Injection: 7) Purified by and the product [2,4'-bipyridin]-3-yl(4-fluoro-4-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-1-yl)methanone (31.9 mg, 20.8% ) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.94-8.56(m,3H),7.89-7.55(m,3H),7.45(br dd,J=4.8,7.5 Hz,1H),4.75-4.48(m,1H),3.90(br dd,J=3.3 ,11.3 Hz,2H),3.36(br t,J=11.8 Hz,2H),3.17-2.60(m,3H),2.05-1.69(m,1H),1.58-1.33(m,5H),1.32-0.73 (m,5H).LC-MS purity 100%, C 22 H 26 FN 3 O 2[ M+H] + MS ESI calculated value 384.3, measured value 384.3. 19 F-NMR (376.5MHz, CDCl 3 )δ F -162.
[0272] Example 6. Synthesis of (4-fluoro-4-(4-(trifluoromethyl)benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 4) [ka]
[0273] step 1 Me in DMSO (100mL) 3 To a solution of SOI (12.1 g, 55.1 mmol) was added t-BuOK (6.74 g, 60.1 mmol) at 0°C, and the mixture was stirred at 20°C for 1 hour. The mixture was cooled to 0° C. and a solution of tert-butyl 4-oxopiperidine-1-carboxylate (10 g, 50.1 mmol) in DMSO (50 mL) was added portionwise. The mixture was stirred at 0 °C for 3 h and then diluted with NH 4 Poured into aqueous Cl solution (200 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine (2 x 100 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was applied to a silica gel pad and eluted with PE:EtOAc (3:1, 3 x 150 mL). The filtrate was concentrated to give tert-butyl-1-oxa-6-azaspiro[2.5]octane-6-carboxylate (9 g, 85%), which was used directly in the next reaction.
[0274] Step 2 A solution of [4-(trifluoromethyl)phenyl]magnesium chloride (9.5 mmol) in THF (20 mL) was added to a solution of tert-butyl-1-oxa-6-azaspiro[2.5]octane-6- in THF (10 mL). Carboxylate (1.5g, 7.03mmol) was added slowly at 25°C and the mixture was stirred at 25°C for 2 hours. NH mixture 4 Poured into aqueous Cl (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (20 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The crude product was purified by silica gel chromatography (0-30% EtOAc in PE) to give tert-butyl 4-hydroxy-4-(4-(trifluoromethyl)benzyl)piperidine-1-carboxylate (900 mg, 36%), which was used directly in the next reaction.
[0275] Step 3 A mixture of tert-butyl 4-hydroxy-4-(4-(trifluoromethyl)benzyl)piperidine-1-carboxylate (900 mg, 2.50 mmol) in dioxane (5 mL) was added with HCl / dioxane (4M, 5 mL, 20 mmol). ) was added and the mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated to give 4-(4-(trifluoromethyl)benzyl)piperidin-4-ol hydrochloride (600 mg, crude), which was used directly in the next step.
[0276] Step 4 of 4-(4-(trifluoromethyl)benzyl)piperidin-4-ol hydrochloride (300 mg, 1.01 mmol) and 2-(pyrimidin-4-yl)nicotinic acid (243 mg, 1.21 mmol) in DMF (5 mL). To the solution were added HATU (640 mg, 1.51 mmol) and DIPEA (651 mg, 5.05 mmol). After stirring at 25 °C for 16 h, the mixture was dissolved in H 2 Diluted with O (10 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were heated with H 2 Wash sequentially with O (2 x 30 mL) and brine (2 x 30 mL), and 2 S.O. 4 Dry on top, filter and concentrate to give the crude product (300 mg, crude). The crude product (100 mg) was purified by preparative HPLC (column: Phenomenex Gemini-NX 150*30mm*5μm; conditions: A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )- B=ACN; starting B: 29%, ending 59%) and purified by (4-hydroxy-4-(4-(trifluoromethyl)benzyl)piperidin-1-yl)(2-(pyrimidin-4 -yl)pyridin-3-yl)methanone (34.6 mg, 11%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H9.24-9.01(m,1H),8.93-8.81(m,1H),8.79-8.70(m,1H),8.30-8.21(m,1H),7.75-7.65(m,1H),7.64-7.54(m ,2H),7.50-7.42(m,1H),7.35-7.27(m,2H),4.65-4.45(m,1H),3.50-3.33(m,1H),3.28-3.10(m,1H),2.92 -2.77(m,2H),2.00-1.85(m,1H),1.82-1.65(m,2H),1.47-1.16(m,2H). 19 F NMR(376.5 MHz,CDCl3)δ F -62.501.LCMS: 99% purity, C 23 H 21 F 3 N 4 O 2 [M+H] + MS ESI calculated value 443.2, measured value 443.0
[0277] Step 5 (4-hydroxy-4-(4-(trifluoromethyl)benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (60 mg, 0.14 DAST (26.2 mg, 0.20 mmol) was added at -78°C. After stirring for 2 h at -78 °C, the mixture was diluted with NaHCO 3 Poured into saturated aqueous solution (10 mL) and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine (10 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (MeOH in EtOAc = 5%~10%) to give 40 mg of product (impure), which was triturated from isopropyl ether (2 mL) at 25 °C to give (4-fluoro -4-(4-(trifluoromethyl)benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (7.8 mg, 12%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.19(s,1 H),8.84-8.98(m,2 H),8.74-8.72(m,1 H),8.27-8.21(m,1 H),7.72-7.64(m,2 H),7.57( d,J=7.60 Hz,2 H),7.44-7.41(m,1H),7.32-7.29(m,2 H),5.22-5.44(m,1 H),4.50-4.76(m,1 H), 3.36-3.49(m,1 H),2.91-3.27(m,4 H),2.22(t,J=7.60 Hz,1 H),1.62-2.03(m,4 H),1.35-1.24(m,4 H),0.84-0.91(m,1 H).LCMS: 99% purity, C 23 H 20 N 4 F 4 O[M+H] + Calculated MS ESI value for 445.2, measured value 445.0. 19 F-NMR (376.5MHz, CDCl 3 )δ F -62.5,-162.
[0278] Example 7. Synthesis of (4-fluoro-4-(pyridin-2-ylmethyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 5) [ka]
[0279] step 1 To a solution of 2-methylpyridine (2 g, 21.4 mmol) in THF (20 mL) was added n-BuLi (10.2 mL, 2.5 M solution in hexanes, 25.6 mmol) dropwise at -78° C. under nitrogen. The reaction mixture was stirred at −78° C. for 30 minutes and tert-butyl 4-oxopiperidine-1-carboxylate (4.26 g, 21.4 mmol) in THF (10 mL) was added over 15 minutes. The mixture was warmed to 25°C and stirred for 16 hours. saturated NH 4 Aqueous Cl (100 mL) was added and the mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter, and concentrate to give tert-butyl 4-hydroxy-4-(pyridin-2-ylmethyl)piperidine-1-carboxylate (6.06 g, crude). 1 H-NMR(400 MHz, CDCl 3 )δ H 8.48-8.46(m,1H),7.64-7.60(m,1H),7.26-7.08(m,2H),3.77-.3.69(m,2H),3.22-3.20(m,2H),2.86-.2.84 (m,2H),1.48-1.43(m,12H).
[0280] Step 2 To a mixture of tert-butyl 4-hydroxy-4-(pyridin-2-ylmethyl)piperidine-1-carboxylate (2 g, 6.84 mmol) in dioxane (30 mL) was added HCl / dioxane (4M, 30 mL, 120 mmol). Ta. The mixture was stirred at 20°C for 16 hours. The reaction mixture was filtered and the filter cake was washed with 10 mL of EtOAc and dried to give 4-(pyridin-2-ylmethyl)piperidin-4-ol hydrochloride (1.5 g, crude). 1 H-NMR(400 MHz, CDCl 3 )δ H 8.81-8.80(m,1H),8.62-8.57(m,1H),8.08-8.02(m,2H),3.32-3.24(m,5H),2.09-2.03(m,2H),1.78-1.74(m ,2H).
[0281] Step 3 2-(pyrimidin-4-yl)nicotinic acid (600 mg, 2.98 mmol), 4-[(pyridin-2-yl)methyl]piperidin-4-ol hydrochloride (612 mg, 2.68 mmol) in DMF (15 mL), DIPEA (1.92 g, 14.9 mmol) was added to a solution of HATU (1.69 g, 4.47 mmol). The mixture was stirred at 20°C for 2 hours. Reaction mixture with H 2 Poured into O (50 mL) and extracted the aqueous layer with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (100 mL) and anhydrous Na 2 S.O. 4 dried over water and evaporated under reduced pressure to obtain the crude product, which was purified by preparative HPLC (column: Phenomenex Gemini-NX 150*30mm*5um; conditions: A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN; starting B: 10%; ending 40%) to give the product (200 mg, impure), which was further purified by preparative TLC to 4-[(pyridin-2-yl ) methyl]-1-[2-(pyrimidin-4-yl)pyridine-3-carbonyl]piperidin-4-ol (57 mg, 6%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.22-.918(m,1H),8.86-8.83(m,1H),8.72-8.71(m,1H),8.47-8.46(m,1H),7.69-7.67(m,1H),7.63-7.62( m,1H),7.44-7.43(m,1H),7.18-7.17(m,1H),7.12-7.10(m,2H),4.52-4.46(m,1H)3.52-3.49(m,1H),3.38 -3.35(m,2H),3.14-3.10(m,1H),2.91-2.88(m,1H),1.74-1.71(m,2H),1.51-1.50(m,2H),1.34-1.31(m, 1H).HPLC: 99% purity, C 21 H 22 N 5 O 2[ M+H] + MS ESI calculated value for 376.3, measured value 376.3.
[0282] Step 4 A mixture of 4-[(pyridin-2-yl)methyl]-1-[2-(pyrimidin-4-yl)pyridine-3-carbonyl]piperidin-4-ol (90 mg, 0.2397 mmol) in DCM (2 mL) To this, DAST (77.2 mg, 0.4794 mmol) was added at 0°C. After stirring at 20°C for 16 hours, the reaction mixture was concentrated. The residue was purified by preparative HPLC (column: YMC-Triart Prep C18 150*40mm*7um; conditions: A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN; starting B: 42%, ending 42%) and purified by (4-fluoro-4-(pyridin-2-ylmethyl)piperidin-1-yl)(2-(pyrimidin-4-yl) Pyridin-3-yl)methanone (2.2 mg, 2.4%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.24-8.53(m,4H),8.28-8.17(m,1H),7.65(br d,J=7.8 Hz,2H),7.44(br d,J=4.5 Hz,1H),7.18(br d,J =5.0 Hz,2H),4.82-4.38(m,1H),3.43(br d,J=8.5 Hz,1H),3.26-3.08(m,4H),2.00(br d,J=15.8 Hz,2H) ,1.69(br s,2H).LC-ELSD / MS purity 96%, C 21 H 20 FN 5O[M+H] + MS ESI calculated value for 378.3, measured value 378.3. 19 F-NMR (376.5MHz, CDCl 3 )δ F -158.
[0283] Example 8. Synthesis of 4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)methyl)benzonitrile (compound 6) [ka]
[0284] step 1 Et 2 Mg (3.90g, 150mmol) and I in O (60mL) 2 (100 mg, 0.391 mmol) was added to a suspension of Et 2 1-Bromo-4-(bromomethyl)benzene (9.37 g, 37.5 mmol) in O (10 mL) was added at 20° C. under nitrogen. The reaction mixture was stirred at 40° C. for 30 minutes and tert-butyl 4-oxopiperidine-1-carboxylate (3 g, 15.0 mmol) in diethyl ether (10 mL) was added slowly. The mixture was heated at 40°C for 1 hour. Cool the mixture and saturated NH 4 Aqueous Cl solution (30 mL) was added and the mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (50 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-10% EtOAc in PE) to yield tert-butyl 4-(4-bromobenzyl)-4-hydroxypiperidine-1-carboxylate (4 g, 72.0%). . 1 H-NMR(400MHz, CDCl 3 )δ H 7.44(d,J=8.4 Hz,2H),7.07(d,J=8.4 Hz,2H),3.93-3.76(m,2H),3.16-2.99(m,2H),2.71(s,2H),1.62 -1.55(m,2H),1.45(s,11H).
[0285] Step 2 Zn(CN) was added to a solution of tert-butyl 4-(4-bromobenzyl)-4-hydroxypiperidine-1-carboxylate (4 g, 10.8 mmol) in DMF (40 mL). 2 (8.76g, 75.6mmol) was added at 20°C under nitrogen. In this mixture, Pd 2 (dba) 3 (1.67g, 1.83mmol) and dppf (2.81g, 5.07mmol) were added. The mixture was stirred at 130°C for 16 hours. Ice water (70 mL) was added and the mixture was extracted with EtOAc (70 mL x 2). organic phase with Na 2 S.O. 4 tert-butyl 4-(4-cyanobenzyl)-4-hydroxypiperidine-1-carboxylate (4 g, impure ), which was used in the next step without further purification. 1 H-NMR(400MHz, CDCl 3 )δ H 7.65-7.58(m,2H),7.34-7.30(m,2H),3.94-3.77(m,2H),3.16-2.99(m,2H),2.82(s,2H),1.66-1.56(m,2H) ),1.50-1.47(m,2H),1.45(s,9H).
[0286] Step 3 To a solution of tert-butyl 4-(4-cyanobenzyl)-4-hydroxypiperidine-1-carboxylate (1 g, 3.16 mmol) in dioxane (2 mL) was added 25 mL of HCl / dioxane (10 mL, 4M, 40.0 mmol). Added at °C. The mixture was stirred at 25°C under nitrogen for 12 hours. The mixture was concentrated to give 4-((4-hydroxypiperidin-4-yl)methyl)benzonitrile hydrochloride (800 mg, crude), which was used directly in the next step.
[0287] Step 4 2-(pyrimidin-4-yl)nicotinic acid (762 mg, 3.78 mmol), HOBt (853 mg, 6.32 mmol), EDCI (1.20 g, 6.32 mmol), DIPEA (1.64 mL, 9.48 mmol) in DCM (2 mL), A solution of 4-((4-hydroxypiperidin-4-yl)methyl)benzonitrile hydrochloride (800 mg, 3.16 mmol) was stirred at 0° C. for 2 hours. The mixture was filtered and preparative HPLC (column: Xtimate C18 150*40mm*5um; conditions: A=water (10mM NH 4 HCO 3 )-B=ACN; start B: 25; end B: 35; gradient time (min): 8; 100% B retention time (min): 2) and purified by 4-((4-hydroxy-1-( 2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)methyl)benzonitrile (250 mg, 19.8%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.18(s,0.5H),9.03(s,1H),8.93-8.81(m,0.5H),8.78-8.71(m,1H),8.25(d,J=4.4 Hz,1H),7.74-7.64( m,1H),7.64-7.59(m,2H),7.50-7.41(m,1H),7.35-7.28(m,2H),4.66-4.46(m,1H),3.46-3.32(m,1H), 3.30-3.12(m,2H),2.91-2.78(m,2H),1.92(br s,0.5H),1.78-1.63(m,1.5H),1.42(s,0.5H),1.30-1.19(m ,1.5H).LCMS purity 99%, C 23 H 22 N 5 O 2 [M+H] + MS ESI calculated value for 400, measured value 400.
[0288] Step 5 DAST ( 28.0 mg, 0.90 mmol) was added at 0°C. The mixture was stirred at 0°C for 2 hours. The reaction mixture was concentrated and the residue was purified by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); conditions: water (0.1%NH 3 H 2 O IPA; Start B: 40%; End 40%) and purified by 4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)methyl)benzonitrile ( 17.6 mg, 14%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.18(s,0.3H),8.95(s,0.6H),8.92-8.83(m,1H),8.79-8.71(m,1H),8.30-8.21(m,1H),7.72-7.64(m,1H) ),7.63-7.57(m,2H),7.48-7.42(m,1H),7.35-7.28(m,2H),4.76-4.53(m,1H),3.49-3.32(m,1H),3.29-3.05 (m,2H),3.05-2.88(m,2H),2.05-1.59(m,3.5H),1.52-1.46(m,0.5H).LCMS purity 98%, C 23 H 21 FN 5 O[M+H] + MS ESI calculated value for 402, measured value 402.
[0289] Example 9. (4-((5-cyclopropylpyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 7) Synthesis [ka]
[0290] step 1 5-bromo-2-methylpyridine (2.0 g, 11.6 mmol), cyclopropylboronic acid (1.19 g, 13.9 mmol), xanthophos (1.34 g, 2.76 mmol), Pd in dioxane (20 mL). 2 (dba) 3 (1.26g, 1.38mmol), and Cs 2 C.O. 3 A mixture of (4.80 g, 34.8 mmol) was stirred at 100° C. under nitrogen for 16 hours. Reaction mixture with H 2 Poured into O (50 mL) and extracted the aqueous layer with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (30 mL) and anhydrous Na 2 S.O. 4 Dry on top and concentrate. The crude product was purified by silica gel chromatography (5-30% EtOAc in PE) to give 5-cyclopropyl-2-methylpyridine (600 mg, 38.9%). 1 H-NMR(400 MHz, CDCl 3 )δ H 8.31(d,J=2.0 Hz,1H),7.19(dd,J=2.4,8.0 Hz,1H),7.02(d,J=8.0 Hz,1H),2.50(s,3H),1.92-1.79(m ,1H),1.02-0.94(m,2H),0.91-0.81(m,2H).
[0291] Step 2 To a solution of 5-cyclopropyl-2-methylpyridine (300 mg, 2.25 mmol) in THF (10 mL) was added n-BuLi (1.80 mL, 2M in hexane, 4.50 mmol) at -70 °C. After 30 minutes, tert-butyl 4-oxopiperidine-1-carboxylate (537 mg, 2.70 mmol) was added at -70°C and the mixture was stirred at -70°C for 2 hours. Saturated NH in the mixture 4 Aqueous Cl solution (20 mL) was added. The mixture was extracted with EtOAc (2 x 20 mL). The combined organic layer was diluted with Na 2 S.O. 4 tert-butyl 4-((5-cyclopropylpyridin-2-yl)methyl )-4-hydroxypiperidine-1-carboxylate (280 mg, 37.4%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 8.30(d,J=2.0 Hz,1H),7.26-7.22(m,1H),6.98(d,J=8.0 Hz,1H),3.87-3.65(m,2H),3.33-3.12(m,2H) ,2.83(s,2H),1.93-1.81(m,1H),1.50-1.45(m,4H),1.45(s,10H),1.07-0.94(m,2H),0.74-0.63(m,2H) .
[0292] Step 3 A solution of tert-butyl 4-((5-cyclopropylpyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (300 mg, 0.90 mmol) in HCl / dioxane (10 mL, 4M, 40.0 mmol) was added at 25°C. The mixture was stirred under nitrogen for 16 hours. The mixture was concentrated to give 4-((5-cyclopropylpyridin-2-yl)methyl)piperidin-4-ol hydrochloride (250 mg, crude), which was used directly in the next reaction.
[0293] Step 4 2-(pyrimidin-4-yl)nicotinic acid (89.8 mg, 3.78 mmol), HOBt (100 mg, 0.74 mmol), EDCI (142 mg, 0.74 mmol), DIPEA (0.32 mL, 1.85 mmol) in DMF (2 mL), A solution of 4-((5-cyclopropylpyridin-2-yl)methyl)piperidin-4-ol hydrochloride (100 mg, 0.37 mmol) was stirred at 0° C. for 2 hours. The mixture was filtered, concentrated and preparative HPLC (column: Phenomenex Gemini-NX 80*40mm*3um; conditions: A=water (0.05%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN; start B: 15; end B: 45; gradient time (min): 8; 100% B retention time (min): 2.5) and purified by (4-((5-cyclopropylpyridine- 2-yl)methyl)-4-hydroxypiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (150 mg, impure) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.29-9.17(m,1H),8.92-8.82(m,1H),8.77-8.69(m,1H),8.31-8.27(m,1H),8.26-8.21(m,1H),7.74-7.65(m ,1H),7.48-7.40(m,1H),7.26-7.24(m,1H),7.04-6.95(m,1H),4.57-4.40(m,1H),3.52-3.10(m,3H),2.91 -2.79(m,2H),1.93-1.81(m,1H),1.69(d,J=12.0 Hz,1H),1.50-1.26(m,4H),1.07-0.96(m,2H),0.74-0.65 (m,2H).LCMS purity 95%, C 24 H 26 N 5 O 2 [M+H] + Calculated MS ESI value for 416, measured value 416.
[0294] Step 5 (4-((5-cyclopropylpyridin-2-yl)methyl)-4-hydroxypiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone in DCM (5 mL) (140 mg, 0.34 mmol) was added DAST (108 mg, 0.67 mmol) at 0°C. The mixture was stirred at 0°C for 15 minutes. The mixture was slowly poured into ice water (20 mL) and the aqueous layer was extracted with DCM (2 x 20 mL). Combined organic layers with NaHCO 3 (20 mL) and brine (10 mL), anhydrous Na 2 S.O. 4 Dry on top and concentrate. The residue was purified by SFC (column: DAICEL CHIRALCEL OD-H (250 mm * 30mm, 5um), conditions: A=0.1%NH 3 H 2 O B=EtOH; start B: 35%; end 35%) and purified by (4-((5-cyclopropylpyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidine -4-yl)pyridin-3-yl)methanone (7.3mg 5.21%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.18(s,0.3H),8.85(d,J=5.2 Hz,1H),8.76-8.65(m,1.7H),8.39-8.30(m,1H),8.28-8.14(m,1H),7.75- 7.58(m,1H),7.49-7.38(m,1H),7.11(d,J=7.6 Hz,2H),4.74-4.41(m,1H),3.49-3.33(m,1H),3.28-2.99( LCMS purity 99%, C 24 H 25 FN 5 O[M+H] + Calculated MS ESI value for 418, measured value 418.
[0295] Example 10. Synthesis of (4-fluoro-4-phenylpiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 8) [ka]
[0296] step 1 To a solution of tert-butyl 4-oxopiperidine-1-carboxylate (3.0 g, 15.0 mmol) in THF (20 mL) was added phenylmagnesium bromide (15.0 mL, 45.0 mmol) dropwise at 0 °C under nitrogen. . The mixture was stirred at 0°C for 30 minutes, then warmed to 20°C and stirred for 1 hour. The mixture was slowly poured into ice water (100 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (3 x 400 mL). The combined organic layers were washed with brine (2 x 200 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (10-30% EtOAc in PE) to give tert-butyl 4-hydroxy-4-phenylpiperidine-1-carboxylate (2.6 g, impure). 1 H-NMR(400 MHz, CDCl 3 )δ H 7.42-7.50(m,2H),7.32-7.39(m,2H),7.28-7.26(m,1H),2.79-3.58(m,4H),1.61-2.02(m,4H),1.47-1.49(s ,9H).
[0297] Step 2 To a solution of tert-butyl 4-hydroxy-4-phenylpiperidine-1-carboxylate (1.8 g, 6.48 mmol) in dioxane (20 mL) was added HCl / dioxane (4M, 20 mL). The mixture was stirred at 25° C. for 16 hours and the reaction mixture was concentrated under reduced pressure to give 4-phenylpiperidin-4-ol hydrochloride (1.4 g, crude), which was used directly in the next reaction.
[0298] Step 3 To a solution of 2-(pyrimidin-4-yl)nicotinic acid (657 mg, 3.27 mmol) in DMF (5 mL) was added HATU (1.86 g, 4.90 mmol) and DIPEA (1.70 mL, 9.80 mmol) at 25 °C. . The mixture was stirred at 25°C for 30 minutes. 4-Phenylpiperidin-4-ol hydrochloride (700 mg, 3.27 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated and the residue was purified by preparative HPLC (column Phenomenex Gemini NX C18 150*40mm*5 μm, conditions A=water (10mM NH4HCO3)-B=ACN, start B 10, end B 40, gradient time (min) 10 , 100% B retention time (min) 2, flow rate (ml / min) 60, injection 9), purified by (4-hydroxy-4-phenylpiperidin-1-yl)(2-(pyrimidin-4-yl) Pyridin-3-yl)methanone (300 mg, 37.6%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H9.13-9.34(m,1H),8.70-8.92(m,2H),8.28(br dd,J=19.6,4.8 Hz,1H),7.70-7.84(m,1H),7.49(br dd,J=7.7 ,4.6 Hz,3H),7.37-7.45(m,2H),7.31-7.37(m,1H),4.64-4.84(m,1H),3.28-3.70(m,3H),1.92-2.40(m,3H) ),1.60(br d,J=14.8 Hz,1 H);LC-ELSD / MS purity 99%,C 21 H 21 N 4 O 2 [M+H] + MS ESI calculated value 361.2, actual value 361.2
[0299] Step 4 DAST (89.4 mg, 0.559 mmol) was added at 0°C. The mixture was stirred at 0°C for 30 minutes. Transfer the residue to ice water and NaHCO 3 (80 mL) and stirred for 20 minutes. The aqueous phase was extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was analyzed by HPLC (column Boston Prime C18 150*30mm*5um, condition A=water (0.05%NH 3. H 2 O+10mM NH 4 HCO 3 )-B=ACN, start B 40, end B 70, gradient time (min) 7, 100% B retention time (min) 0, flow rate (ml / min) 25, injection 5)), purified by (4- Fluoro-4-phenylpiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (19.7 mg, 19%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.20-9.30(m,1H),8.74-8.93(m,2H),8.22-8.34(m,1H),7.69-7.81(m,1H),7.48(dd,J=7.6,5.2 Hz,1H), 7.32-7.43(m,5H),4.73-4.94(m,1H),3.59(br s,1H),3.16-3.44(m,2H),2.09-2.42(m,2H),1.76-1.99(m, 1H),1.21-1.38(m,1H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -161.675.LC-ELSD / MS purity 99%, C 21 H 20 FN 4 O[M+H] + MS ESI calculated value for 363.1, measured value 363.1
[0300] Example 11. Synthesis of 3-fluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)methyl)benzonitrile (compound 9) [ka]
[0301] step 1 Et 2 Mg (3.90g, 150mmol) and I in O (60mL) 2 (100 mg, 0.3906 mmol) in a suspension of Et 2 4-Bromo-1-(bromomethyl)-2-fluorobenzene (9.37 g, 37.5 mmol) in O (10 mL) was added at 20° C. under nitrogen. The reaction mixture was heated to 40°C and stirred for 30 minutes. Then tert-butyl 4-oxopiperidine-1-carboxylate (597 mg, 3 mmol) in diethyl ether (10 mL) was added slowly. The mixture was heated at 40°C for 1 hour. Cool the mixture and saturated NH 4 Aqueous Cl solution (30 mL) was added. The mixture was extracted with EtOAc (20 mL x 2) and the combined organic layers were washed with brine (50 mL) and Na 2 S.O. 4 Dry on top, filter and concentrate. The crude product was purified by silica gel chromatography (0-10% EtOAc in PE) to give tert-butyl 4-(4-bromo-2-fluorobenzyl)-4-hydroxypiperidine-1-carboxylate (1.1 g , 94.8%). 1 H-NMR(400MHz, CDCl 3 )δ H =7.25-7.22(m,2H),7.15-7.06(m,1H),3.85(s,2H),3.19-3.02(m,2H),2.85-2.74(m,2H),1.68-1.57(m, 2H),1.50-1.41(m,12H).
[0302] Step 2 Zn(CN) was added to a solution of tert-butyl 4-(4-bromo-2-fluorobenzyl)-4-hydroxypiperidine-1-carboxylate (1.1 g, 2.83 mmol) in DMF (40 mL). 2 (2.29g, 19.8mmol) was added at 20°C under nitrogen. Then, Pd 2 (dba) 3 (440 mg, 0.4811 mmol) and dppf (737 mg, 1.33 mmol) were added. The mixture was stirred at 130°C for 16 hours. The mixture was cooled and ice water (70 mL) was added. The mixture was extracted with EtOAc (70 mL x 2). The combined organic layer was diluted with Na 2 S.O. 4 dried over, concentrated and purified by silica gel chromatography (0-90% EtOAc in PE) to give tert-butyl 4-(4-cyano-2-fluorobenzyl)-4-hydroxypiperidine-1-carboxylate. (400mg, 42.2%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H =7.45-7.34(m,3H),3.95-3.77(m,2H),3.18-3.00(m,2H),2.87(s,2H),1.69-1.58(m,2H),1.45(s,12H) .
[0303] Step 3 To a solution of tert-butyl 4-(4-cyano-2-fluorobenzyl)-4-hydroxypiperidine-1-carboxylate (400 mg, 1.19 mmol) in DCM (20 mL) was added 0% DAST (397 mg, 2.38 mmol). Added at °C. The mixture was stirred at 0°C for 5 minutes. The reaction mixture was slowly poured into ice water (30 mL) and the mixture was extracted with DCM (2 x 30 mL). Combined organic layers with NaHCO 3 Wash with aqueous solution (20 mL) then brine (10 mL) and anhydrous Na 2 S.O. 4 dried over water, filtered and concentrated to give tert-butyl 4-(4-cyano-2-fluorobenzyl)-4-fluoropiperidine-1-carboxylate (350 mg, 87.5%), which was It was used directly in the reaction.
[0304] Step 4 To a solution of tert-butyl 4-(4-cyano-2-fluorobenzyl)-4-fluoropiperidine-1-carboxylate (350 mg, 1.04 mmol) was added HCl / dioxane (10 mL, 4 M, 40.0 mmol) at 15 °C. added. The mixture was stirred at 15°C under nitrogen for 16 hours. The mixture was concentrated to give 3-fluoro-4-((4-fluoropiperidin-4-yl)methyl)benzonitrile hydrochloride (250 mg, crude), which was used directly in the next step.
[0305] Step 5 2-(pyrimidin-4-yl)nicotinic acid (201 mg, 1.00 mmol), HATU (695 mg, 1.83 mmol), DIPEA (0.796 mL, 4.58 mmol), and 3-fluoro-4-(( A mixture of 4-fluoropiperidin-4-yl)methyl)benzonitrile hydrochloride (250 mg, 0.917 mmol) was stirred at 15° C. for 16 hours. The mixture was poured into water (20 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (30 mL). The organic layer was washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by SFC (column: DAICEL CHIRALPAK AS (250mm*30mm, 10um), condition 0.1%NH 3 H 2 Purification by O EtOH, start B 25, end B 25, flow rate (ml / min) 60) gave the desired product (100 mg). The residue was purified by preparative TLC (DCM / MeOH=10 / 1, eluted twice) to give 3-fluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidine- 4-yl)methyl)benzonitrile (41.6 mg, 10%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H =9.18(s,1H),9.01(s,1H),8.94-8.83(m,1H),8.80-8.70(m,1H),8.26(s,1H),7.79-7.60(m,1H),7.50 -7.33(m,4H),4.78-4.50(m,1H),3.58-3.31(m,1H),3.28-2.97(m,4H),2.14-1.82(m,2H),1.67(s,1H) .LCMS purity 100%, C 23 H 20 F 2 N 5 O[M+H]+ MS ESI calculated value for 420, measured value 420.
[0306] Example 12: (4-fluoro-4-((5-fluoropyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 10 ) synthesis [ka]
[0307] step 1 To a solution of 2-bromo-5-fluoropyridine (100 mg, 0.568 mmol) in THF (5 mL) was slowly added n-BuLi solution (0.22 mL, 2.5 M in hexane, 0.5682 mmol) at -78 °C and the mixture was stirred at -78°C for 30 minutes. BF 3· Et 2 O (0.72ml, 5.68mmol) and CuI (1.08g, 5.68mmol) were added to the reaction and stirred at -78°C for 10 minutes. To the resulting mixture was added dropwise a solution of tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (1.2 g, 5.62 mmol) in THF (5 mL) at -70 °C under nitrogen. added. After stirring at −70° C. for 1 hour, the mixture was poured into water (20 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by flash chromatography (0-30% EtOAc in PE) to give tert-butyl 4-((5-fluoropyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (230 mg , impurity). 1 H-NMR(400MHz, CDCl 3 )δ 8.39(m,1H),7.44-7.35(m,1H),7.13(m,1H),3.80(br s,2H),3.23(s,2H),1.58(m,3H),1.52-1.48 (m,2H),1.46(s,9H).
[0308] Step 2 DAST (0.195 mL, 1.48 mmol) was added at 0°C. The mixture was stirred at 20°C for 30 minutes. The mixture was poured into water (50 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine (2 x 50 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate to give tert-butyl 4-fluoro-4-((5-fluoropyridin-2-yl)methyl)piperidine-1-carboxylate (200 mg, crude), which is used directly in the next step. did. 1 H-NMR(400MHz, CDCl 3 )δ 8.46-8.33(m,1H),7.45-7.31(m,1H),7.26-7.15(m,1H),3.90(s,2H),3.50(m,2H),3.13-2.99(m,2H ),2.14-1.98(m,1H),1.79-1.57(m,3H),1.46(m,9H).
[0309] Step 3 A mixture of tert-butyl 4-fluoro-4-((5-fluoropyridin-2-yl)methyl)piperidine-1-carboxylate (0.2 g, 0.6402 mmol) in dioxane (5 mL) was added with HCl / dioxane (5 mL). , 4M in dioxane, 18.1 mmol) was added. The mixture was stirred at 25°C for 4 hours. The mixture was concentrated to give 5-fluoro-2-((4-fluoropiperidin-4-yl)methyl)pyridine hydrochloride (150 mg, impure). 1 H-NMR(400MHz, CDCl 3 )δ 8.67-8.55(m,1H),8.15-7.99(m,1H),7.85-7.65(m,1H),4.08-3.91(m,2H),3.13-2.91(m,2H),2.10(s ,4H),1.51-1.46(m,2H).
[0310] Step 4 2-(pyrimidin-4-yl)nicotinic acid (161 mg, 0.8041 mmol), 5-fluoro-2-((4-fluoropiperidin-4-yl)methyl)pyridine hydrochloride (200 mg, 0.8041 mmol) in DMF (5 mL) DIPEA (0.42 mL, 2.41 mmol) was added to a solution of HATU (456 mg, 1.20 mmol). The mixture was stirred at 20°C for 12 hours. H the mixture 2 Pour into O (50 mL) and stir for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. SFC the residue (column DAICEL CHIRALCEL OD-H (250mm*30mm, 5um), condition A=0.1%NH 3 H 2 Purified by (4-fluoro-4 -((5-fluoropyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (20 mg, 6.3%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ 9.20(s,1H),8.90(d,J=13.1 Hz,1H),8.75(s,1H),8.40(s,1H),8.24(s,1H),7.68(m,1H),7.51 -7.34(m,2H),7.31-7.27(m,1H),4.75-4.48(m,1H),3.43(s,1H),3.27-3.08(m,4H),2.08-1.90(m,2H) ,1.73-1.57(m,2H). 19 F NMR(400 MHz, CDCl 3 )δ F- 129.492,-160.008.LC-ELSD / MS purity ≧98%, C 21 H 19 F 2 N 5 O[M+H] + MS ESI calculated value for 396.2, measured value 396.2.
[0311] Example 13. Synthesis of 3,5-difluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)methyl)benzonitrile (Compound 11) [ka] step 1 To a solution of 3,5-difluorobenzonitrile (2 g, 14.3 mmol) in THF (20 mL) was added a LiHMDS solution (28.6 mL, 1M in hexanes, 28.6 mmol) at -78 °C. The mixture was stirred at -78 °C for 30 min and BF 3 ·EtO (2.02g, 14.3mmol) was added. A solution of tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (1.68 g, 7.89 mmol) in THF (10 mL) was added dropwise to the mixture and stirring was continued for 1 h. . Reaction mixture with H 2 Slowly poured into O (20 mL). The aqueous phase was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top and concentrate. The residue was purified by flash chromatography (5-30% EtOAc in PE) and preparative HPLC (Column Phenomenex Gemini-NX 80*30mm*3um, condition A=water (10mM NH 4 HCO 3 )-B=ACN, start B 36, end B 66, gradient time (min): 9, 100% B retention time (min): 2.5) and tert-butyl 4-(4-cyano-2, 6-difluorobenzyl)-4-hydroxypiperidine-1-carboxylate (100 mg, 3.95%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H =7.24-7.21(m,2H),3.88(s,2H),3.09(s,2H),2.90(s,2H),1.45(s,10H).
[0312] Step 2 A mixture of tert-butyl 4-(4-cyano-2,6-difluorobenzyl)-4-hydroxypiperidine-1-carboxylate (100 mg, 0.284 mmol) in DCM (10 mL) was added with DAST (94.7 mg, 0.5674 mmol). ) was added at 0°C. The mixture was stirred at 0°C for 5 minutes. The mixture was slowly poured into ice water (30 mL) and extracted with DCM (2 x 30 mL). Combined organic layers with NaHCO 3 (20 mL), then brine (10 mL), anhydrous Na 2 S.O. 4 dried over water and concentrated to give tert-butyl 4-(4-cyano-2,6-difluorobenzyl)-4-fluoropiperidine-1-carboxylate (90 mg, 89.9%), which was used in the next reaction. used directly.
[0313] Step 3 To a solution of tert-butyl 4-(4-cyano-2,6-difluorobenzyl)-4-fluoropiperidine-1-carboxylate (90 mg, 0.254 mmol) was added 15 mL of HCl / MeOH (5 mL, 4 M, 40.0 mmol). Added at °C. The mixture was stirred at 15°C under nitrogen for 16 hours. The mixture was concentrated to give 3,5-difluoro-4-((4-fluoropiperidin-4-yl)methyl)benzonitrile hydrochloride (80 mg, crude), which was used directly in the next step.
[0314] Step 4 2-(pyrimidin-4-yl)nicotinic acid (66.4 mg, 0.33 mmol), HATU (209 mg, 0.55 mmol), DIPEA (0.142 mL, 0.825 mmol), and 3,5-difluoro-4 in DMF (2 mL). A solution of -((4-fluoropiperidin-4-yl)methyl)benzonitrile hydrochloride (80 mg, 0.275 mmol) was stirred at 15° C. for 16 hours. The mixture was poured into water (10 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (10 x 2 mL). The combined organic layers were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography [2 elutions: 1st elution: (PE / EtOAc=1 / 0~0 / 1), 2nd elution: (DCM / MEOH=0 / 1 to 10 / 1)]. Purified to obtain 30mg, which was purified by SFC (column DAICEL CHIRALPAK AS (250mm*30mm, 10um), condition A=0.1%NH 3 H 2 O ) Nicotinoyl)piperidin-4-yl)methyl)benzonitrile (3.1 mg, 10%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H =9.18(s,0.4H),8.99(s,0.6H),8.94-8.85(m,1H),8.80-8.72(m,1H),8.27(s,1H),7.75-7.64(m,1H) ,7.47(br s,1H),7.26(s,2H),4.83-4.51(m,1H),3.54-3.33(m,1H),3.10(d,J=19.6 Hz,3H),2.06-1.94( m,2H),0.91-0.78(m,3H).LCMS purity 100%, C 23 H 19 F 3 N 5 O[M+H] + MS ESI calculated value for 438, measured value 438. 19 F NMR(400 MHz, CDCl 3 )δ F- 108.0, -161.9
[0315] Example 14. Synthesis of (4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)(4-(trifluoromethyl)phenyl)methanone (compound 12) [ka]
[0316] step 1 To a solution of 1-bromo-4-(trifluoromethyl)benzene (5.0 g, 22.2 mmol) in THF (50 mL) at -78 °C was added a solution of n-BuLi (13.3 mL, 2.5 M in hexane, 33.3 mmol). ) was added slowly and the mixture was stirred at -78°C for 30 minutes. To this mixture at −70° C. was added dropwise a solution of tert-butyl 4-formylpiperidine-1-carboxylate (3.37 g in THF, 22.2 mmol) in THF (10 mL). After stirring for 1 h at -70 °C, the mixture was NH 4 Poured into Cl solution (200 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 200 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (10-30% EtOAc in PE) to give tert-butyl 4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)piperidine-1-carboxylate (3.0 g, impure ) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 7.62(d,J=8.0 Hz,2H),7.44(d,J=8.0 Hz,2H),4.49(d,J=5.8 Hz,1H),4.13(m,2H),2.64(d,J=10.3 Hz,2H),1.90(d,J=12.8 Hz,1H),1.80-1.69(m,2H),1.45(s,9H),1.36-1.18(m,5H).
[0317] Step 2 To a solution of tert-butyl 4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)piperidine-1-carboxylate (3.0 g, 8.34 mmol) in DCM (30 mL) at 25 °C was added DMP (7.04 g , 16.6 mmol) was added little by little. The reaction was stirred at 25°C for 0.5 hour. Saturate the reaction mixture with aqueous NaHCO 3 / Na 2 S 2 O 3 (1:1) mixture (500 mL). The mixture was extracted with DCM (2 x 100 mL). Saturate the combined organic layers with aqueous NaHCO 3 / Na 2 S 2 O 3 (1:1) (2 x 200 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (10-30% EtOAc in PE) to yield tert-butyl 4-(4-(trifluoromethyl)benzoyl)piperidine-1-carboxylate (2.7 g, 91%). Ta. 1 H-NMR(400MHz, CDCl 3 )δ H 8.04(d,J=8.3 Hz,2H),7.75(d,J=8.1 Hz,1H),7.83-7.68(m,1H),4.16(s,2H),3.40(m,1H),2.92(m ,2H),2.53-2.37(m,1H),1.92-1.61(m,5H),1.47(s,9H),1.46(s,2H),0.91(m,1H).
[0318] Step 3 To a solution of tert-butyl 4-(4-(trifluoromethyl)benzoyl)piperidine-1-carboxylate (2.0 g, 5.59 mmol) in THF (20 mL) was added LiHMDS (8.38 mL, 8.38 mmol) under nitrogen. Added dropwise at 78°C. The mixture was stirred at -78°C for 30 minutes. To this mixture was added dropwise a solution of NFSI (1.76 g, 5.59 mmol) in THF (2 mL) at -78 °C. NaHCO mixture 3 Pour into solution (200 mL) and stir for 20 minutes. The mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (5-15% EtOAc in PE) to give tert-butyl 4-fluoro-4-(4-(trifluoromethyl)benzoyl)piperidine-1-carboxylate (1.2 g, 57.4 %) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 8.16(d,J=8.4 Hz,2H),7.73(d,J=8.3 Hz,2H),4.10(s,3H),3.21(m,2H),3.08-2.95(m,1H),2.82(m ,1H),2.31-1.91(m,5H),1.52-1.42(m,12H).
[0319] Step 4 A solution of tert-butyl 4-fluoro-4-(4-(trifluoromethyl)benzoyl)piperidine-1-carboxylate (0.2 g, 0.53 mmol) in dioxane (5 mL) was added with HCl / dioxane (5 mL, in dioxane). 4M, 18.1 mmol) was added and the mixture was stirred at 25°C for 4 hours. The mixture was concentrated to give (4-fluoropiperidin-4-yl)(4-(trifluoromethyl)phenyl)methanone hydrochloride (150 mg, crude). 1 H-NMR(400MHz, CDCl 3 )δ H 8.16(d,J=7.8 Hz,2H),7.84-7.67(m,2H),4.20-4.01(m,1H),3.65-2.99(m,3H),2.82-2.57(m,1H),2.35( s,1H),2.21-1.94(m,3H),1.73(s,3H).
[0320] Step 5 2-(pyrimidin-4-yl)nicotinic acid (116 mg, 0.5774 mmol), (4-fluoropiperidin-4-yl)(4-(trifluoromethyl)phenyl)methanone hydrochloride (180 mg) in DMF (5 mL) , 0.5774 mmol) and HATU (329 mg, 0.8661 mmol) was added DIPEA (0.30 mL, 1.73 mmol). The mixture was stirred at 20°C for 12 hours. Reaction mixture with H 2 Pour into O (50 mL) and stir for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O.4 Dry on top, filter and concentrate. Preparative HPLC of the residue (Phenomenex Gemini-NX C18 75*30mm*3um, conditions A=water (0.225%FA)-B=ACN, start B 42, end B 62, gradient time (min) 7, 100% B retention Purified by (4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)(4-( Trifluoromethyl)phenyl)methanone (49.3 mg, 18.6%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.45-9.21(m,1H),8.92(s,1H),8.78(d,J=4.3 Hz,1H),8.35-8.23(m,1H),8.18(d,J=8.3 Hz,2H),7.75 (d,J=8.3 Hz,3H),7.50(d,J=4.8 Hz,1H),4.92-4.57(m,1H),3.73-3.27(m,3H),2.80-2.48(m,1H), 2.38-1.82(m,3H) 19 F-NMR(400 MHz, CDCl 3 )δ F- 63.311,-165.406.LC-ELSD / MS purity ≥95%, C 23 H 18 F 4 N 4 O 2 [M+H] + MS ESI calculated for 459.1, measured 459.1.
[0321] Example 15 and Example 16(R)-(4-fluoro-4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridine- Synthesis of (S)-(4-fluoro-4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)piperidin-1-yl)(2-(pyrimidine-4) Synthesis of -yl)pyridin-3-yl)methanone (compound 14) [ka]
[0322] step 1 A solution of tert-butyl 4-fluoro-4-(4-(trifluoromethyl)benzoyl)piperidine-1-carboxylate (400 mg, 1.06 mmol) in MeOH (5 mL) was added with NaBH 4 (200 mg, 5.03 mmol) was added slowly in small portions at 25°C. The mixture was stirred at 25°C for 1 hour. Na 2 S 2 O 3 Aqueous solution (20 mL) was added and stirring continued for 30 minutes. The mixture was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry over, filter and concentrate to give racemic tert-butyl 4-fluoro-4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)piperidine-1-carboxylate (400 mg, crude). 1 H-NMR(400MHz, CDCl 3 )δ H 7.63(d,J=8.3 Hz,2H),7.49(d,J=8.1 Hz,2H),4.72(d,J=13.4 Hz,1H),4.01(s,2H),2.98(s,2H), 1.91-1.72(m,3H),1.66-1.55(m,4H),1.46(s,2H),1.43(s,9H),0.99(m,1H).
[0323] Step 2 HCl / dioxane ( 5 mL, 4M in dioxane, 18.1 mmol) was added and the mixture was stirred at 25° C. for 4 hours. The mixture was cooled and concentrated to give racemic-(4-fluoropiperidin-4-yl)(4-(trifluoromethyl)phenyl)methanol hydrochloride (360 mg, crude). 1 H-NMR(400MHz, CDCl 3 )δ H 7.64(d,J=8.5 Hz,2H),7.54-7.47(m,2H),4.77-4.57(m,1H),4.04(s,1H),3.58(s,4H),2.97(s,2H) ,0.98(d,J=8.0 Hz,4H).
[0324] Step 3 2-(pyrimidin-4-yl)nicotinic acid (229 mg, 1.14 mmol) in DMF (5 mL), racemic-(4-fluoropiperidin-4-yl)(4-(trifluoromethyl)phenyl)methanol hydrochloride ( DIPEA (0.59 mL, 1.73 mmol) was added to a solution of 360 mg, 1.14 mmol) and HATU (650 mg, 1.71 mmol). The mixture was stirred at 20°C for 12 hours. H the mixture 2 Pour into O (50 mL) and stir for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. SFC the residue (column DAICEL CHIRALPAK IG (250mm*30mm, 10um), condition A=0.1%NH 3 H 2 Purified by O B = EtOH, starting B 35%, ending B 35%, gradient time (min) 100% B retention time (min), flow rate (ml / min): 70, injection 55) to yield:
[0325] (R)-(4-fluoro-4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (58.5 mg, 32.5%). 1 H-NMR(400MHz, CDCl 3 )δ H 9.19(s,1H),8.91-8.62(m,3H),8.33-8.13(m,1H),7.73-7.57(m,3H),7.57-7.37(m,3H),4.94-4.59(m,2H) ),3.58-2.95(m,3H),2.83-2.59(m,1H),2.18-1.83(m,2H),1.57-1.41(m,1H) 19 F NMR(400 MHz, CDCl 3 )δ F- 162.565.LC-ELSD / MS purity ≧98%, ee%=100%;C 23 H 20 F 4 N 4 O 2 [M+H] + MS ESI calculated for 461.1, measured 461.1.
[0326] (S)-(4-fluoro-4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (65.8 mg, 36.7%): 1 H NMR(400MHz, CDCl 3 )δ H 8.83-8.56(m,3H),8.27-8.04(m,1H),7.69-7.50(m,3H),7.47-7.31(m,3H),4.81-4.52(m,2H),3.51-2.58(m ,4H),2.33-1.72(m,2H),1.51-1.21(m,1H). 19 F NMR(400 MHz, CDCl 3 )δ F- 162.565.LC-ELSD / MS purity ≧98%, ee%=100%;C 23 H 20 F 4 N 4 O 2 [M+H] + MS ESI calculated for 461.1, measured 461.1.
[0327] Examples 17 and 18 (S)-3-fluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)(hydroxy)methyl)benzonitrile Synthesis of (Compound 15) and (R)-3-fluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)(hydroxy)methyl)benzonitrile Synthesis of (compound 16) [ka]
[0328] step 1 To a solution of iPrMgCl·LiCl (22.9 mL, 1.3 M, 29.8 mmol) in THF (10 mL) was added 4-bromo-3-fluorobenzonitrile (5 g, 24.9 mmol) in THF (10 mL). The mixture was stirred at −10° C. under nitrogen for 0.5 h, then tert-butyl 4-formylpiperidine-1-carboxylate (5 g, 23.4 mmol) in THF (50 mL) was added dropwise at −70° C. After stirring for 1 h at -70 °C, the mixture was NH 4 Slowly poured into a saturated aqueous solution of Cl (40 mL). The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4Dry on top and concentrate. The residue was purified by silica gel chromatography (5-30% EtOAc in PE) to give tert-butyl 4-((4-cyano-2-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (6.6 g, 84.3%). 1 H-NMR(400MHz, CDCl 3 )δ H =7.67-7.56(m,1H),7.54-7.43(m,1H),7.36-7.31(m,1H),4.92-4.82(m,1H),4.26-3.93(m,2H),2.71-2.52( m,2H),2.11-2.01(m,1H),1.85-1.66(m,2H),1.44(s,9H),1.40-1.23(m,3H).
[0329] Step 2 A solution of tert-butyl 4-((4-cyano-2-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (3g, 8.97mmol) in DCM (30mL) was added with DMP (7.58g, 17.9mmol). ) was added. The reaction mixture was stirred at 60°C for 0.5 hour. Add NaHCO to the mixture 3 Aqueous solution (50mL) and NaS 2 O 3 Aqueous solution (50 mL) was added. The mixture was extracted with DCM (2 x 50 mL). The combined organic layers were washed with brine (50 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate to give tert-butyl 4-(4-cyano-2-fluorobenzoyl)piperidine-1-carboxylate (2.5g, 83.8%). 1 H-NMR(400MHz, CDCl 3 )δ H =7.90-7.78(m,1H),7.60-7.52(m,1H),7.50-7.43(m,1H),4.24-3.99(m,2H),3.29-3.12(m,1H),2.95-2.78( m,2H),1.97-1.81(m,2H),1.64-1.56(m,2H),1.45(s,9H).
[0330] Step 3 To a solution of tert-butyl 4-(4-cyano-2-fluorobenzoyl)piperidine-1-carboxylate (1.2 g, 3.61 mmol) in THF (10 mL) was added LiHMDS (7.22 mL, 1M, 7.22 mmol). It was added dropwise at 70°C. The mixture was stirred at -78°C for 30 minutes. NFSI (1.36 g, 4.33 mmol) in THF (5 mL) was then added dropwise. The mixture was stirred at -78 °C for 2 h and then treated with NaHCO 3 It was poured into an aqueous solution (10 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 tert-butyl 4-(4-cyano-2-fluorobenzoyl)-4-fluoropiperidine- 1-carboxylate (550 mg, 43.6%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H =7.57-7.51(m,2H),7.48-7.43(m,1H),4.21-4.01(m,2H),3.09(s,2H),2.17-1.93(m,4H),1.48(s,9H) .
[0331] Step 4 A solution of tert-butyl 4-(4-cyano-2-fluorobenzoyl)-4-fluoropiperidine-1-carboxylate (400 mg, 1.14 mmol) in MeOH (10 mL) was added with NaBH 4 (86.6 mg, 2.28 mmol) was slowly added in portions at 25°C. The mixture was stirred at 25°C for 1 hour. N.H. 4 Aqueous Cl (50 mL) was added and the mixture was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate to give tert-butyl 4-((4-cyano-2-fluorophenyl)(hydroxy)methyl)-4-fluoropiperidine-1-carboxylate (250 mg, crude). 1 H-NMR(400MHz, CDCl 3 )δ H =7.75-7.60(m,1H),7.54-7.47(m,1H),7.38-7.33(m,1H),5.06(d,J=15.2 Hz,1H),4.08-3.93(m,2H),3.07 -2.87(m,2H),1.64-1.51(m,5H),1.43(s,9H).
[0332] Step 5 tert-Butyl 4-((4-cyano-2-fluorophenyl)(hydroxy)methyl)-4-fluoropiperidine-1-carboxylate (250 mg, 0.709 mmol) in dioxane (10 mL) was treated with HCl / MeOH (10 mL). , 4M, 40.0 mmol) was added at 15°C. The mixture was stirred at 15°C under nitrogen for 16 hours. The mixture was concentrated to give 3-fluoro-4-((4-fluoropiperidin-4-yl)(hydroxy)methyl)benzonitrile hydrochloride (200 mg, crude), which was used directly in the next reaction.
[0333] Step 6 2-(pyrimidin-4-yl)nicotinic acid (153 mg, 0.762 mmol), HATU (524 mg, 1.38 mmol), DIPEA (0.602 mL, 3.46 mmol), and 3-fluoro-4-(( A solution of 4-fluoropiperidin-4-yl)(hydroxy)methyl)benzonitrile hydrochloride (200 mg, 0.917 mmol) was stirred at 15° C. for 16 hours. The mixture was poured into water (20 mL) and stirred for 20 minutes. The aqueous phase was extracted with EtOAc (30 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by SFC (column: DAICEL CHIRALPAK AS (250mm*30mm, 10um), condition A=0.1%NH 3 H 2 O B=EtOH, start B 25, end B 25, flow rate (ml / min) 60), racemic-3-fluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl) Nicotinoyl)piperidin-4-yl)(hydroxy)methyl)benzonitrile (200mg, 66.4%) was obtained, and this was converted to SFC (column: DAICEL CHIRALPAK AD (250mm*30mm, 10um), condition A=0.1%NH 3 H 2 Further purification by O B=MEOH, start B 45, end B 45, flow rate (ml / min) 60) yielded:
[0334] (S)-3-Fluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)(hydroxy)methyl)benzonitrile (69.2mg, 34.7%) . 1 H-NMR(400MHz, CDCl 3 )δ H =9.17(s,0.4H),8.84(br s,1H),8.75(s,1.6H),8.33-8.15(m,1H),7.74-7.61(m,2H),7.56-7.42(m,2H) ),7.41-7.31(m,1H),5.20-5.02(m,1H),4.87-4.54(m,1H),3.59-2.50(m,4H),2.34-1.84(m,3H).LCMS purity 100 %,ee=100%,C 23 H 20 F 2 N 5 O 2 [M+H] + MS ESI calculated value for 436, measured value 436.
[0335] (R)-3-Fluoro-4-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)(hydroxy)methyl)benzonitrile (62.3mg, 31.3%) . 1 H NMR(400MHz, CDCl 3 )δ H =9.22-9.10(m,1H),9.22-9.10(m,1H),8.85(s,1H),8.74(s,2H),8.31-8.15(m,1H),7.73-7.60(m,2H) ,7.55-7.41(m,2H),7.41-7.31(m,1H),5.18-5.04(m,1H),4.86-4.56(m,1H),3.60-2.65(m,3H),2.30-1.82( m,3H).LCMS purity 100%, ee=99.8%. C 23 H 20 F 2 N 5 O 2 [M+H] + MS ESI calculated value for 436, measured value 436.
[0336] Example 19. Synthesis of 3-fluoro-4-(4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidine-4-carbonyl)benzonitrile (compound 17) [ka]
[0337] step 1 A solution of tert-butyl 4-(4-cyano-2-fluorobenzoyl)-4-fluoropiperidine-1-carboxylate (150 mg, 0.428 mmol) in ??? was added with HCl / MeOH (10 mL, 4M, 40.0 mmol) ) was added at 15°C. The mixture was stirred at 15°C under nitrogen for 16 hours. The mixture was concentrated to give 3-fluoro-4-(4-fluoropiperidine-4-carbonyl)benzonitrile hydrochloride (120 mg, crude). The crude residue was used directly in the next step.
[0338] Step 2 2-(pyrimidin-4-yl)nicotinic acid (92.6 mg, 0.46 mmol), HATU (318 mg, 0.84 mmol), DIPEA (0.363 mL, 2.09 mmol), and 3-fluoro-4-( A mixture of 4-fluoropiperidine-4-carbonyl)benzonitrile hydrochloride (120 mg, 0.418 mmol) was stirred at 15° C. for 16 hours. The mixture was poured into water (20 mL) and stirred for 20 minutes. The aqueous phase was extracted with EtOAc (30 mL). The combined organic phases were washed with brine (3 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX 80*30mm*3um, condition A=water (10mM NH 4 HCO 3 )-B=ACN, start B 27, end B 57, flow rate (ml / min) 60) purified by 3-fluoro-4-(4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl) ) Piperidine-4-carbonyl)benzonitrile (82.6 mg, 45.6%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H =9.43(s,0.6H),9.19(s,0.4H),8.97-8.84(m,1H),8.81-8.71(m,1H),8.36-8.17(m,1H),7.82-7.64(m, 1H),7.61-7.53(m,2H),7.52-7.43(m,2H),4.92-4.62(m,1H),3.77-3.51(m,1H),3.31-3.05(m,2H),2.81- 2.12(m,3H),1.94-1.76(m,1H).LCMS purity 100%, C 23 H 18 F 2 N 5 O 2 [M+H] + MS ESI calculated value for 434, measured value 434. 19 F-NMR (400MHz, CDCl 3 )δ F- 106.0, -162.
[0339] Example 20. (4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (Compound 18 ) synthesis [ka]
[0340] step 1 To a solution of 2-bromo-5-chloropyridine (2 g, 10.3 mmol) in toluene (20 mL) at -78 °C under nitrogen was slowly added a solution of n-BuLi (8.24 mL, 2.5 M in hexane, 20.6 mmol). was added and the mixture was stirred at -78°C for 30 minutes. tert-Butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (2.43 g, 11.4 mmol) and BF in toluene (10 mL) 3 ·Et 2 A solution of O (1.47g, 10.4mmol) was added dropwise and the resulting mixture was stirred at -70°C for 2 hours. Saturate the mixture with NH 4 It was slowly poured into aqueous Cl solution (200 mL) and the mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry above and concentrate to give tert-butyl 4-((5-chloropyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (400 mg, impure). 1 H-NMR(400 MHz, CDCl 3 )δ H 8.47(d,J=2.4 Hz,1H),7.62(dd,J=8.4,2.4 Hz,1H),7.08(d,J=8.4 Hz,1H),5.27(br s,1H),3.67-3.89( m,2H),3.21(br s,2H),2.88(s,2H),1.56-1.25(m,13H).
[0341] Step 2 A solution of tert-butyl 4-((5-chloropyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (400 mg, 1.22 mmol) in DCM (10 mL) was added with DAST (393 mg, 2.44 mmol). ) was added at 0°C. The mixture was stirred at 0°C for 30 minutes. Mix the mixture with ice-cold NaHCO 3 (80 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate to give tert-butyl 4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (400 mg, crude). 1 H-NMR(400 MHz, CDCl 3 )δ H 8.50(d,J=2.3 Hz,1H),7.60(td,J=7.9,2.5 Hz,1H),7.06-7.20(m,1H),5.30(s,1H),3.72-4.00(m,2H) ,3.33-3.53(m,2H),2.99-3.16(m,2H),1.45(d,J=3.0 Hz,12H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -160.379.
[0342] Step 3 A solution of tert-butyl 4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (400 mg, 1.21 mmol) in dioxane (5 mL) was added with HCl / dioxane (1.51 mL). , 4M, 6.05 mmol) was added and the mixture was stirred at 25°C for 4 hours. The mixture was concentrated to give 5-chloro-2-((4-fluoropiperidin-4-yl)methyl)pyridine hydrochloride (400 mg, crude), which was used directly in the next reaction.
[0343] Step 4 2-(pyrimidin-4-yl)nicotinic acid (301 mg, 1.5 mmol), HATU (855 mg, 2.25 mmol), DIPEA (969 mg, 7.5 mmol), and 5-chloro-2-((4 -fluoropiperidin-4-yl)methyl)pyridine hydrochloride (400 mg, 1.5 mmol) was stirred at 25° C. for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX 80*40mm*3 μm, condition A=water (0.05%NH 3 H 2 O)-B=ACN, starting B 18, ending B 48), purified by (4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidine -4-yl)pyridin-3-yl)methanone (50.1 mg, 8%) was obtained. 1 H NMR(400 MHz, CDCl 3 )δ H 9.18-8.97(m,2H),8.74(d,J=3.2 Hz,1H),8.49(br s,1H),8.24(br d,J=5.2 Hz,1H),7.54-7.73(m,2H) ,7.45(br s,1H),7.22(br t,J=8.4 Hz,1H),4.42-4.72(m,1H),3.33-3.54(m,1H),2.98-3.29(m,4H),1.64 -2.06(m,4H).LC-ELSD / MS purity 99%, C 21 H 20 ClFN 5 O[M+H] + MS ESI calculated value for 412.1, measured value 412.1. 19 F-NMR (376.5MHz, CDCl 3 )δ F -160.064.
[0344] Example 21. Synthesis of (4-(2,4-difluorobenzyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 19) [ka]
[0345] step 1 Mg (0.46g, 19.3mmol) and I in THF (5mL) 2(2.45 mg, 0.00966 mmol) was added 1-(bromomethyl)-2,4-difluorobenzene (2.0 g, 9.66 mmol) in THF (5 mL) at 25° C. under nitrogen. The mixture was heated to 50°C and stirred for 1 hour. The mixture was cooled to room temperature and then added to a solution of tert-butyl 4-oxopiperidine-1-carboxylate (1.98 g, 9.94 mmol) in THF (10 mL) at 25°C. The mixture was stirred at 25°C for 1 hour. NH mixture 4 It was poured into a Cl aqueous solution (100 mL) and stirred for 1 hour. The mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (2 x 100 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (10-40% EtOAc in PE) to give tert-butyl 4-(2,4-difluorobenzyl)-4-hydroxypiperidine-1-carboxylate (720 mg, 22.1%). Obtained. 1 H NMR(400MHz, CDCl 3 )δ H 8.39(m,1H),7.44-7.35(m,1H),7.13(m,1H),3.80(s,2H),3.23(s,2H),1.58(m,3H),1.52-1.48(m, 2H),1.46(s,9H).
[0346] Step 2 To a mixture of tert-butyl 4-(2,4-difluorobenzyl)-4-hydroxypiperidine-1-carboxylate (400 mg, 1.22 mmol) in DCM (5 mL) was added DAST (0.322 mL, 2.44 mmol) at 0 °C. I added it. The mixture was stirred at 20°C for 0.5 hour. The mixture was poured into water (50 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine (2 x 50 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate to give tert-butyl 4-(2,4-difluorobenzyl)-4-fluoropiperidine-1-carboxylate (400 mg, crude), which was used directly in the next reaction.
[0347] Step 3 A solution of tert-butyl 4-(2,4-difluorobenzyl)-4-fluoropiperidine-1-carboxylate (0.4 g, 1.21 mmol) in dioxane (5 mL) was added with HCl / dioxane (5 mL, 4M in dioxane, 18.1 mmol) was added and the mixture was stirred at 25°C for 4 hours. The mixture was concentrated to give 4-(2,4-difluorobenzyl)-4-fluoropiperidine hydrochloride (350 mg, crude), which was used directly in the next reaction.
[0348] Step 4 2-(pyrimidin-4-yl)nicotinic acid (263 mg, 1.31 mmol), 4-(2,4-difluorobenzyl)-4-fluoropiperidine hydrochloride (350 mg, 1.31 mmol), and HATU in DMF (5 mL). (745 mg, 1.96 mmol) was added DIPEA (0.68 mL, 3.93 mmol). The mixture was stirred at 20°C for 12 hours. Reaction mixture with H 2 Pour into O (50 mL) and stir for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-10% MeOH in DCM) and SFC (column DAICEL CHIRALCEL OD-H (250mm*30mm, 5um), condition A=0.1%NH 3 H 2 Further purification by O B = EtOH, start B 30%, end B 30%, gradient time (min) 100% B retention time (min), flow rate (ml / min) 60, injection 100), (4-(2, 4-difluorobenzyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (107 mg, 20%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.19(s,1H),8.91-8.81(m,1H),8.75(dd,J=1.4,4.8 Hz,1H),8.33-8.19(m,1H),7.75-7.63(m,1H),7.51- 7.41(m,1H),7.26-7.17(m,1H),6.93-6.77(m,2H),4.75-4.51(m,1H),3.53-3.35(m,1H),3.31-3.09(m,2H) ),3.03-2.88(m,2H),2.09-1.81(m,2H),1.73-1.61(m,1H). 19 F-NMR(400 MHz, CDCl 3 )δ F- 111.176,-160.979.LC-ELSD / MS purity ≥98%, C 22 H 19 F 3 N 4 O[M+H] + MS ESI calculated for 413.2, measured 413.2.
[0349] Example 22. Synthesis of (4-(3,5-difluorobenzyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 20) [ka]
[0350] step 1 Et 2 Mg (0.56 g, 23.2 mmol) and I in O (10 mL) 2 (2.94 mg, 0.0116 mmol), Et 2 1-(Bromomethyl)-3,5-difluorobenzene (3.0 g, 11.6 mmol) in O (10 mL) was added at 25° C. under nitrogen. The mixture was stirred at 50°C for 1 hour. The mixture was cooled and added dropwise to a solution of tert-butyl 4-oxopiperidine (1.98 g, 9.94 mmol) in THF at 25° C. and stirred for 1 h. NH mixture 4 It was poured into a Cl aqueous solution (50 mL) and stirred for 0.5 hour. The mixture was extracted with EtOAc (50 mL x 3) and the combined organic layers were washed with brine (2 x 10 mL) and Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (10-40% EtOAc in PE) to give tert-butyl 4-(3,5-difluorobenzyl)-4-hydroxypiperidine-1-carboxylate (600 mg, 18%). Obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 6.82-6.66(m,3H),3.86(br s,2H),3.10(m,2H),2.74(s,2H),1.65-1.50(m,4H),1.46(s,9H).
[0351] Step 2 To a mixture of tert-butyl 4-(3,5-difluorobenzyl)-4-hydroxypiperidine-1-carboxylate (600 mg, 1.83 mmol) in DCM (5 mL) was added DAST (0.482 mL, 3.66 mmol) at 0 °C. and the mixture was stirred at 20° C. for 0.5 h. The mixture was poured into water (50 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 20 mL) and the combined organic layers were washed with brine (2 x 50 mL) and anhydrous Na 2 S.O. 4 dried over water, filtered, and concentrated to give tert-butyl 4-(3,5-difluorobenzyl)-4-fluoropiperidine-1-carboxylate (600 mg, crude), which was directly used in the next reaction. used.
[0352] Step 3 A mixture of tert-butyl 4-(3,5-difluorobenzyl)-4-fluoropiperidine-1-carboxylate (0.4 g, 1.21 mmol) in dioxane (5 mL) was added with HCl / dioxane (3.0 mL, 4M in dioxane). , 12.1 mmol) was added and the mixture was stirred at 25°C for 4 hours. The mixture was cooled and concentrated to give 4-(3,5-difluorobenzyl)-4-fluoropiperidine hydrochloride (600 mg, crude), which was used directly in the next reaction.
[0353] Step 4 2-(pyrimidin-4-yl)nicotinic acid (340 mg, 1.69 mmol), 4-(3,5-difluorobenzyl)-4-fluoropiperidine hydrochloride (450 mg, 1.69 mmol), and HATU in DMF (5 mL). (962 mg, 2.53 mmol) was added DIPEA (0.88 mL, 5.06 mmol). The mixture was stirred at 20°C for 12 hours. H the mixture 2 Pour into O (50 mL) and stir for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-10% MeOH in DCM) to give the desired product (700 mg, impure), which was purified by SFC (column DAICEL CHIRALCEL OD-H (250 mm*30 mm, 5 um), conditions A=0.1%NH 3 H 2Further purification by O B = EtOH, start B 30%, end B 30%, gradient time (min) 100% B retention time (min), flow rate (ml / min) 60, injection 100), (4-(3, 5-difluorobenzyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (234 mg, 33.6%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.12(s,1H),8.87-8.75(m,1H),8.68(m,1H),8.17(d,J=4.6 Hz,1H),7.68-7.56(m,1H),7.38(m,1H) ,6.66(d,J=5.4 Hz,3H),4.72-4.43(m,1H),3.44-3.27(m,1H),3.20-3.00(m,2H),2.95-2.72(m,2H),1.97 -1.57(m,3H). 19 F-NMR(400 MHz, CDCl 3 )δ F- 110.005,-161.317.LC-ELSD / MS purity ≧99%, C 22 H 19 F 3 N 4 O[M+H] + MS ESI calculated for 413.2, measured 413.2.
[0354] Example 23. Synthesis of 6-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)methyl)nicotinonitrile (Compound 21) [ka]
[0355] step 1 To a mixture of 6-methylnicotinonitrile (1 g, 8.46 mmol) in THF (15 mL) was added LDA (6.3 mL, 2M in THF, 12.6 mmol) dropwise at -78 °C and the mixture was stirred under nitrogen at -78 °C. Stirred at ℃ for 1 hour. Tert-butyl 4-oxopiperidine-1-carboxylate (2.51 g, 12.6 mmol) was then added and stirring continued at -70°C for 2 hours. The mixture was poured into water (100 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (2 x 30 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX 80*40mm*3um, conditions A=water (0.05%NH3H2O)-B=ACN, start B 24, end B 54) to give tert-butyl 4- ((5-cyanopyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (100 mg, impure) was obtained. 1 H-NMR(400 MHz, CDCl3)δ H ppm 8.80(d,J=2.0 Hz,1H),7.92(dd,J=8.0,2.0 Hz,1H),7.29(br d,J=8.0 Hz,1H),4.81(br s,1H),3.81( br s,2H),3.20(br s,2H),3.00(s,2H),1.48-1.53(m,4H),1.45(s,9H).
[0356] Step 2 A solution of tert-butyl 4-((5-cyanopyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (100 mg, 0.3150 mmol) in DCM (10 mL) was added with DAST (101 mg, 0.63 mmol). ) was added at 0°C. The mixture was stirred at 0°C for 5 minutes. Mix the reaction mixture with ice water and NaHCO 3 (80ml) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate to obtain tert-butyl 4-((5-cyanopyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (100 mg, crude), which is used directly in the next reaction. did.
[0357] Step 3 A solution of tert-butyl 4-((5-cyanopyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (100 mg, 0.3131 mmol) in dioxane (10 mL) was added with HCl / dioxane (0.39 mL). , 4M in dioxane, 1.56 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was cooled and concentrated to give 6-((4-fluoropiperidin-4-yl)methyl)nicotinonitrile hydrochloride (100 mg, crude), which was used directly in the next reaction.
[0358] Step 4 2-(pyrimidin-4-yl)nicotinic acid (117 mg, 0.5865 mmol), HATU (334 mg, 0.8797 mmol), DIPEA (378 mg, 2.93 mmol), and 6-((4-fluoropiperidin-4-yl)methyl) Nicotinonitrile hydrochloride (150 mg, 0.5865 mmol) was mixed in DMF (5 mL) and stirred at 25° C. for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX 80*40mm*3um, condition A=water (0.05%NH 3 H 2 O)-B=ACN, start B 14, end B) purified by 6-((4-fluoro-1-(2-(pyrimidin-4-yl)nicotinoyl)piperidin-4-yl)methyl)nicotino Nitrile (38.7 mg, 16%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.18-9.05(s,1H),8.88(br dd,J=13.2,4.4 Hz,1H),8.72-8.83(m,2H),8.25(br s,1H),7.91(dd,J=8.0,2.0 Hz,1H),7.60-7.74(m,1H),7.36-7.50(m,2H),4.32-4.80(m,1H),3.40(br d,J=15.2 Hz,1H),3.11-3.30(m ,4H),1.88-2.10(m,2H),1.67(br d,J=17.2 Hz,2H).LC-ELSD / MS purity 100%, C 22 H 20 FN 6 O[M+H] + MS ESI calculated value for 403.2, measured value 403.2. 19 F-NMR (376.5MHz, CDCl 3 )δ F -160.607.
[0359] Example 24. (4-fluoro-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 22) [ka]
[0360] step 1 To a solution of 2-methyl-5-(trifluoromethyl)pyridine (2.0 g, 12.4 mmol) in THF (15 mL) was added LDA (18.6 mL, 2M in THF, 37.2 mmol) dropwise at -78 °C. , the mixture was stirred at -78 °C for 1 h. Then tert-butyl 4-oxopiperidine-1-carboxylate (2.47g, 12.4mmol) was added and the mixture was stirred at -70°C for 2 hours. The mixture was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 50 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini NX C18 150*40mm*5 μm, condition A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN, start B 32, end B 62) purified by tert-butyl 4-hydroxy-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (280mg, 6.27%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.79(s,1H),7.89(m,1H),7.28(s,1H),5.23(s,1H),3.71-3.93(m,2H),3.14-3.31(m,2H),2.99(s, 2H), 1.48-1.63(m, 10H), 1.45(s, 10H).
[0361] Step 2 DAST ( 249 mg, 1.55 mmol) was added at 0°C, and the mixture was stirred at 0°C for 5 minutes. NaHCO mixture 3 It was poured into an aqueous solution (80 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 30 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4dried over, filtered and concentrated to give tert-butyl 4-fluoro-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (280 mg, crude). This was used directly in the next reaction.
[0362] Step 3 A solution of tert-butyl 4-fluoro-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (280 mg, 0.7726 mmol) in dioxane (10 mL) was added with HCl / Dioxane (0.965 mL, 4M in dioxane, 3.86 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to give 2-((4-fluoropiperidin-4-yl)methyl)-5-(trifluoromethyl)pyridine hydrochloride (280 mg, crude), which was used directly in the next reaction.
[0363] Step 4 2-(pyrimidin-4-yl)nicotinic acid (188 mg, 0.9373 mmol), HATU (532 mg, 1.40 mmol), DIPEA (604 mg, 4.68 mmol), and 2-((4-fluoropiperidin-4-yl)methyl) -5-(Trifluoromethyl)pyridine hydrochloride (280 mg, 0.9373 mmol) was mixed in DMF (5 mL) and stirred at 25°C for 2 hours. The mixture was poured into water (30 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX 80*40mm*3 μm, condition A=water (0.05%NH 3 H 2 O)-B=ACN, start B 25, end B 55) and purified by (4-fluoro-4-((5-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)( 2-(pyrimidin-4-yl)pyridin-3-yl)methanone (72.4 mg, 17.3%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.18-9.03(s,1H),8.87(d,J=12.0,4.0 Hz,1H),8.72-8.81(m,2H),8.18-8.30(m,1H),7.88(d,J=8.0,2.0 Hz,1H),7.63-7.72(m,1H),7.34-7.48(m,2H),7.34-7.48(m,1H),4.42-4.78(m,1H),3.33-3.52(m,1H), 3.12-3.31(m,4H),1.76-2.25(m,3H).LC-ELSD / MS purity 95%, C 22 H 20 F 4 N 5 O[M+H] + MS ESI calculated value for 446.2, measured value 446.2. 19 F-NMR (376.5MHz, CDCl 3 )δ F -62.355;-160.521.
[0364] Example 25. (4-fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 23) [ka]
[0365] step 1 To a solution of 5-bromo-2-(trifluoromethyl)pyridine (5.0 g, 22.1 mmol) in THF (10 mL) was added a solution of iPrMgCl·LiCl (17.0 mL, 1.3 M in hexane, 22.1 mmol) at 0 °C. It was added slowly and the mixture was stirred at 0°C for 30 minutes. To this mixture was added dropwise a solution of tert-butyl 4-formylpiperidine-1-carboxylate (4.64 g, 21.8 mmol) in THF (5 mL) at 0° C. under nitrogen. After stirring at 0° C. for 1 h, the mixture was poured into water (100 mL), stirred for 20 min, and then extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (10-30% EtOAc in PE) to give tert-butyl 4-(hydroxy(6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine-1-carboxylate ( 5.7g, 72.6%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 8.58(s,1H),7.79(d,J=6.5 Hz,1H),7.62(d,J=8.0 Hz,1H),4.53(m,1H),4.06(s,2H),2.55(d,J =14.1 Hz,2H),2.13(d,J=3.0 Hz,1H),1.82-1.63(m,2H),1.42-1.34(m,11H),1.29-1.17(m,3H).
[0366] Step 2 A solution of tert-butyl 4-(hydroxy(6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine-1-carboxylate (5.6 g, 15.5 mmol) in DCM (50 mL) was added with DMP (13.1 g). , 31.0 mmol) was added little by little at 25°C. The reaction mixture was stirred at 25 °C for 0.5 h and then treated with NaHCO 3 / Na 2 S 2 O 3 (1:1) in a saturated aqueous solution (200 mL). The mixture was extracted with DCM (2 x 50 mL) and the combined organic layers were dissolved in saturated aqueous NaHCO 3 / Na 2 S 2 O 3 (1:1) (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to give tert-butyl 4-(6-(trifluoromethyl)nicotinoyl)piperidine-1-carboxylate (6.0 g, impure). . 1 H-NMR(400MHz, CDCl 3 )δ H 9.21(d,J=1.5 Hz,1H),8.39(m,1H),8.25(m,1H),8.06-7.90(m,1H),7.82(d,J=8.3 Hz,1H),7.75-7.69 (m,1H),4.17(d,J=9.0 Hz,2H),3.38(m,1H),2.93(m,2H),2.26(s,1H),1.87(d,J=12.3 Hz,2H) ,1.77-1.65(m,3H),1.46(s,9H).
[0367] Step 3 To a solution of tert-butyl 4-(6-(trifluoromethyl)nicotinoyl)piperidine-1-carboxylate (6.0 g, 16.7 mmol) in THF (50 mL) was added LiHMDS (25.0 mL, 25.0 mmol) at -78 °C. Added dropwise. The mixture was stirred at -78°C for 30 minutes. A solution of NFSI (6.30 g, 20.0 mmol) in THF (10 mL) was added dropwise at -78°C. NaHCO mixture 3 The solution was poured into solution (100 mL) and stirred for 20 minutes, then extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with saturated brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to give tert-butyl 4-fluoro-4-(6-(trifluoromethyl)nicotinoyl)piperidine-1-carboxylate (4.7 g, 74.8 %) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 9.33(s,1H),8.49(d,J=7.5 Hz,1H),7.81(d,J=8.3 Hz,1H),4.23-4.01(m,2H),3.29-3.12(m,2H),2.25 -2.00(m,4H),1.64(s,2H),1.49(s,9H).
[0368] Step 4 A solution of tert-butyl 4-fluoro-4-(6-(trifluoromethyl)nicotinoyl)piperidine-1-carboxylate (1.0 g, 2.65 mmol) in MeOH (20 mL) was added with NaBH 4 (0.2g, 5.30mmol) was added slowly in small portions at 25°C. The mixture was stirred at 25 °C for 1 h, then Na 2 S 2 O 3 A saturated aqueous solution of (200 mL) was added and the resulting mixture was stirred for 30 minutes. The mixture was extracted with DCM (2 x 50 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dry over, filter, and concentrate to give tert-butyl 4-fluoro-4-(hydroxy(6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine-1-carboxylate (1.0 g, impure ), which was used directly in the next reaction.
[0369] Step 5 A solution of tert-butyl 4-fluoro-4-(hydroxy(6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine-1-carboxylate (1.0 g, 2.64 mmol) in DCM (10 mL) was added to TEA (1.1 mL, 7.92 mmol) and salt methanesulfonyl chloride (0.6 g, 5.28 mmol) were added in one portion at 0°C. The mixture was stirred at 0 °C for 2 h, then heated with H 2 Slowly poured into O (50 mL). The mixture was extracted with DCM (3x20mL) and the combined organic layers were washed with brine (2x10mL) and anhydrous Na 2 S.O. 4 dried over, filtered and concentrated to give tert-butyl4-fluoro-4-(((methylsulfonyl)oxy)(6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine-1-carboxy The rate (1.3g, crude) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ 8.75(s,1H),8.26-8.16(m,1H),7.97(d,J=8.0 Hz,1H),7.77(d,J=8.3 Hz,1H),6.53-6.46(m,1H) ,5.50(d,J=17.6 Hz,1H),4.07(s,2H),2.98(s,3H),1.81-1.57(m,6H),1.46(s,9H).
[0370] Step 6 tert-Butyl 4-fluoro-4-(((methylsulfonyl)oxy)(6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine-1-carboxylate (1.3 g, 2.84 g in THF (5 mL)) LAH (215 mg, 5.68 mmol) was added to a solution of 1 mmol). After stirring at 50° C. for 2 hours, the mixture was diluted with water (30 mL) and extracted with EtOAc (2×20 mL). Combined organic layers with 10% NH 4 Wash with Cl aqueous solution (40 mL) and remove Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was partitioned between EtOAc (20 mL) and HCl (3M, 20 mL). After stirring for 2 h at 15 °C, the mixture was dissolved in NaHCO 3 The mixture was neutralized with a saturated aqueous solution (60 mL). The organic layer was separated, washed with brine (20 mL), and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was subjected to preparative HPLC (column Phenomenex Gemini-NX C18 75*30mm*3um, conditions A=water (0.225%FA)-B=ACN, start B 48, end B 78, gradient time (min) 7, 100%B tert-Butyl4-fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine- 1-carboxylate (170 mg, 16.6%) was obtained. 1 H-NMR(400MHz, CDCl 3 )δ H 8.57(s,1H),7.76(d,J=8.0 Hz,1H),7.65(d,J=8.1 Hz,1H),3.96(s,2H),3.09-2.98(m,3H),2.96(s ,1H),1.75-1.64(m,4H),1.46(s,9H),1.48-1.44(m,1H).
[0371] Step 7 A solution of tert-butyl 4-fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidine-1-carboxylate (0.2 g, 0.5519 mmol) in dioxane (5 mL) was added with HCl / dioxane (1.37 mL, 4M in dioxane, 5.51 mmol) was added and the mixture was stirred at 25° C. for 4 hours. The mixture was concentrated to give 5-((4-fluoropiperidin-4-yl)methyl)-2-(trifluoromethyl)pyridine hydrochloride (200 mg, crude), which was used directly in the next reaction.
[0372] Step 8 2-(pyrimidin-4-yl)nicotinic acid (121 mg, 0.6025 mmol) in DMF (5 mL), 5-((4-fluoropiperidin-4-yl)methyl)-2-(trifluoromethyl)pyridine hydrochloride (180 mg, 0.6025 mmol) and HATU (343 mg, 0.9037 mmol) was added DIPEA (0.31 mL, 1.80 mmol). The mixture was stirred at 20°C for 12 hours. H the mixture 2 Pour into O (50 mL) and stir for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was analyzed by preparative HPLC (column Phenomenex Gemini-NX 80*40mm*3um, condition A=water (0.05%NH 3 H 2 Purified by (4- Fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (132mg, 49.2%) I got it. 1 H-NMR(400MHz, CDCl 3 )δ H 9.19(s,1H),9.08(s,1H),8.90(m,1H),8.76(m,1H),8.57(s,1H),8.27(d,J=4.8 Hz,1H),7.85-7.61 (m,3H),7.47(m,1H),4.80-4.56(m,1H),3.54-3.34(m,1H),3.27-2.91(m,4H),2.06-1.82(m,2H),1.53 (s,1H). 19 F NMR(400 MHz, CDCl 3 )δ F- 67.530,-163.259.LC-ELSD / MS purity ≧98%, C 22 H 19 F 4 N 5 O[M+H] + MS ESI calculated for 446.2, measured 446.2.
[0373] Example 26. (4-fluoro-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 24) [ka]
[0374] step 1 To a solution of 2-methyl-6-(trifluoromethyl)pyridine (2 g, 12.4 mmol) in THF (15 mL) was added LDA (9.30 mL, 2M in THF, 18.6 mmol) dropwise at -78 °C. . After stirring at -78 °C for 1 h, a solution of tert-butyl 4-oxopiperidine-1-carboxylate (3.70 g, 18.6 mmol) in THF (10 mL) was added and the reaction was stirred at -70 °C for 2 h. did. The mixture was poured into water (100 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (2 x 30 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Xtimate C18 150*40mm*5um, condition A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN, start B 38, end B 68) purified by tert-butyl 4-hydroxy-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (120 mg, impure) was obtained and used directly in the next reaction.
[0375] Step 2 DAST ( 107 mg, 0.6658 mmol) was added at 0°C. The mixture was stirred at 0 °C for 5 min, then NaHCO 3 It was poured into an aqueous solution (30 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 20 mL) and the combined organic layers were washed with saturated brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dried over, filtered and concentrated to give tert-butyl 4-fluoro-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (120 mg, crude). This was used directly in the next reaction.
[0376] Step 3 A solution of tert-butyl 4-fluoro-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (120 mg, 0.33111 mmol) in dioxane (10 mL) was added with HCl / Dioxane (4.12 mL, 4M in dioxane, 1.65 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to give 2-((4-fluoropiperidin-4-yl)methyl)-6-(trifluoromethyl)pyridine hydrochloride (100 mg, crude), which was used directly in the next reaction.
[0377] Step 4 2-(pyrimidin-4-yl)nicotinic acid (80.8 mg, 0.4017 mmol), HATU (229 mg, 0.6025 mmol), DIPEA (258 mg, 2.00 mmol), and 2-((4-fluoropiperidine) in DMF (5 mL). A mixture of -4-yl)methyl)-6-(trifluoromethyl)pyridine hydrochloride (120 mg, 0.4017 mmol) was stirred at 25° C. for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was analyzed by preparative HPLC (column Phenomenex Gemini-NX 80*40mm*3um, condition A=water (0.05%NH 3 H 2 O)-B=ACN, start B 26, end B 56) to obtain (50 mg, impure), which was purified by SFC (column DAICEL CHIRALCEL OD-H (250 mm * 30 mm, 5 um), condition A = 0.1% N.H. 3 H 2 Further purification by (4-fluoro-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)( 2-(pyrimidin-4-yl)pyridin-3-yl)methanone (35.6 mg, 20%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.11(s,1 H),8.79(d,J=4.0 Hz,1 H),8.68(m,1 H),8.17(m,1 H),7.76(m,1 H),7.48-7.66(m ,2 H),7.34-7.44(m,2 H),4.37-4.66(m,1 H),3.25-3.41(m,1 H),3.03-3.24(m,4 H),1.68-2.02(m ,3 H),1.13-1.29(m,1 H).LC-ELSD / MS purity 99%, C 22 H 20 F 4 N 5 O[M+H] + MS ESI calculated value for 446.3, measured value 446.3. 19 F NMR (376.5MHz, CDCl 3 )δ F -67.889;-157.22.
[0378] Example 27. (4-fluoro-4-((4-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 25) [ka]
[0379] step 1 To a solution of 2-bromo-4-(trifluoromethyl)pyridine (2 g, 8.84 mmol) in toluene (20 mL) was added a solution of n-BuLi (7.04 mL, 2.5 M in hexane, 17.6 mmol) under nitrogen at -78 Add slowly at °C. The mixture was stirred at -78 °C for 30 min, then tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (1.98 g, 9.33 mmol) and BF in toluene (10 mL) 3 ·EtO 2 A solution of (1.20 g, 8.49 mmol) was added dropwise at -70°C. After stirring at -70 °C for 2 h, the mixture was converted into NH 4 It was slowly poured into saturated aqueous Cl solution (200 mL) and the aqueous phase was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was analyzed by HPLC (column: Phenomenex Gemini NX C18 150*40mm*5um, condition A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN, start B 32, end B 62) purified by tert-butyl 4-hydroxy-4-((4-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (100mg, 3.27%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.71-8.70(m,1H),7.30-7.49(m,2H),3.81(s,2H),3.22(s,2H),3.00(s,2H),2.96(s,1H),2.88(s, 1H), 2.80(s, 1H), 1.49-1.54(m, 4H), 1.45(s, 10H).
[0380] Step 2 DAST ( 89.4 mg, 0.5548 mmol) was added at 0°C. The mixture was stirred at 0 °C for 5 min, then NaHCO 3 It was poured into an aqueous solution (30 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 10 mL) and the combined organic layers were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 dry over, filter, and concentrate to give tert-butyl 4-fluoro-4-((4-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (100 mg, crude). This was used directly in the next reaction.
[0381] Step 3 A solution of tert-butyl 4-fluoro-4-((4-(trifluoromethyl)pyridin-2-yl)methyl)piperidine-1-carboxylate (100 mg, 0.2759 mmol) in dioxane (10 mL) was added with HCl / Dioxane (0.342 mL, 4M in dioxane, 1.37 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to give 2-((4-fluoropiperidin-4-yl)methyl)-4-(trifluoromethyl)pyridine hydrochloride (100 mg, crude), which was used directly in the next reaction.
[0382] Step 4 2-(pyrimidin-4-yl)nicotinic acid (67.3 mg, 0.335 mmol), HATU (190 mg, 0.502 mmol), DIPEA (215 mg, 1.67 mmol), and 2-((4-fluoropiperidin-4-yl)methyl )-4-(Trifluoromethyl)pyridine hydrochloride (100 mg, 0.335 mmol) was mixed in DMF (5 mL) and stirred at 25° C. for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX 80*40mm*3um, condition A=water (0.05%NH 3 H 2 O)-B=ACN, start B 25, end B 55) to obtain (25 mg, impure), which was purified by SFC (column Phenomenex Gemini-NX 80*40mm*3um, condition A=water (0.05% NH 3 H 2 Further purification by O+10mM NH4HCO3)-B=ACN, start B 40, end B 40, gradient time (min) 8 100% B retention time (min) 2.5, flow rate (ml / min) 30, injection 4), (4-fluoro-4-((4-(trifluoromethyl)pyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (11 mg, 7%). 1 H-NMR(400 MHz, CDCl 3 )δ H 9.12-9.24(m,1H),8.81-8.97(m,1H),8.73(s,2H),8.17-8.31(m,1H),7.59-7.74(m,1H),7.45(s,3H), 4.50-4.76(m,1H),3.12-3.53(m,5H),1.69-2.11(m,3H),1.25(s,1H).LC-ELSD / MS purity 99%, C 22 H 20 F 4 N 5 O[M+H] + MS ESI calculated value for 446.2, measured value 446.2. 19 F-NMR (376.5MHz, CDCl 3 )δ F -64.454;-159.925.
[0383] Example 28. (4-fluoro-4-(2,4,6-trifluorobenzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 26) synthesis [ka]
[0384] step 1 NaBH in MeOH (50 mL) 4 (2.37 g, 62.4 mmol) was added 2,4,6-trifluorobenzaldehyde (5 g, 31.2 mmol), and the resulting mixture was stirred at 25° C. for 1 hour. Saturated Na 2 S 2 O 3 Aqueous solution (50 mL) was added and stirring continued for 30 minutes. The mixture was extracted with EtOAc (2 x 50 mL) and the combined organic layers were washed with anhydrous Na2 S.O. 4 Dry on top, filter and concentrate to give (2,4,6-trifluorophenyl)methanol (5 g, crude). 1 H-NMR(400 MHz, CDCl 3 )δ H 6.76-6.57(m,2H),4.81-4.65(m,2H),1.89-1.80(m,1H). 19 F NMR(376.5 MHz, CDCl 3 )δ F -107.514,-113.359.
[0385] Step 2. CHCl 3 To a solution of (2,4,6-trifluorophenyl)methanol (5.0 g, 30.8 mmol) in (30 mL) at 25 °C was added tribromophosphane (16.6 g, 61.6 mmol) in one portion and the mixture was Stirred at ℃ for 0.5 hour. The mixture was slowly poured into ice water (20 mL) and extracted with DCM (3 x 25 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter, and concentrate to give 2-(bromomethyl)-1,3,5-trifluorobenzene (4.5 g, 64.9%). 1 H-NMR(400 MHz, CDCl 3 )δ H 6.76-6.59(m,2H),4.48(s,2H). 19 F NMR(376.5 MHz, CDCl 3 )δ F -105.975,-111.206.
[0386] Step 3 Et 2 Mg (0.80g, 33.3mmol) and I in O (10mL) 2 (2.81 mg, 0.011 mmol), Et 2 A solution of 2-(bromomethyl)-1,3,5-trifluorobenzene (2.5 g, 11.1 mmol) in O (15 mL) was added at 25° C. under nitrogen. The mixture was stirred at 50°C for 1 hour. The mixture was cooled and tert-butyl 4-oxopiperidine-1-carboxylate (1.10 g, 5.55 mmol) was added to the mixture at 25°C. The mixture was stirred at 25° C. for 2 hours, then poured into ice water (30 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to give tert-butyl 4-hydroxy-4-(2,4,6-trifluorobenzyl)piperidine-1-carboxylate (0.7 g, impurity). 1 H-NMR(400 MHz, CDCl 3 )δ H 6.75-6.63(m,2 H),3.96-3.67(m,2 H),3.15-3.07(m,2 H),2.78(s,2H),1.67-1.62(m,1 H),1.54-1.43 (m,12 H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -109.293.
[0387] Step 4 DAST (1.01 g, 6.06 mmol) was added to tert-butyl 4-hydroxy-4-(2,4,6-trifluorobenzyl)piperidine-1-carboxylate (0.7 g, 2.02 mmol) in DCM (10 mL). Added at -10°C. The mixture was stirred at −10° C. for 15 minutes and then slowly poured into ice water (20 mL). The mixture was extracted with DCM (2x20mL) and the combined organic layers were diluted with NaHCO 3 (20 mL) and brine (10 mL), anhydrous Na 2 S.O. 4 dried over water and concentrated to give tert-butyl 4-fluoro-4-(2,4,6-trifluorobenzyl)piperidine-1-carboxylate (600 mg, crude), which was directly used in the next reaction. used.
[0388] Step 5 A solution of tert-butyl 4-fluoro-4-(2,4,6-trifluorobenzyl)piperidine-1-carboxylate (0.6 g, 1.72 mmol) in dioxane (10 mL) was added with HCl / dioxane (4.3 mL, 4M HCl in dioxane) was added at 25°C under nitrogen. The mixture was stirred at 25°C for 16 hours. The reaction mixture was concentrated to give 4-fluoro-4-(2,4,6-trifluorobenzyl)piperidine hydrochloride (450 mg, crude), which was used directly in the next step.
[0389] Step 6 2-(pyrimidin-4-yl)nicotinic acid (412 mg, 2.05 mmol), HATU (901 mg, 2.37 mmol), DIPEA (1.02 mg, 7.9 mmol), and 4-fluoro-4-(2,4,6-tri Fluorobenzyl)piperidine hydrochloride (450 mg, 1.58 mmol) was mixed in DMF (5 mL) and stirred at 25° C. for 2 hours. The mixture was poured into water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by SFC (Column: Phenomenex-Cellulose-2 (250mm*30mm, 10um); Conditions: A=0.1%NH 3 H 2 O B=IPA; Start B: 35; End B: 35) and purified by (4-fluoro-4-(2,4,6-trifluorobenzyl)piperidin-1-yl)(2-(pyrimidin-4- yl)pyridin-3-yl)methanone (252 mg, 41.9%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.02-8.69(m,3H),8.29-8.01(m,1H),7.74-7.63(m,1H),7.50-7.40(m,1H),6.76-6.62(m,2H),4.85-4.61(m ,1H),3.51-2.93(m,5H),2.01-1.60(m,4H).LCMS purity 99%, C 22 H 20 F 4 N 4 O[M+H] + Calculated value 431.2, actual value 431.2. 19 F NMR (376.5 MHz, CDCl 3 )δ F -109.228, -161.132.
[0390] Example 29. (4-fluoro-4-((5-(trifluoromethoxy)pyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 27) [ka]
[0391] step 1 To a solution of 2-bromo-5-(trifluoromethoxy)pyridine (2 g, 8.26 mmol) in toluene (20 mL) was added a solution of n-BuLi (6.60 mL, 2.5 M in hexane, 16.5 mmol) under nitrogen at -78 Add slowly at °C. The mixture was stirred at -78°C for 30 minutes. tert-Butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (1.80 g, 8.45 mmol) and BF in toluene (10 mL) 3 .Et 2 A solution of O (1.09g, 7.69mmol) was added dropwise at -70°C under nitrogen. After stirring at -70 °C for 2 h, the reaction mixture was diluted with NH 4 Slowly poured into saturated aqueous Cl solution (100 mL). The mixture was extracted with EtOAc (3 x 30 mL) and the combined organic layers were washed with brine (2 x 40 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini NX C18 150*40mm*5um, condition A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN, starting B 32, ending B 62) purified by tert-butyl 4-hydroxy-4-((5-(trifluoromethoxy)pyridin-2-yl)methyl)piperidine-1-carboxylate (150 mg, impure) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.46-8.45(d,J=4.0 Hz,1H),7.49-7.56(m,1H),7.20-7.18(d,J=8.0 Hz,1H),5.18(s,1H),3.69-3.87(m, 2H),3.13-3.29(m,2H),2.93(s,2H),1.47-1.52(m,4H),1.45(s,10H).
[0392] Step 2 DAST (128 mg, 0.797 mmol) was added at 0°C. The mixture was stirred at 0°C for 5 minutes. Then the mixture was diluted with NaHCO 3It was poured into an aqueous solution (80 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 30 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dry over, filter, and concentrate to give tert-butyl 4-fluoro-4-((5-(trifluoromethoxy)pyridin-2-yl)methyl)piperidine-1-carboxylate (150 mg, crude). This was used directly in the next reaction.
[0393] Step 3 tert-Butyl 4-fluoro-4-((5-(trifluoromethoxy)pyridin-2-yl)methyl)piperidine-1-carboxylate (150 mg, 0.3964 mmol) in dioxane (10 mL) was added with HCl / dioxane ( 0.495mL, 4M in dioxane, 1.98mmol) was added and the mixture was stirred at 25°C for 2 hours. The mixture was concentrated to give 2-((4-fluoropiperidin-4-yl)methyl)-5-(trifluoromethoxy)pyridine hydrochloride (150 mg, crude), which was used directly in the next reaction.
[0394] Step 4 2-(pyrimidin-4-yl)nicotinic acid (95.8 mg, 0.4766 mmol), HATU (271 mg, 0.7149 mmol), DIPEA (307 mg, 2.38 mmol), and 2-((4-fluoropiperidin-4-yl)methyl )-5-(trifluoromethoxy)pyridine hydrochloride (150 mg, 0.4766 mmol) was mixed in DMF (5 mL) and stirred at 25° C. for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-3% MeOH in DCM) to give the desired product (300 mg, impure), which was purified by preparative HPLC (column: DAICEL CHIRALCEL OD-H (250 mm*30 mm, 5um), condition A=0.1%NH 3 H 2 Further purification by (4-fluoro-4-((5-(trifluoromethoxy)pyridin-2-yl)methyl)piperidin-1-yl) (2-(pyrimidin-4-yl)pyridin-3-yl)methanone (28.6 mg, 13%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.18-9.01(s,1H),8.87(d,J=4.0 Hz,1H),8.74(m,1H),8.47(s,1H),8.24(m,1H),7.68-7.65(m,1H) ,7.42-7.55(m,2H),7.32(m,1H),4.51-4.70(m,1H),3.32-3.50(m,1H),3.07-3.27(m,4H),1.86-2.08(m, 2H),1.68(s,2H).LC-ELSD / MS purity 99%, C 22 H 20 F 4 N 5 O 2 [M+H] + MS ESI calculated value for 462.1, measured value 462.1. 19 F-NMR (376.5MHz, CDCl 3 )δ F -58.176;-160.589.
[0395] Example 30. (4-fluoro-4-(2-fluoro-4-(trifluoromethyl)benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 28) synthesis [ka]
[0396] step 1 To a solution of 1-bromo-2-fluoro-4-(trifluoromethyl)benzene (2 g, 8.23 mmol) in toluene (20 mL) was added a solution of n-BuLi (6.55 mL, 2.5 M in hexane, 16.4 mmol). It was added slowly at -78°C under nitrogen and the mixture was stirred at -78°C for 30 minutes. To this mixture was added tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (1.79 g, 8.40 mmol) in toluene (10 mL) and BF 3 ·Et 2 A solution of O (1.08g, 7.64mmol) was added dropwise at -70°C. After stirring at -70 °C for 2 h, the reaction mixture was diluted with NH 4 Slowly poured into saturated aqueous Cl solution (100 mL). The mixture was extracted with EtOAc (3 x 40 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by preparative HPLC (column: Phenomenex Gemini NX C18 150*40mm*5um, condition A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN, start B 54, end B 64), purified by tert-butyl 4-fluoro-4-(2-fluoro-4-(trifluoromethyl)benzyl)piperidine-1-carboxylate (500 mg, impurity). 1 H-NMR(400 MHz, CDCl 3 )δ H 7.36-7.39(m,2H),7.33(d,J=8.0 Hz,1H),3.87(s,2H),3.10(m,2H),2.87(s,2H),1.59-1.67(m,2H) ,1.50(s,1H),1.45(s,10H).
[0397] Step 2 DAST (425 mg, 2.64 mmol) was added to tert-butyl 4-fluoro-4-(2-fluoro-4-(trifluoromethyl)benzyl)piperidine-1-carboxylate (500 mg, 1.32 mmol) in DCM (10 mL). was added at 0°C. The mixture was stirred at 0 °C for 5 min, then NaHCO 3 It was poured into an aqueous solution (100 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 40 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dried over water, filtered and concentrated to give tert-butyl 4-(2-fluoro-4-(trifluoromethyl)benzyl)-4-hydroxypiperidine-1-carboxylate (500 mg, crude), which was used directly in the next reaction.
[0398] Step 3 To tert-butyl 4-(2-fluoro-4-(trifluoromethyl)benzyl)-4-hydroxypiperidine-1-carboxylate (500 mg, 1.31 mmol) in dioxane (10 mL) was added HCl / dioxane (1.63 mL, 4M in dioxane, 6.55 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to give 4-fluoro-4-(2-fluoro-4-(trifluoromethyl)benzyl)piperidine hydrochloride (460 mg, crude), which was used directly in the next reaction.
[0399] Step 4 2-(pyrimidin-4-yl)nicotinic acid (140 mg, 0.6967 mmol), HATU (361 mg, 0.9501 mmol), DIPEA (408 mg, 3.16 mmol), and 4-fluoro-4-(2-fluoro-4-(tri- Fluoromethyl)benzyl)piperidine hydrochloride (200 mg, 0.6334 mmol) was mixed in DMF (10 mL) and stirred at 25°C for 2 hours. The mixture was poured into water (40 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-3% MeOH in DCM) to give the desired product (330 mg, impure), which was purified by preparative HPLC (column: DAICEL CHIRALPAK AS (250 mm*30 mm, 10 um) , condition A=0.1%NH 3 H 2 Further purification by (4-fluoro-4-(2-fluoro-4-(trifluoromethyl)benzyl)piperidin-1-yl)(2-(pyrimidin- 4-yl)pyridin-3-yl)methanone (76.7 mg, 26%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.18-8.99(s,1H),8.89(s,1H),8.75-8.74(m,1H),8.23(d,J=4.0 Hz,1H),7.66(s,1H),7.28-7.50(m, 4H),4.69(d,J=12.0 Hz,1H),3.33-3.49(m,1H),2.97-3.27(m,4H),1.59-2.10(m,4H); 19 F-NMR(376.5 MHz, CDCl 3 )δ F -62.708;-114.065;-161.752.LC-ELSD / MS purity 99%, C 23 H 20 F 5 N 4 O[M+H] + MS ESI calculated for 463.2, measured 463.2.
[0400] Example 31. Synthesis of (4-(4-chlorobenzyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (compound 29) [ka]
[0401] step 1 Et 2 Mg (0.35g, 14.5mmol) and I in O (5mL) 2 (2.46 mg, 0.02 mmol), Et 2 1-(bromomethyl)-4-chlorobenzene (1 g, 4.86 mmol) in O (10 mL) was added at 25° C. under nitrogen. The mixture was stirred at 35°C for 1 hour. Et 2 The mixture was added to tert-butyl 4-oxopiperidine-1-carboxylate (0.773 g, 3.88 mmol) in O (10 mL) at 25°C. The mixture was stirred at 25° C. for 2 hours, then the mixture was poured into ice water (30 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to yield tert-butyl 4-(4-chlorobenzyl)-4-hydroxypiperidine-1-carboxylate (280 mg, 17.7%). . 1 H-NMR(400 MHz, CDCl 3 )δ H 7.31-7.27(m,2H),7.15-7.10(m,2H),3.95-3.77(m,2H),3.15-3.00(m,2H),2.76-2.68(m,2H),1.59-1.44(m ,13H).
[0402] Step 2 To tert-butyl 4-(4-chlorobenzyl)-4-hydroxypiperidine-1-carboxylate (0.28 g, 0.86 mmol) in DCM (10 mL) was added DAST (0.429 g, 2.57 mmol) at -10 °C. Ta. The mixture was stirred at −10° C. for 15 minutes and then slowly poured into ice water (20 mL). The mixture was extracted with DCM (2x20mL) and the combined organic layers were diluted with NaHCO 3 (20 mL) and brine (10 mL), anhydrous Na 2 S.O. 4 dried over, filtered, and concentrated to give tert-butyl 4-(4-chlorobenzyl)-4-fluoropiperidine-1-carboxylate (280 mg, crude), which was used directly in the next reaction. .
[0403] Step 3 A solution of tert-butyl 4-(4-chlorobenzyl)-4-fluoropiperidine-1-carboxylate (0.28 g, 0.85 mmol) in dioxane (5 mL) was added with HCl / dioxane (2.13 mL, 4M HCl in dioxane). was added at 25°C under nitrogen. The mixture was stirred at 25° C. for 2 hours and concentrated to give 4-(4-chlorobenzyl)-4-fluoropiperidine hydrochloride (200 mg, crude), which was used directly in the next reaction.
[0404] Step 4 2-(pyrimidin-4-yl)nicotinic acid (201 mg, 1.0 mmol), HATU (0.47 g, 1.24 mmol), DIPEA (0.537 g, 4.16 mmol), and 4-(4-chlorobenzyl)-4-fluoropiperidine Hydrochloride (220 mg, 0.83 mmol) was mixed in DMF (5 mL) and stirred at 25°C for 2 hours. The mixture was poured into water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-20% MeOH in DCM) to give the desired product (200 mg, impure). LC-ELSD / MS purity 83%, C 22 H 21 ClFN 4 O[M+H] + MS ESI calculated for 411.1, measured 411.1.
[0405] The residue was purified by preparative SFC (column: DAICEL CHIRALCEL OD-H (250 mm * 30mm, 5um), conditions: A=0.1%NH 3 H 2 Further purification by O B=IPA; start B: 35; end B: 35) and trituration of the residue from water (10 mL) at 80 °C yielded (4-(4-chlorobenzyl)-4-fluoropiperidine-1 -yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (23.7 mg, 7%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.25-8.72(m,3H),8.28-8.19(m,1H),7.71-7.69(m,1H),7.47-7.41(m,1H),7.32-7.27(m,2H),7.16-7.08(m ,2H),4.75-4.52(m,1H),3.44-3.37(m,1H),3.25-3.06(m,2H),2.99-2.85(m,2H),1.99-1.61(m,3H),1.55 -1.48(m,1H). 19 F-NMR (376.5MHz, CDCl 3 )δ F -161.33.LC-ELSD / MS purity 99%, C 22 H 21 ClFN 4 O[M+H] + MS ESI calculated for 411.1, measured 411.2.
[0406] Example 32. (4-((5-chloro-3-fluoropyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 30) [ka]
[0407] step 1 To 5-chloro-3-fluoropyridin-2-amine (5.0 g, 34 mmol) was slowly added HBr (48%, 20 mL) at 0° C. with stirring. The reaction mixture was cooled to -10 °C and diluted with NaNO in water (20 mL). 2 (5.88g, 85.3mmol) was added over 1.5 hours. The mixture was stirred for an additional 30 minutes at -10°C. A solution of NaOH (12g, 300mmol) in water (20mL) was then added over 30 minutes and the mixture was warmed to 20°C. The mixture was extracted with EtOAc (3 x 100 mL) and the combined organic layers were washed with brine (100 mL) and Na 2 S.O. 4 Dried on top, filtered and concentrated to give the crude product (6.0g). A sample of the crude product (3 g, 14.1 mmol) was purified by silica gel chromatography (0-30% EtOAc in PE) and purified with (4-((5-chloro-3-fluoropyridin-2-yl)methyl)- 4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (2.3 g, 76.9%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.22(d,J=2.0 Hz,1H),7.47(d,J=8,2.0 Hz,1H),1.99-2.08(m,1H),1.60(s,1H).
[0408] Step 2 (4-((5-chloro-3-fluoropyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3- in toluene (20 mL)) To a solution of n-BuLi (8.72 mL, 2.5 M in hexanes, 21.8 mmol) was slowly added to a solution of (2.3 g, 10.9 mmol) under nitrogen at -78 °C. After the addition was complete, the mixture was stirred at -78°C for 30 minutes. tert-Butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (2.15 g, 10.1 mmol) and BF in toluene (10 mL) 3· Et 2 A solution of O (1.43g, 10.1mmol) was added dropwise at -70°C. After stirring at -70 °C for 2 h, the reaction mixture was diluted with NH 4 Slowly poured into saturated aqueous Cl solution (200 mL). The mixture was extracted with EtOAc (3 x 80 mL) and the combined organic layers were washed with brine (2 x 50 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-20% EtOAc in PE) to give tert-butyl 4-((5-chloro-3-fluoropyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate. (800 mg, impure) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.27-8.26(d,J=4.0 Hz,1H),7.40(m,1H),3.66-3.83(m,2H),3.02-3.23(m,2H),2.88-2.87(d,J=4.0 Hz, 2H),1.54(s,2H),1.44-1.50(m,3H),1.37-1.40(m,9H).
[0409] Step 3 DAST (373 mg, 2.32 mmol) was added at 0°C. The mixture was stirred at 0 °C for 5 min, then NaHCO 3 It was slowly poured into an aqueous solution (100 mL) and stirred for 20 minutes. The mixture was extracted with DCM (3 x 40 mL) and the combined organic layers were washed with brine (2 x 30 mL) and anhydrous Na 2 S.O. 4 dry over, filter, and concentrate to give tert-butyl 4-((5-chloro-3-fluoropyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (400 mg, crude). This was used directly in the next reaction.
[0410] Step 4 tert-Butyl 4-((5-chloro-3-fluoropyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (400 mg, 1.15 mmol) in dioxane (10 mL) was added with HCl / dioxane ( 1.43 mL, 4M in dioxane, 5.75 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to give 5-chloro-3-fluoro-2-((4-fluoropiperidin-4-yl)methyl)pyridine hydrochloride (400 mg, crude), which was used directly in the next step.
[0411] Step 5 2-(pyrimidin-4-yl)nicotinic acid (283 mg, 1.41 mmol), HATU (802 mg, 2.11 mmol), DIPEA (911 mg, 7.05 mmol), and 5-chloro-3-fluoro-2-((4-fluoro Piperidin-4-yl)methyl)pyridine hydrochloride (400 mg, 1.5 mmol) was mixed in DMF (5 mL) and stirred at 25° C. for 2 hours. The mixture was poured into water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dried over, filtered, concentrated and purified by silica gel chromatography (0-3% MeOH in DCM), SFC (column: Phenomenex-Cellulose-2 (250mm*30mm10um), condition A=0.1%NH 3 H 2 Further purification by (4-((5-chloro-3-fluoropyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2- (Pyrimidin-4-yl)pyridin-3-yl)methanone (24.2 mg, 4%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 9.17(s,1H),8.87(s,1H),8.74(m,1H),8.38(s,1H),8.24-8.22(d,J=8.0 Hz,1H),7.66(d,J=8.0 Hz ,1H),7.45(d,J=8.0 Hz,2H),4.52-4.74(m,1H),3.43(s,1H),3.00-3.33(m,4H),1.72-2.11(m,4H), 0.81-0.91(m,1H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -120.045;-159.763.LC-ELSD / MS purity 99%, C 21 H 19 ClF 2 N 5 O[M+H] + MS ESI calculated for 430.1, measured 430.1.
[0412] Example 33. (R)-(4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 31) [ka]
[0413] step 1 EtPPh in THF (100mL) 3 To a mixture of Br (74.2g, 200mmol) was added t-BuOK (22.4g, 200mmol) at 25°C under nitrogen. The resulting mixture was stirred at 60°C for 30 minutes. tert-Butyl 4-oxopiperidine-1-carboxylate (20 g, 100 mmol) in THF (100 mL) was added in portions so that the reaction temperature was maintained below 60 °C. The reaction mixture was stirred at 60°C for 16 hours. The mixture was cooled and concentrated. The residue was poured into ice water (150 mL), stirred for 20 minutes, then extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-100% EtOAc in PE) to give tert-butyl 4-ethylidenepiperidine-1-carboxylate (20 g, impure). 1 H-NMR(400 MHz, CDCl 3 )δ H 5.32-5.23(m,1H),3.42-3.32(m,4H),2.23-2.09(m,4H),1.60(s,3H),1.47(s,9H).
[0414] Step 2 To a solution of tert-butyl 4-ethylidenepiperidine-1-carboxylate (15 g, 70.9 mmol) in DCM (50 mL) at 25° C. was added m-CPBA (15.3 g, 212 mmol). After stirring for 2 h at 25 °C, the reaction mixture was dissolved in NaHCO 3 quenched with a saturated aqueous solution (50 mL) of Na 2 S 2 O 3 A saturated aqueous solution (50 mL) was added. The mixture was extracted with DCM (2 x 50 mL) and the combined organic layers were diluted with NaHCO 3 Aqueous solution (50mL) and Na 2 S 2 O 3 Wash with saturated aqueous solution (50 mL) and remove Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to give tert-butyl 2-methyl-1-oxa-6-azaspiro[2.5]octane-6-carboxylate (15 g, 93.1%). Obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 3.79-3.64(m,2H),3.44-3.32(m,2H),2.96-2.89(m,1H),1.47(s,9H),1.44-1.34(m,2H).
[0415] Step 3 Et 2 A solution of tert-butyl 2-methyl-1-oxa-6-azaspiro[2.5]octane-6-carboxylate (2.0 g, 8.79 mmol) in O (20 mL) was added with CuI (834 mg, 4.39 mmol), bromo( 3,5-difluorophenyl), and magnesium (3.80 g, 17.5 mmol) were added at 25°C. The mixture was stirred at 25°C for 2 hours. The mixture was poured into ice water (30 mL) and stirred for 20 minutes. The mixture was extracted with EtOAc (3 x 20 mL) and the combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to give tert-butyl 4-(1-(3,5-difluorophenyl)ethyl)-4-hydroxypiperidine-1-carboxylate (2 g , impurity). 1 H-NMR(400 MHz, CDCl 3 )δ H 6.82-6.65(m,1H),4.05-3.65(m,2H),3.44-3.30(m,1H),3.11-2.87(m,2H),1.85-1.62(m,3H),1.56-1.41(m ,9H),1.32-1.28(m,2H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -110.06. A sample of the impure racemic product was subjected to preparative SFC (Column: DAICEL CHIRALPAK AD 250mm*50mm, 10um); Conditions: A=0.1%NH 3 H 2 Further purification by O B=EtOH; start B: 45; end B: 45) rate (350 mg, 17.5%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 6.81-6.65(m,4H),4.05-3.76(m,2H),3.13-2.69(m,2H),1.70-1.59(m,2H),1.53-1.49(m,2H),1.45(m,9H) ),1.34-1.27(m,3H),1.24-1.18(m,1H).ee=100%. 19 F-NMR(376.5 MHz, CDCl 3 )δ F -110.04.
[0416] Step 4 DAST ( 245 mg, 1.47 mmol) was added at -10°C. The mixture was stirred at −10° C. for 15 minutes and then slowly added to ice water (20 mL). The mixture was extracted with DCM (2x20mL) and the combined organic layers were diluted with NaHCO 3 (20 mL) and brine (10 mL), anhydrous Na 2 S.O. 4 dried over, filtered and concentrated to give tert-butyl(R)-4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidine-1-carboxylate (320 mg, crude). Obtained. LC-ELSD / MS purity 70%, C 13 H 17 F 3 N[M+H] + MS ESI calculated value for 244.1, measured value 244.1.
[0417] Step 5 A solution of tert-butyl (R)-4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidine-1-carboxylate (320 mg, 0.93 mmol) in dioxane (5 mL) was added with HCl / Dioxane (2.32 mL, 4M HCl in dioxane) was added at 25° C. under nitrogen. The mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated to obtain (R)-4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidine hydrochloride (220 mg, crude). LC-ELSD / MS purity 90%, C 13 H 17 F 3 N[M+H] + MS ESI calculated value for 244.1, measured value 244.1.
[0418] Step 6 2-(pyrimidin-4-yl)nicotinic acid (217 mg, 1.08 mmol), HATU (0.513 g, 1.35 mmol), DIPEA (0.584 g, 4.52 mmol), and (R)-4-(1-(3,5 -difluorophenyl)ethyl)-4-fluoropiperidine hydrochloride (220 mg, 0.904 mmol) was mixed in DMF (5 mL) and stirred at 25°C for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-10% MeOH in DCM) to give (300 mg, impure) which was purified by HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; conditions: A=water (0.225%FA)-B=ACN; start B: 45%; end B: 65%) to obtain (50 mg, impure), which was purified by SFC (column: DAICEL CHIRALCEL OD-H (250 mm*30 mm ,5um);Condition: A=0.1%NH 3 H 2 Purified by (R)-(4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidin-1-yl) (2-(pyrimidin-4-yl)pyridin-3-yl)methanone (10.9 mg, 3%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.93-8.66(m,3H),8.28-8.19(m,1H),7.75-7.61(m,1H),7.50-7.40(m,1H),6.80-6.64(m,3H),4.79-4.57(m ,1H),3.50-2.73(m,5H),2.27-1.65(m,2H),1.41-1.29(m,4H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -109.81,-170.14,-171.74.LC-ELSD / MS purity 99%, C 23 H 21 F 3 N 4 ONa[M+Na] + MS ESI calculated for 449.2, measured 449.2.
[0419] Example 34. (S)-(4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 32) [ka]
[0420] step 1 Racemic tert-butyl 4-(1-(3,5-difluorophenyl)ethyl)-4-hydroxypiperidine-1-carboxylate (1.00g, impure) was added to SFC (column: DAICEL CHIRALPAK AD 250mm*50mm, 10um). );Condition: A=0.1%NH 3 H 2 Purification by OB=EtOH; start B: 45; end B: 45) gave the desired product (1 g, impure). The residue was purified by SFC (column: DAICEL CHIRALPAK AD (250mm*50mm, 10um); conditions: A=0.1%NH 3 H 2 Further purification by O B=EtOH; start B: 15%; end B: 15%) and tert-butyl(S)-4-(1-(3,5-difluorophenyl)ethyl)-4-hydroxypiperidine-1 -carboxylate (350 mg, 35.1%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 6.81-6.65(m,4H),4.03-3.72(m,2H),3.17-2.88(m,2H),2.73-2.34(m,1H),1.72-1.57(m,1H),1.55-1.47(m ,3H),1.45(m,9H),1.33-1.18(m,4H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -110.04.
[0421] Step 2 DAST (425 mg , 2.55 mmol) was added at -10°C. After stirring at −10° C. for 15 min, the mixture was slowly poured into ice water (20 mL). The mixture was extracted with DCM (2x20mL) and the combined organic layers were diluted with NaHCO 3 (20 mL) and brine (10 mL), anhydrous Na 2 S.O. 4 dried over, filtered and concentrated to give tert-butyl(S)-4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidine-1-carboxylate (320 mg, crude). This was used directly in the next reaction.
[0422] Step 3 A solution of tert-butyl (S)-4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidine-1-carboxylate (0.32 g, 0.93 mmol) in dioxane (5 mL) was added with HCl / dioxane (2.32 mL, 4M HCl in dioxane) was added at 25° C. under nitrogen. The mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated to give (S)-4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidine hydrochloride (220 mg, crude), which was used directly in the next step. .
[0423] Step 4 2-(pyrimidin-4-yl)nicotinic acid (217 mg, 1.08 mmol), HATU (0.513 g, 1.35 mmol), DIPEA (0.584 g, 4.52 mmol), and (S)-4-(1-(3,5 -difluorophenyl)ethyl)-4-fluoropiperidine hydrochloride (220 mg, 0.904 mmol) was mixed in DMF (5 mL) and stirred at 25°C for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; conditions: A=water (0.225% FA)-B=ACN; start B: 40%; end B: 70%) to give (90 mg , impurity). The impure residue was purified by SFC (Column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); Conditions: A=0.1%NH 3 H 2 Further purification by (S)-(4-(1-(3,5-difluorophenyl)ethyl)-4-fluoropiperidin-1-yl) )(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (40.6 mg, 11%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.95-8.69(m,3H),8.34-8.16(m,1H),7.72-7.62(m,1H),7.53-7.36(m,1H),6.84-6.65(m,3H),4.84-4.51(m ,1H),3.53-2.73(m,5H),2.27-1.65(m,2H),1.47-1.29(m,4H). 19 F-NMR(376.5 MHz, CDCl3 )δ F -109.83,-170.14,-171.74.LC-ELSD / MS purity 99%, C 23 H 22 F 3 N 4 O[M+H] + MS ESI calculated value for 427.3, measured value 427.3.
[0424] Example 35 and Example 36 (S)-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridine -3-yl)methanone (compound 33) and (R)-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-1-yl)(2-(pyrimidine) Synthesis of -4-yl)pyridin-3-yl)methanone (compound 34) [ka]
[0425] step 1 Et 2 Mg (1.26g, 52.7mmol) and I in O (10mL) 2 (2.23 mg, 0.01 mmol), Et 2 1-bromo-4-(trifluoromethyl)benzene (3.93 g, 17.5 mmol) in O (20 mL) was added at 25° C. under nitrogen. The mixture was stirred at 35 °C for 1 h, then Et 2 tert-Butyl 2-methyl-1-oxa-6-azaspiro[2.5]octane-6-carboxylate (2.0 g, 8.79 mmol) in O (20 mL) was added to the mixture at 25°C. The mixture was stirred at 25°C for 2 hours. The mixture was poured into ice water (30 mL), stirred for 20 minutes, then extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. The residue was purified by silica gel chromatography (0-30% EtOAc in PE) to give tert-butyl 4-hydroxy-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidine-1-carboxylate. (2g, 60.9%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 7.61-7.53(m,2H),7.39-7.30(m,2H),4.04-3.77(m,2H),3.11-2.89(m,2H),2.83-2.73(m,1H),1.60-1.48(m ,3H),1.46-1.43(m,10H),1.36-1.31(m,3H),1.22-1.14(m,1H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -62.45.
[0426] Step 2 DAST (1.11 g, 6.67 mmol) was added at -10°C. After stirring at −10° C. for 15 min, the reaction mixture was slowly poured into ice water (20 mL) and the aqueous layer was extracted with DCM (2×20 mL). Combined organic layers with NaHCO 3 Wash with aqueous solution (20 mL) and brine (10 mL), anhydrous Na 2 S.O. 4 dried over, filtered and concentrated to give tert-butyl 4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidine-1-carboxylate (1 g, crude), This was used directly in the next reaction.
[0427] Step 3 HCl / dioxane ( 6.62 mL, 4M HCl in dioxane) was added at 25° C. under nitrogen. The mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated to obtain 4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidine hydrochloride (700 mg, crude). LC-ELSD / MS purity 90%, C 14 H 18 F 4 N[M+H] + MS ESI calculated for 276.1, measured 276.1.
[0428] Step 4 2-(pyrimidin-4-yl)nicotinic acid (611 mg, 3.04 mmol), HATU (1.44 g, 3.81 mmol), DIPEA (1.64 g, 2.21 mmol), and 4-fluoro-4-(1-(4-( Trifluoromethyl)phenyl)ethyl)piperidine hydrochloride (700mg, 2.54mmol) was mixed in DMF (10mL) and stirred at 25°C for 2 hours. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with saturated brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. HPLC the residue (column: Xtimate C18 150*40mm*5um; conditions: A=water (0.04%NH 3 H 2 O+10mM NH 4 HCO 3 )-B=ACN; Start B: 45%; End B: 75%) to give (800 mg, impure). The residue was purified by HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; conditions: A=water (0.225% FA)-B=ACN; start B: 40%; end B: 70%) to obtain racemic (4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (400 mg, impure) I got it. LC-ELSD / MS purity 60%, C 24 H 23 F 4 N 4 O[M+H] + MS ESI calculated value 459.2, measured value 459.2. Racemic-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (400mg) , SFC(Column:DAICEL CHIRALCEL OD-H(250mm * 30mm, 5um), conditions: A=0.1%NH 3 H 2 (S)-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidine-1- yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (90 mg, impure) and (R)-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl) )piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (170 mg, impure) was obtained.
[0429] Impure (S)-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Methanone was repurified by SFC (column: DAICEL CHIRALPAK IC (250mm*30mm, 10um); conditions: A=neutral-B=ethanol; start B: 40%; end B: 40%), and (S)- (4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (40.8 mg, 10 %) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H 8.94-8.68(m,3H),8.31-8.15(m,1H),7.73-7.62(m,1H),7.61-7.51(m,2H),7.48-7.28(m,3H),4.80-4.53(m ,1H),3.53-2.82(m,5H),2.27-1.68(m,2H),1.48-1.34(m,4H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -62.45,-170.80,-172.18.LC-ELSD / MS purity 99%, C 24 H 23 F 4 N 4 O[M+H] + MS ESI calculated value for 459.3, measured value 459.3.
[0430] Impure (R)-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Methanone was added to SFC (Column: DAICEL CHIRALPAK IC (250mm*30mm, 10um); Conditions: A=0.1%NH 3 H 2 (R)-(4-fluoro-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidine-1- yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (32.8 mg, 8%) was obtained. 1 H-NMR(400 MHz, CDCl 3 )δ H8.95-8.68(m,3H),8.29-8.17(m,1H),7.72-7.62(m,1H),7.61-7.51(m,2H),7.49-7.28(m,3H),4.81-4.53(m ,1H),3.51-2.82(m,4H),2.30-1.66(m,3H),1.48-1.29(m,4H). 19 F-NMR(376.5 MHz, CDCl 3 )δ F -62.47,-62.52.LC-ELSD / MS purity 99%, C 24 H 23 F 4 N 4 O[M+H] + MS ESI calculated value for 459.3, measured value 459.3.
[0431] Example 37. [2,4'-Bipyridin]-3-yl(4-fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidin-1-yl)methanone (Compound 35 ) synthesis [ka]
[0432] To a solution of [2,4'-bipyridine]-3-carboxylic acid (0.133g, 0.669mmol) and HATU (0.38g, 1.00mmol) in DMF (5mL) was added DIPEA (0.258mL, 2.0mmol). . 5-((4-fluoropiperidin-4-yl)methyl)-2-(trifluoromethyl)pyridine hydrochloride (0.2 g, 0.6695 mmol) in DMF (5 mL) was added slowly. The mixture was stirred at 20°C for 12 hours. Reaction mixture with H 2 Pour into O (50 mL) and stir for 20 minutes. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with saturated brine (2x20mL) and anhydrous Na 2 S.O. 4 dried over, filtered, concentrated and washed with a flash column (column Phenomenex Gemini-NX 80*40mm*3um, conditioned water (0.05%NH 3 H 2 Purified by [2,4' -bipyridin]-3-yl(4-fluoro-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)piperidin-1-yl)methanone (156.0 mg, 53%) was obtained. 1 H NMR(400MHz, CDCl 3 )δ H 8.83-8.76(m,2H),8.71-8.69(m,1H),8.50-8.42(m,1H),7.82-7.57(m,5H),7.45-7.41(m,1H),4.76-4.51(m ,1H),3.09-2.88(m,3H),2.80-2.50(m,2H),1.88-1.73(m,1H),1.50-1.23(m,1H),1.19-1.08(m,1H),1.03 -1.01(m,1H). 19 F NMR(376.5 MHz, CDCl 3 )δ F- 67.631,-164.927.LCMS purity >99%, C 23 H 20 F 4 N 4 O[M+H] + MS ESI calculated for 445.2, measured 445.2.
[0433] Example 38. (4-fluoro-4-((6-(trifluoromethyl)pyridazin-3-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 36) [ka]
[0434] step 1 A solution of 3-methyl-6-(trifluoromethyl)pyridazine (800 mg, 4.93 mmol) in dry THF (24 mL) was added with LDA (2.58 mL, 5.17 mmol, 2M in THF) and tert-butyl 4 at -78 °C. -Oxopiperidine-1-carboxylate (1.03 g, 5.17 mmol) was added and the reaction mixture was 2 Stirred under atmosphere for 20 minutes. Pour the reaction mixture on ice and saturated NH 4 Poured into Cl (20 mL). The residue was dissolved in DCM (20 mL), diluted with water (10 mL), then extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine (20 mL) and anhydrous Na 2 S.O. 4 The filtrate was concentrated and the resulting residue was purified by flash column (0-30% EtOAc in PE) to give tert-butyl 4-hydroxy-4-((6-(tri- Fluoromethyl)pyridazin-3-yl)methyl)piperidine-1-carboxylate (1.278g, 63%) was obtained.
[0435] Step 2 DAST (1.13g, 7.02mmol) in N 2 It was added under atmosphere at 0°C and the reaction mixture was stirred at 0°C for 5 minutes and then concentrated under reduced pressure. The residue was dissolved in DCM (20 mL), diluted with water (10 mL), then extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine (20 mL) and anhydrous Na 2 S.O. 4 dried over, filtered, concentrated and purified by silica gel column chromatography (50% EtOAc in PE) to give tert-butyl 4-fluoro-4-((6-(trifluoromethyl)pyridazin-3-yl). ) Methyl)piperidine-1-carboxylate (1.27 g) was obtained.
[0436] Step 3 A solution of tert-butyl 4-fluoro-4-((6-(trifluoromethyl)pyridazin-3-yl)methyl)piperidine-1-carboxylate (1.27 g) in 1,4-dioxane (3 mL) was Hydrogen chloride (3 mL, 7.02 mmol, in 1,4-dioxane) with N 2 It was added under atmosphere at 25°C and the reaction mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated under reduced pressure to give 3-((4-fluoropiperidin-4-yl)methyl)-6-(trifluoromethyl)pyridazine hydrochloride (1.04g).
[0437] Step 4 3-((4-fluoropiperidin-4-yl)methyl)-6-(trifluoromethyl)pyridazine hydrochloride (1.04 g, crude), 2-(pyrimidin-4-yl)pyridine- in DMF (10 mL) To a stirred solution of 3-carboxylic acid (698 mg, 3.47 mmol), HATU (1.38 g, 3.64 mmol) was added DIEA (1.78 g, 13.8 mmol, 2.39 mL) and the reaction mixture was purged with N 2 The mixture was stirred at 20° C. for 12 hours under atmosphere. The residue was dissolved in EtOAc (20 mL), diluted with water (10 mL), and then extracted with EtOAc. The combined organic layers were washed with brine (20 mL) and anhydrous Na 2 S.O. 4 The filtrate was concentrated using preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; conditions: water (0.05%NH 3 H 2 O+10mM NH 4 HCO 3 )-ACN; Start B: 60; End B: 80; Gradient time (min): 7; 100% B retention time (min): 2). Fluoromethyl)pyridazin-3-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (100 mg, 0.22 mmol, 6%) was obtained. 1 H NMR(400 MHz, CDCl 3 )δ H 9.17(s,1H),8.88(m,1H)8.75(m,1H)8.26(s,1H)7.85-7.75(m,1H)7.61-7.74(m,2H)7.46(d,J=4.40 Hz, 1H)4.74-4.47(m,1H)3.51-3.17(m,5H)2.01(s,4H). 19 F NMR(376.5 MHz, CDCl 3 )δ F -67.015.LCMS purity 95.1%, C 21 H 18 F 4 N 6 MS ESI calculated for O[M+H]+ 447.4, observed 447.2.
[0438] Example 39. [2,4'-Bipyridin]-3-yl(4-fluoro-4-((6-(trifluoromethyl)pyridazin-3-yl)methyl)piperidin-1-yl)methanone (Compound 37 ) synthesis [ka]
[0439] 3-((4-fluoropiperidin-4-yl)methyl)-6-(trifluoromethyl)pyridazine hydrochloride (115 mg), 2-(pyrimidin-4-yl)pyridine-3-carvone in DMF (10 mL) To a stirred solution of acid (80.8 mg, 0.402 mmol) and HATU (1.38 g, 3.64 mmol) was added DIPEA (1.78 g, 13.8 mmol, 2.39 mL). Reaction mixture N 2 The mixture was stirred at 20° C. for 12 hours under atmosphere. The residue was dissolved in EtOAc (20 mL), diluted with water (10 mL), then extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter, and concentrate the filtrate under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; conditions: water (0.05%NH 3 H 2 O+10mM NH 4 HCO 3 )-ACN; Start B: 60; End B: 80; Gradient time (min): 7; 100% B retention time (min): 2) and purified by [2,4'-bipyridin]-3-yl ( 4-Fluoro-4-((6-(trifluoromethyl)pyridazin-3-yl)methyl)piperidin-1-yl)methanone (2 mg, 0.22 mmol, 7%) was obtained. 1 H NMR(400 MHz, CDCl 3 )δ H 8.90-8.57(m,3H),7.87-7.38(m,6H),4.56(m,1H),3.53-3.29(m,1H),3.23-2.49(m,4H),2.10-1.67(m,2H) ),1.41-1.22(m,2H). 19 F NMR(376.5 MHz, CDCl 3 )δ F -67.023,-160.709,-162.840.LCMS purity 95.1%, C 22 H 19 F 4 N 5 MS ESI calculated for O[M+H]+ 445.9, observed 446.2.
[0440] Example 40. Synthesis of [2,4'-bipyridin]-3-yl(4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)methanone (compound 38) [ka]
[0441] step 1 N 2 Bottom, i-Pr in THF (100 mL) 2 To a solution of NH (12.5 g, 123 mmol) was added n-BuLi (49.2 mL, 2.5 M in hexanes, 123 mmol) at -78 °C. The mixture was stirred at -78°C for 30 minutes. 5-chloro-2-methylpyridine (10g, 78.3mmol) in THF (100mL) was added at -75°C and the mixture was stirred for 1 hour. tert-Butyl 4-oxopiperidine-1-carboxylate (18.7g, 93.9mmol) was added to the mixture at -75°C and stirred for 2 hours. The reaction mixture was converted into aqueous NH 4 Quenched with Cl (400 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. Purification by flash column (0-20% EtOAc in PE) gave tert-butyl 4-((5-chloropyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (12 g, 48%). I got it. 1 H NMR(400 MHz, CDCl 3 )δ H 8.47(d,J=2.4 Hz,1H),7.62(dd,J=2.4,8.4 Hz,1H),7.08(d,J=8.4 Hz,1H),5.41-5.08(m,1H),3.79(s ,2H),3.21(s,2H),2.88(s,2H),1.49(s,4H),1.44(s,9H).
[0442] Step 2 DAST (5.89 g, 36.6 mmol) was added at 0°C and the mixture was stirred at 0°C for 10 minutes. The residue was dissolved in ice water (80 mL) and NaHCO 3 (80 mL) and stirred for 20 minutes. The aqueous phase was extracted with DCM (3 x 40 mL). The combined organic phases were washed with brine (2 x 50 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate to give tert-butyl 4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (5g).
[0443] Step 3 A solution of tert-butyl 4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (0.8 g, 2.43 mmol) in 1,4-dioxane (5 mL) was added with chloride. Hydrogen (5 mL, 20.0 mmol, 4 M in 1,4-dioxane) in N 2 The reaction mixture was stirred at 25°C for 0.5 h. The reaction mixture was concentrated under reduced pressure to give 5-chloro-2-((4-fluoropiperidin-4-yl)methyl)pyridine hydrochloride (1 g).
[0444] Step 4 To a solution of [2,4'-bipyridine]-3-carboxylic acid (904 mg, 4.52 mmol) and HATU (2.14 g, 5.65 mmol) in DMF (5 mL) was added DIPEA (3.27 mL, 18.8 mmol). 5-chloro-2-((4-fluoropiperidin-4-yl)methyl)pyridine hydrochloride (1 g, 3.77 mmol) in DMF (5 mL) was added slowly. The mixture was stirred at 20°C for 16 hours. Reaction mixture with H 2 Poured into O (50 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dried over water, filtered, and HPLC (column: Phenomenex Gemini-NX 80*40mm*3um; conditions: water (0.05%NH 3 H 2 Purified by O)-ACN; Start B: 18; End B: 48; Gradient time (min): 8, 100% B retention time (min): 2.8; Flow rate (ml / min): 30; Injection 10); [2,4'-bipyridin]-3-yl(4-((5-chloropyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)methanone (106.6 mg, 6.88%) was obtained. 1 H NMR(400 MHz, CDCl 3 )δ H 8.82-8.76(m,1H),8.73-8.68(m,2H),8.50-8.43(m,1H),7.82-7.70(m,2H),7.68-7.62(m,1H),7.60-7.55(m ,1H),7.45-7.40(dd,1H),7.30-7.05(m,1H)4.60-4.58(m,1H),3.16-2.93(m,3H),2.90-2.5(m,2H),1.98- 1.70(m,2H),1.60-1.26(m,2H). 19 F NMR(376.5 MHz, CDCl 3 )δ F- 160.341.LC-ELSD / MS purity 97%, C 22 H 20 ClFN 4 O[M+H] + MS ESI calculated for 410.9, observed 410.9.
[0445] Example 41. (4-((5-chloro-4-(trifluoromethyl)pyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridine- Synthesis of 3-yl)methanone (compound 39) [ka]
[0446] step 1 Pd (PPh) in DME (16 mL) and water (4 mL) 3 ) 4 (266mg, 0.231mmol), Na 2 C.O. 3 (981 mg, 9.26 mmol), 2,5-dichloro-4-(trifluoromethyl)pyridine (1 g, 4.63 mmol), and tert-butyl 4-[(4,4,5,5-tetramethyl-1,3 ,2-dioxaborolan-2-yl)methylidene]piperidine-1-carboxylate (1.64 g, 5.09 mmol) was mixed with N 2 The mixture was stirred at 80° C. for 16 hours. After cooling to 25° C., the mixture was poured into water (15 mL) and extracted with EtOAc (2×15 mL). The combined organic phases were washed with water (15 mL) and brine (15 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. The crude product was purified by flash chromatography on silica gel (0%~1%~3%~20% EtOAc in PE) and purified with tert-butyl 4-((5-chloro-4-(trifluoromethyl)pyridine- 2-yl)methylene)piperidine-1-carboxylate (1.2g, 69%) was obtained. 1 H NMR(400MHz, CDCl 3 )δ H 8.66(s,1H),7.37(s,1H),6.34(s,1H),3.58-3.45(m,4H),2.95-2.86(m,2H),2.42-2.34(m,2H),1.48( s,9H).
[0447] Step 2 A solution of 4-((5-chloro-4-(trifluoromethyl)pyridin-2-yl)methylene)piperidine-1-carboxylate (600 mg, 1.59 mmol) in DCM (10 mL) was added with m-CPBA (644 mg , 3.18 mmol) was added at 0°C and the reaction mixture was stirred at 0°C for 2 hours. H the mixture 2 Diluted with O (10 mL) and extracted with DCM (3 x 10 mL), the combined organic phases were 2 S.O. 4 dried, filtered and concentrated. The residue was purified by flash chromatography on silica gel to give tert-butyl 2-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)-1-oxa-6-azaspiro[2.5]octane-6 -carboxylate (380 mg, 60.8%) was obtained. 1 H NMR(400MHz, CDCl 3 )δ H 8.71(s,1H),7.56(s,1H),4.06(s,1H),3.80-3.68(m,1H),3.62-3.37(m,3H),1.99-1.89(m,1H),1.77- 1.67(m,1H),1.48-1.38(m,11H).
[0448] Step 3 tert-Butyl 2-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)-1-oxa-6-azaspiro[2.5]octane-6-carboxylate (530 mg, 1.34 mmol) of 0.1M SmI in THF at 20 °C. 2 (80.3mL, 8.04mmol) was added. A solution of 0.17M pivalic acid in THF (11.8 mL, 2.01 mmol) was added and the solution was stirred for 48 hours. The reaction was quenched with a solution of sodium potassium tartrate (40 mL). The mixture was extracted with diethyl ether (3 x 20 mL) and the organic layer was extracted with H 2 Wash with O (2 x 20 mL) and Na 2 S.O. 4 Dry on top and filter. The solvent was removed in vacuo and the resulting residue was purified by flash chromatography on silica gel to give tert-butyl 4-((5-chloro-4-(trifluoromethyl)pyridin-2-yl)methyl). -4-Hydroxypiperidine-1-carboxylate (260 mg, 49%) was obtained. 1 H NMR(400MHz, CDCl 3 )δ H 8.67(s,1H),7.42(s,1H),3.91-3.76(m,2H),3.27-3.12(m,2H),2.98(s,2H),1.54-1.49(m,4H),1.45( s,9H).
[0449] Step 4 A mixture of tert-butyl 4-((5-chloro-4-(trifluoromethyl)pyridin-2-yl)methyl)-4-hydroxypiperidine-1-carboxylate (200 mg, 0.507 mmol) in DCM (5 mL) To this, DAST (162 mg, 1.01 mmol) was added at 0°C. The mixture was stirred at 0°C for 5 minutes. The residue was dissolved in ice water (10 mL) and NaHCO 3 (10 mL) and stirred for 10 minutes. The aqueous phase was extracted with DCM (3 x 10 mL). The combined organic phases were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate to obtain the product. The product was combined with another batch of the same reaction and the mixture was purified by column chromatography (0-30% EtOAc in PE) and purified with tert-butyl 4-((5-chloro-4-(trifluoromethyl)pyridine). -2-yl)methyl)-4-fluoropiperidine-1-carboxylate (85 mg, 34%) was obtained. 1 H NMR(400MHz, CDCl 3 )δ H 8.67(s,1H),7.54(s,1H),3.99-3.87(m,2H),3.20(s,1H),3.14(s,1H),3.10-3.01(m,2H),1.78-1.68( m,4H),1.45(s,9H).
[0450] Step 5 A mixture of tert-butyl 4-((5-chloro-4-(trifluoromethyl)pyridin-2-yl)methyl)-4-fluoropiperidine-1-carboxylate (85 mg, 0.214 mmol) in dioxane (2 mL). To this, HCl / dioxane (0.535 mL, 4M in dioxane, 2.14 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was filtered and concentrated to yield 5-chloro-2-((4-fluoropiperidin-4-yl)methyl)-4-(trifluoromethyl)pyridine hydrochloride, which was used directly in the next step. did.
[0451] Step 6 To a solution of 2-(pyrimidin-4-yl)pyridine-3-carboxylic acid (47.0 mg, 0.234 mmol), HATU (111 mg, 0.292 mmol) in DMF (3 mL) was added DIPEA (0.170 mL, 0.975 mmol). Ta. 5-chloro-2-((4-fluoropiperidin-4-yl)methyl)-4-(trifluoromethyl)pyridine hydrochloride (65.0 mg, 0.195 mmol) in DMF (2 mL) was added slowly. The mixture was stirred at 20 °C for 2 h, then heated with H 2 Poured into O (15 mL) and stirred for 20 minutes. The aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phases were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate. Flash column (Column: Phenomenex Gemini-NX 80*40mm*3um; Conditions: Water (0.05%NH 3 H 2 Purified by (4-( (5-chloro-4-(trifluoromethyl)pyridin-2-yl)methyl)-4-fluoropiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (26.4 mg , 28%). 1 H NMR(400MHz, CDCl 3 )δ H 9.17-9.01(m,1H),8.89-8.85(m,1H),8.75-8.74(m,1H),8.66(s,1H),8.30-8.20(m,1H),7.77-7.66(m,1H) ),7.52-7.43(m,2H),4.68-4.53(m,1H),3.43-3.39(m,1H),3.22-3.13(m,4H),1.97-1.94(m,2H),1.75-1.55 (m,2H).LCMS purity 99%, C 22 H 18 ClF 4 N 5 O[M+H] + MS ESI calculated for 480.1, measured 480.1.
[0452] Example 42. (4-fluoro-4-((5-(trifluoromethyl)pyrazin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Synthesis of methanone (compound 40) [ka]
[0453] step 1 Pd (PPh) in DME (10 mL) and water (2.5 mL) 3 ) 4 (127mg, 0.11mmol), Na 2 C.O. 3 (466 mg, 4.40 mmol), 2-bromo-5-(trifluoromethyl)pyrazine (500 mg, 2.20 mmol), and tert-butyl 4-[(4,4,5,5-tetramethyl-1,3,2 A mixture of -dioxaborolan-2-yl)methylidene]piperidine-1-carboxylate (782 mg, 2.42 mmol) was added to the flask at 20°C. The mixture was then heated with N 2 The mixture was stirred at 80°C for 16 hours and cooled to 20°C. The residue was poured into water (10 mL) and the mixture was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with water (10 mL) and brine (10 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. Purified by flash chromatography (0-20% EtOAc in PE) on silica gel to produce tert-butyl 4-((5-(trifluoromethyl)pyrazin-2-yl)methylene)piperidine-1-carboxylate ( 450 mg, 59.6%). 1 H NMR(400 MHz, CDCl 3 )δ H 8.95-8.81(m,1H),8.51(s,1H),6.42(s,1H),3.65-3.44(m,4H),2.99(m,2H),2.44(m,2H),1.48(s, 9H).
[0454] Step 2 A solution of m-CPBA (352 mg, 1.74 mmol, 85% purity) was added at 0°C and the reaction mixture was stirred at 0°C for 5 hours. The reaction mixture was 2 S 2 O 3 (10 mL), extracted with DCM (5 ml x 2), and the combined organic phases were 2 S.O. 4 dried, filtered and concentrated. Purified by flash column (0-20% EtOAc in PE) to give tert-butyl 2-(5-(trifluoromethyl)pyrazin-2-yl)-1-oxa-6-azaspiro[2.5]octane-6- Carboxylate (50 mg, 48%) was obtained. 1 H NMR(400 MHz, CDCl 3 )δ H 8.91(s,1H),8.70(s,1H),4.13(s,1H),3.84-3.69(m,1H),3.62-3.49(m,2H),3.47-3.37(m,1H),1.98( m,1H),1.79-1.67(m,1H),1.55(s,2H),1.45(s,9H). 19 F NMR(376.5 MHz, CDCl 3 )δ F- 67.493.
[0455] Step 3 tert-Butyl 2-(5-(trifluoromethyl)pyrazin-2-yl)-1-oxa-6-azaspiro[2.5]octane-6-carboxylate (50 mg, 0.139 mmol) in THF (10 mL) and Pd A solution of / C (50 mg, 10% palladium on carbon) was hydrogenated at 20° C. under 15 psi of hydrogen for 6 hours. The mixture was filtered, washed with THF (30 mL), and the filtrate was concentrated to give tert-butyl4-hydroxy-4-((5-(trifluoromethyl)pyrazin-2-yl)methyl)piperidine-1-carboxy rate (60 mg) was obtained.
[0456] Step 4 DAST ( 53.5 mg, 0.332 mmol) was added at 0° C. and the mixture was stirred for 10 minutes. Mixture with ice water (5 mL) and NaHCO 3 (10 mL) and stirred for 10 minutes. The aqueous phase was extracted with DCM (2 x 10 mL) and the combined organic phases were washed with saturated brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 Dry on top, filter and concentrate. Purification by flash column (0-10% EtOAc in PE) gave tert-butyl 4-fluoro-4-((5-(trifluoromethyl)pyrazin-2-yl)methyl)piperidine-1-carboxylate (60 mg ) was obtained.
[0457] Step 5 Solution of tert-butyl 4-fluoro-4-((5-(trifluoromethyl)pyrazin-2-yl)methyl)piperidine-1-carboxylate (60 mg, 0.165 mmol) in 1,4-dioxane (5 mL) Add hydrogen chloride (5 mL, 20.0 mmol, 4 M in 1,4-dioxane) to N 2 The reaction mixture was stirred at 20°C for 2 hours. The reaction mixture was concentrated to obtain 2-((4-fluoropiperidin-4-yl)methyl)-5-(trifluoromethyl)pyrazine hydrochloride (60 mg).
[0458] Step 6 To a solution of 2-(pyrimidin-4-yl)pyridine-3-carboxylic acid (48.2 mg, 0.24 mmol) and HATU (114 mg, 0.3 mmol) in DMF (3 mL) was added DIPEA (0.174 mL, 1 mmol). . 2-((4-fluoropiperidin-4-yl)methyl)-5-(trifluoromethyl)pyrazine hydrochloride (60 mg, 0.2 mmol) in DMF (2 mL) was added slowly. The mixture was stirred at 20°C for 16 hours. Reaction mixture with H 2 Poured into O (10 mL) and stirred for 20 minutes. The aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phases were washed with brine (2 x 10 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate. HPLC (Column: Phenomenex Gemini-NX 80*40mm*3um; Conditions: Water (0.05%NH 3 H 2 O)-ACN; Start B: 23; End B: 53; Gradient time (min): 8; 100% B retention time (min): 2; Flow rate (ml / min): 30; Injection: 5). , (4-fluoro-4-((5-(trifluoromethyl)pyrazin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (7.4 mg, 8%). 1 H NMR(400 MHz, CDCl 3 )δ H 9.25-9.10(m,1H),8.95-8.84(m,2H),8.76(dd,J=1.6,4.8 Hz,1H),8.67(s,1H),8.29(d,J=4.4 Hz,1H) ,7.76-7.65(m,1H),7.50-7.45(m,1H),4.76-4.51(m,1H),3.53-3.36(m,1H),3.35-3.12(m,4H),2.18-1.84( m,2H),1.69-1.42(m,1H),1.32-1.22(m,1H). 19 F NMR(400 MHz, CDCl 3 )δ F- 67.466,-161.012.LCMS purity 97%, C 21 H 18 F 4 N 6 O[M+H] + MS ESI calculated for 447.2, measured 447.2.
[0459] Example 43. (4-fluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl) Methanone (compound 41) [ka]
[0460] 5-((4-fluoropiperidin-4-yl)methyl)-2-(trifluoromethyl)pyrimidine as in Example 42 using 5-bromo-2-(trifluoromethyl)pyrimidine as the starting material. Prepared in a similar manner to 2-((4-fluoropiperidin-4-yl)methyl)-5-(trifluoromethyl)pyrazine.
[0461] To a solution of 2-(pyrimidin-4-yl)pyridine-3-carboxylic acid (134 mg, 667 μmol) and HATU (0.19 g, 500 μmol) in DMF (2 mL) was added DIPEA (0.174 mL, 1.0 mmol). 5-((4-fluoropiperidin-4-yl)methyl)-2-(trifluoromethyl)pyrimidine (0.1 g, 0.3336 mmol) in DMF (2 mL) was added slowly. The mixture was stirred at 20°C for 12 hours. Reaction mixture with H 2 Pour into O (50 mL) and stir for 20 minutes. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate. Flash column (Column: Phenomenex Gemini-NX 80*40mm*3um; Conditions: Water (0.05%NH 3 H 2 O)-ACN; Start B: 24; End B: 54; Gradient time (min): 8; 100% B retention time (min): 4; Flow rate (ml / min): 30; Injection: 6). , (4-fluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (37.0 mg, 25.0%). 1 H NMR(400 MHz, CDCl 3 )δ ppm 9.20(s,1H),8.90(s,1H),8.77(s,3H),8.30(s,1H),7.69(m,1H),7.43-7.55(m,1H),4.59-4.82 (m,1H),3.15-3.56(m,3H),2.90-3.09(m,2H),1.89-2.11(m,2H),1.66-1.88(m,2H).LCMS: Purity 98%, C 21 H 18 F 4 N 6 O[M+H] + MS ESI calculated for 447.1, measured 447.2.
[0462] Example 44. (4-Fluoro-4-((5-methylpyridin-2-yl)methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (Compound 42 ) synthesis [ka]
[0463] step 1 To a solution of 2,5-dimethylpyridine (2.0 g, 18.6 mmol) in THF (15 ml) was added n-BuLi (6.68 mL, 2.5 M, 16.7 mmol) with N 2 It was slowly added dropwise at -70°C. N 2 After stirring for 0.5 h at -70 °C, this mixture was added with tert-butyl 4-oxopiperidine-1-carboxylate (2.94 g, 14.8 mmol) in THF (10 ml) with N 2 The mixture was added at -70°C and stirred at -70°C for 2 hours. After warming to 25° C., the residue was poured into water (20 mL) and the mixture was extracted with EtOAc (2×20 mL). The combined organic phases were washed with water (15 mL) and brine (15 mL) and washed with Na 2 S.O. 4 Dry on top, filter and concentrate. Purified by flash chromatography on silica gel (0%~10%~50% EtOAc in PE) and tert-butyl 4-hydroxy-4-((5-methylpyridin-2-yl)methyl)piperidine-1-carboxy rate (3.5g, 61.5%) was obtained. 1 H NMR(400MHz, CDCl 3 )δ H 8.33(s,1H),7.49-7.42(m,1H),7.01(d,J=7.6 Hz,1H),3.86-3.69(m,2H),3.31-3.12(m,2H),2.86(s, 2H), 2.32(s, 3H), 1.54-1.45(m, 4H), 1.45(s, 9H).
[0464] Step 2 DAST (1.57 g, 9.78 mmol) was added at 0°C. The mixture was stirred at 0°C for 5 minutes. Mixture with ice water (50 mL) and NaHCO 3 (50 mL) and stirred for 10 minutes. The aqueous phase was extracted with DCM (3 x 20 mL). The combined organic phases were washed with saturated brine (2 x 30 mL) and anhydrous Na 2 S.O. 4 Dried above, filtered and concentrated to give tert-butyl 4-fluoro-4-((5-methylpyridin-2-yl)methyl)piperidine-1-carboxylate (1.5g). 1 H NMR(400MHz, CDCl 3 )δ H 8.41-8.34(m,1H),7.53-7.44(m,1H),7.13-7.08(m,1H),3.89(s,2H),3.59-3.42(m,4H),3.15-3.07(m,1H) ),2.33(s,3H),2.06-1.98(m,2H),1.78-1.69(m,1H),1.46-1.42(m,9H).
[0465] Step 3 HCl / dioxane (12.1 mL, 4M in dioxane, 48.6 mmol) was added and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to give 2-((4-fluoropiperidin-4-yl)methyl)-5-methylpyridine hydrochloride (1.5g), which was used directly in the next step.
[0466] Step 4 To a solution of 2-(pyrimidin-4-yl)pyridine-3-carboxylic acid (410 mg, 2.04 mmol) and HATU (1.16 g, 3.06 mmol) in DMF (5 mL) was added DIPEA (1.31 g, 10.2 mmol). Ta. 2-((4-fluoropiperidin-4-yl)methyl)-5-methylpyridine hydrochloride (0.5 g, 2.04 mmol) in DMF (5 mL) was added slowly. The mixture was stirred at 20°C for 16 hours. Reaction mixture with H 2 Pour into O (50 mL) and stir for 20 minutes. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with saturated brine (2 x 20 mL) and anhydrous Na 2 S.O. 4 dry on top 、 Filter and concentrate. HPLC (Column: Phenomenex Gemini-NX 80*40mm*3um; Conditions: Water (0.05%NH 3 H 2 O)-ACN; Start B: 22; End B: 52; Gradient time (min): 8; 100% B retention time (min): 3.5; Flow rate (ml / min): 30; Injection: 7). , a product was obtained, which was transferred to SFC (column: DAICEL CHIRALCEL OJ (250mm*30mm, 10um); conditions: 0.1%NH 3 H 2 O ETOH; Start B: 20%; End B: 20%; Flow rate (ml / min): 60; Injection: 25) and further purified by ) Methyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone (52.9 mg, 6.6%) was obtained. 1 H NMR(400MHz, CDCl 3 )δ H 9.22-8.61(m,3H),8.44-8.33(m,1H),8.30-8.14(m,1H),7.76-7.40(m,3H),7.24-7.09(m,1H),4.72-4.45(m ,1H),3.50-3.45(m,1H),3.35-3.09(m,4H),2.45-2.27(m,3H),2.08-1.89(m,2H),1.70-1.64(m,2H). 19 F NMR(376.5 MHz, CDCl 3 )δ F -159.479.LCMS purity 99%, C 22 H 22 FN 5 O[M+H] + MS ESI calculated for 392.2, measured 392.0.
[0467] Exa...
Claims
1. A compound of formula I, [C214] or a pharma- ceutically acceptable salt thereof, R 1 But, C 6 -C 10 Aryl, C 3 -C 7 cycloalkyl, 3- to 7-membered heterocyclyl, and 5- to 10-membered heteroaryl; R 1 However, as necessary, 1 to 4 R 4 is replaced by R a and R b each independently represents H, halo, —CN, —OH, —NO 2 , -N(R 5 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, and C 1 -C 6 haloalkoxy or R a and R b together with the carbon to which they are attached, substituted or unsubstituted C 3 -C 7 It may form a cycloalkyl, or R a and R b But together they are Oxo, R c , R d , R e , and R f Each of is independently H, substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, and C 1 -C 6 haloalkoxy or R c and R e together with the carbon to which they are attached, substituted or unsubstituted C 1 -C 3 An alkylene bridge may be formed, or R d and R f together with the carbon to which they are attached, substituted or unsubstituted C 1 -C 3 may form an alkylene bridge, Each R 4 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , -S(O) 2 R 5 , substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 3 -C 7 cycloalkyl, and substituted or unsubstituted 3- to 7-membered heterocyclyl; Each R 5 is independently H and substituted or unsubstituted C 1 -C 6 alkyl, Each R 2 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 7 Cycloalkyl, C 1 -C 6 Haloalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, and C 1 -C 6haloalkoxy; Each R 3 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 3 -C 7 Cycloalkyl, and C 1 -C 6 haloalkoxy; A is a 5-6 membered nitrogen-containing heteroaryl; B is C 6 -C 10 aryl and 5-6 membered heteroaryl; m is 0, 1, 2, or 3; n is 0, 1, 2, 3, or 4; o is 0, 1, 2, or 3; p is 0, 1, or 2; However, when n is 0, R 1 is not 4-cyanophenyl or 4-trifluoromethylphenyl, or a pharma- ceutically acceptable salt thereof.
2. The compound of formula I is [C215] 2. The compound of claim 1, which is not:
3. The compound of formula I is [C216] 2. The compound of claim 1, which is not:
4. The compound of formula I is a compound of formula I-a-1, [C217] 4. The compound according to claim 1, wherein:
5. R 1 is C substituted with 1 to 4 R 4 6 -C 10 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, which is aryl.
6. R 1 is unsubstituted C 6 -C 10 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, which is aryl.
7. R 1 but, [C218] wherein each R 4 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , -S(O) 2 R 5 , substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 3 -C 7 cycloalkyl, or substituted or unsubstituted 3- to 7-membered heterocyclyl, and each R 5 is independently H or substituted or unsubstituted C 1 -C 6 5. The compound according to any one of claims 1 to 4, wherein q is alkyl and q is 0, 1, 2, or 3, or a pharma- ceutically acceptable salt thereof.
8. R 1 but, [C219] 8. The compound of claim 7, wherein:
9. R 1 but, [C220] 8. The compound of claim 7, wherein:
10. R 1 but, [C221] 8. The compound of claim 7, wherein:
11. R 1 but, [C222] 8. The compound of claim 7, wherein:
12. R 1 but, [C223] 10. The compound of claim 9, wherein:
13. R 1 but, [C226] 11. The compound of claim 10, wherein:
14. R 1 but, [C227] 11. The compound of claim 10, wherein:
15. R 1 but, [C229] 12. The compound of claim 11, wherein:
16. R 1 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein is 5-10 membered heteroaryl substituted with 1-4 R4.
17. R 1 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein is unsubstituted 5-10 membered heteroaryl.
18. R 1 but, [C230] wherein each X is independently CH or N, and the H of said CH is selected from 1 to 4 R 4 and each R 4 are independently halo, -CN, -OH, -NO 2 , -N(R 5 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 3 -C 7 cycloalkyl, or substituted or unsubstituted 3- to 7-membered heterocyclyl, and each R 5 is independently H or substituted or unsubstituted C 1 -C 6 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.
19. R 1 but, [C231] 18. The compound of claim 17, wherein:
20. R 1but, [C235] 17. The compound of claim 16, wherein:
21. R 1 but, [C238] 21. The compound of claim 16, 17, or 20, which is: or a pharma- ceutically acceptable salt thereof.
22. R 1 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein is 3-7 membered heterocyclyl substituted with 1-4 R4.
23. R 1 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein is unsubstituted 3-7 membered heterocyclyl.
24. a. Each R 4 are independently halo, -CN, substituted C 1 -C 6 Alkyl, substituted C 1 -C 6 Alkoxy or substituted C 3 -C 7 is cycloalkyl; or The compound of any one of claims 1 to 23, or a pharma- ceutically acceptable salt thereof, wherein each R4 is independently halo, -CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, or unsubstituted C3-C7 cycloalkyl.
25. 25. The compound according to any one of claims 1 to 24, wherein n is 1, or a pharma- ceutically acceptable salt thereof.
26. 26. The compound according to any one of claims 1 to 25, wherein p is 1, or a pharma- ceutically acceptable salt thereof.
27. 26. The compound according to any one of claims 1 to 25, wherein p is 0, or a pharma- ceutically acceptable salt thereof.
28. B, [C242] wherein each R 6 is independently N or CR 6a and R 6a is H or R 2 and ** is the point of attachment to the carbonyl, * 28. The compound according to any one of claims 1 to 27, or a pharma- ceutically acceptable salt thereof, wherein: is the point of attachment to A.
29. Maximum 2 R 6 may be N, and R 6 29. The compound of claim 28, or a pharma- ceutically acceptable salt thereof, wherein other occurrences of are CH.
30. B, [C243] where: ** is the point of attachment to the carbonyl, * 30. The compound of any one of claims 1 to 29, or a pharma- ceutically acceptable salt thereof, wherein: is the point of attachment to A.
31. B, [C244] where: ** is the point of attachment to the carbonyl, * 29. The compound of any one of claims 1 to 28, or a pharma- ceutically acceptable salt thereof, wherein: is the point of attachment to A.
32. B, [C250] where: ** is the point of attachment to the carbonyl, * 28. The compound according to any one of claims 1 to 27, or a pharma- ceutically acceptable salt thereof, wherein: is the point of attachment to A.
33. 28. The compound according to any one of claims 1 to 27, or a pharma- ceutically acceptable salt thereof, wherein m is 1.
34. 28. The compound according to any one of claims 1 to 27, or a pharma- ceutically acceptable salt thereof, wherein m is 0.
35. 35. The compound of any one of claims 1 to 34, or a pharma- ceutically acceptable salt thereof, wherein A is pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazinyl, tetrazolyl, oxazolyl, isoxazolyl, or thiozolyl.
36. 36. The compound of any one of claims 1 to 35, wherein A is pyridinyloxazolyl, imidazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, or triazinyl, or a pharma- ceutically acceptable salt thereof.
37. A, [C251] wherein each R 7 are independently N or CH, and up to two R 7 may be N, and R 7 Another occurrence of is CH and the hydrogen of said CH is R 3 35. The compound according to any one of claims 1 to 34, or a pharma- ceutically acceptable salt thereof, optionally substituted with:
38. A, [C252] 38. The compound according to any one of claims 1 to 37, wherein:
39. The compound is [C254] [C255] [C256] [C257] [C258] [C259] [chemical 260] [C261] [C262] [C263] [C264] [C265] 39. The compound according to any one of claims 1 to 38, selected from the group consisting of:
40. The compound is [C266] [C267] [C268] [C269] 40. The compound of claim 39, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
41. The compound is [C270] [C271] 40. The compound of claim 39, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.
42. 42. A pharmaceutical composition comprising a compound according to any one of claims 1 to 41, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.
43. 42. A pharmaceutical composition for treating or preventing a disease or disorder associated with inhibition of CYP46A1 in a subject, comprising a compound according to any one of claims 1 to 41 or a pharma- ceutical acceptable salt thereof, wherein the disease or disorder associated with inhibition of CYP46A1 is selected from the group consisting of neurodegenerative disorders, epilepsy, developmental and epileptic encephalopathies, psychiatric disorders, and convulsions.
44. 44. The pharmaceutical composition of claim 43, wherein the disease or disorder involving inhibition of CYP46A1 is a neurodegenerative disorder.
45. 45. The pharmaceutical composition of claim 44, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, cerebral infarction, glaucoma, and multiple sclerosis.
46. 44. The pharmaceutical composition of claim 43, wherein the disease or disorder involving inhibition of CYP46A1 is epilepsy.
47. 44. The pharmaceutical composition of claim 43, wherein the disease or disorder involving inhibition of CYP46A1 is developmental and epileptic encephalopathy.
48. 44. The pharmaceutical composition of claim 43, wherein the disease or disorder associated with inhibition of CYP46A1 is a psychiatric disorder.
49. 49. The pharmaceutical composition of claim 48, wherein the psychiatric disorder is selected from the group consisting of schizophrenia, autism spectrum disorder, delusional disorder, schizoaffective disorder, and depression.
50. 44. The pharmaceutical composition of claim 43, wherein the disease or disorder associated with inhibition of CYP46A1 is convulsions.
